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Intra-articular (IA) administration is used for the symptomatic treatment of disorders such as 
Osteoarthritis (OA) and Rheumatoid Arthritis (RA) providing a local effect while avoiding 
systemic side effects. For appropriate IA formulations to be developed and for quality control 
purposes, appropriate dissolution models have significant importance. Developing these 
models poses a great challenge, while at the moment, there is no regulatory approved standard 
methods for testing drug dissolution from parenteral formulations. The principal aim of this 
thesis is the development of appropriate in-vitro compendial and biorelevant dissolution 
models of drug absorption after IA administration. A vast number of dissolution methods were 
investigated, based on their potential and suitability as compendial methods (USP apparatus I, 
II, III and IV, dialysis methods and bi-phasic models) and their applicability in simulating in-
vivo conditions for the biorelevant dissolution aspect (Side-Bi-Side diffusion cells and bi-
phasic models). Various parameters of the setups were successfully evaluated towards their 
effect in drug dissolution. The discrimination ability of the USP apparatus IV was demonstrated 
showing the significant potential of this method in order to be considered for compendial 
testing. For the biorelevant dissolution testing, biorelevant synovial fluids (BSFs) of healthy 
and disease states were developed according to performed in-vivo studies of physicochemical 
properties and solubility values of Triamcinolone Acetonide (TA). These media were also used 
in biorelevant dissolution testing, showing the ability of the tested systems to discriminate 
between these media. Finally, surface dissolution imaging has permitted direct visualisation of 
the solvation and dissolution of TA with a detailed insight in the characterisation of the 
dissolution process by evaluating the effect of surfactants and increased viscosity of the 
medium. Overall, this thesis provides essential information on the potential of dissolution 
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Chapter 1: Introduction 
	
Overview 
Intra-articular (IA) is a type of medical administration which delivers the drug directly to the 
joint (local administration) while reducing the systemic side effects. With this type of delivery, 
most of the drug administered, is directly released in the targeted area allowing even drugs with 
poor oral bioavailability to achieve their pharmacological purpose against diseases affecting 
the joint. The most important among these are Osteoarthritis (OA) and Rheumatoid Arthritis 
(RA). Both these diseases have in common the gradual damage of the articular cartilage and 
the bones involved in the joint [1]. The IA pharmacological treatment available [corticosteroids 
and hyaluronic acid (HA)] does not cure or prevent arthritic disorders but reduces moderate to 
severe pain and slows down the progression of the disease [2]. A significant drawback of 
formulations given through the IA route, is that they exit the joint rapidly and distribute through 
the body. This takes place due to the continuous transynovial flow of the synovial fluid in and 
out of the joint, resulting in the need for multiple injections, to maintain the desired drug 
concentration. This is a major issue, with promising strategies available to overcome it, such 
as formulations that stay in the joint longer and are released in a longer length of time [3]. In 
order to develop and characterise these potential drug formulations, specific in-vitro tests need 
to be performed to establish drug dissolution. Currently, there is no official standard method 
for testing drug dissolution from IA formulations. Instead, widely used in-vitro dissolution 
methods include: 1) sample and separate, 2) dialysis and 3) continuous flow through (USP 
apparatus IV). A main issue with these setups is that they are designed for testing dissolution 
of different drug delivery systems and they do not fully cover the dissolution of the drug given 
through the IA route [1]. The goal of this project is the development of appropriate and 
validated in-vitro compendial and biorelevant dissolution models of the drug after IA 
administration. For biorelevant dissolution testing, biorelevant synovial fluids of healthy and 
disease state will be developed for the prediction of in-vivo performance by characterising in-
vivo disease state synovial fluids (OA and RA). Surface dissolution imaging will also be used 
for characterisation of the dissolution process of IA drugs. The methods developed will be used 
for defining critical formulation variables and setting dissolution testing specifications, with 
the biorelevant aspect being used to predict in-vivo performance. These tests may be used for 
other parenteral formulations as well. 
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1.1. Anatomy of the synovial joint and synovial fluid composition  
	
	
Fig. 1.1. The synovial joint and IA drug delivery. Reproduced with kind permission from [2]. 
	
A synovial joint, which is one of the most common joints in the body, has specific anatomic 
properties which make IA delivery feasible. It consists of parts connecting the bones involved 
in the cavity, in which movement takes place and stability is needed (Fig. 1.1). At the end parts 
of the two bones, there is a layer, the articular (hyaline) cartilage, and between the bones inside 
the synovial cavity, there is the synovial fluid that lubricates the joint and reduces friction 
during applied pressure. The synovial fluid also supplies the oxygen and nutrients to the 
articular cartilages for the growth, restoration and viability of the bone [1, 2]. This synovial 
cavity is then “encapsulated” in a membrane, the synovium. The last part involved in the 
synovial joint is the outer fibrous collagen capsule which is in direct contact with the 
subsynovium and the blood circulation.  
	
1.1.1. Articular cartilage 
	
The articular (hyaline) cartilage covers the end part of the bone involved in the joint and has a 
thickness of 1-5 mm [4]. This tissue provides a near no-friction surface when the bones come 
into contact, with reversible deformation properties, meaning that after stress is applied to the 
membrane, it can return to its original state. Apart from reversible compression, the articular 
cartilage can reduce contact pressure and compression (due to water absorbance) between the 
bones and apply any change in stress evenly to the bone surface. These properties exist due to 
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an extensive extracellular matrix (ECM), which has layers of glycosaminoglycans and collagen 
fibres (that also provide the articular cartilage with tensile strength). For the growth, restoration 
and viability of the bone, nutrients and oxygen, are able to diffuse through the articular 
cartilage, from the synovial fluid and reach the chondrocytes [1, 4]. The articular cartilage is 
separated from the bone by a calcified cartilage layer. 
	
1.1.2. Synovial fluid 
	
The synovial fluid is the liquid in which the IA injection is administered. It is located in the 
synovial cavity and surrounded by the synovium, which also forms a thin film over the inner 
cavity. The synovial fluid is a non-Newtonian thixotropic fluid meaning that it is viscous and 
with increased stress conditions, its viscosity decreases and it may flow easier. The composition 
of the synovial fluid of the healthy, OA and RA joint (volume in knee joint: 0.5-2 mL, >3.5 
mL and up to 100 mL respectively) can be seen in Table 1.1. 
 
Table 1.1. Healthy and disease state (OA and RA) synovial fluid composition 
Components 
(mg/mL) 


















8-13 (Similar to 
Healthy state) [4] 




0.5-2.9 (Similar to 
Health state) [4] 
 24.75[15, 17]  
a2-
Macroglobuline 





























Glucose 0.66 [4] 
0.66 (Similar to Health 
state)  [4] 
- 
Urea 0.04 [4] 
0.04 (Similar to Health 
state)  [4] 
- 
Lactate 0.09-0.162 [4] - - 
Ca+ 0.48-0.96 [4] 
0.48-0.96 (Similar to 
Health state)  [4]  
- 
Cl- 3.81 [4] 
3.81 (Similar to Health 
state)  [4]  
- 
Na+ 3.33 [4] 
3.33 (Similar to Health 
state)  [4] 
- 
K+ 0.16 [4] 
0.16 (Similar to Health 




1.14 ± 0.56 [26] 
1.56 ± 1.31 [26] 1.7 ± 0.75 [26] 
Fe2+ 
2.28 [4] 
2.18 ± 0.64 [26] 
2.28 (Similar to Health 
state)  [4] 
3.259 ± 1.781 [26] 
1.91 ± 1 [26] 
Cu2+ 
2.47 [4] 
2.81 ± 0.71 [26] 
2.47 (Similar to Health 
state)  [4] 
5.66 ± 3.48 [26] 
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0.07-0.08 [27]  0.04-1.69 [27] 0.76-1.30 [27] 
Total 
Triglycerides 
0 [27] 0.12-0.59 [27]  0.17-1 	[27]	
* Classified for arthritic disease (i.e. OA) 
The synovial fluid composition is very similar to that of blood plasma with concentrations of 
small, low molecular weight molecules and electrolytes being similar in both fluids, leading to 
the consideration of the synovial fluid as plasma ultra-dialysate. Larger molecules though, such 
as proteins and polymers (albumin, fibrinogen and globulins) are present in lower 
concentrations in synovial fluid or may not be present at all, compared to plasma, due to 
filtration by the synovial capillary walls. The synovial fluid also contains components not 
present in the plasma, such as HA and lubricin which play a major role in the viscoelastic and 
lubricating ability of this fluid [4, 29]. In addition, the HA is useful for bringing together the 
opposing surfaces of the joints by creating tensile strength with little or no shear stress. This 
allows the surfaces to slide easier across each other with limited friction [4]. 
	
1.1.2.1. Transynovial flow 
	
The pathway followed by the blood and eventually the synovial fluid in the synovial joint is 
through a continuous flow. The synovial fluid is drained from the synovial cavity into the sub-
synovial lymphatics and capillaries (subsynovium) while it is produced by the vascularised 
synovial membrane, by filtering the blood into the cavity, with the addition of HA and lubricin 
produced by type B synoviocytes (Fig. 1.1) [2]. The two pathways which regulate the flow of 
the synovial fluid through the synovial membrane are: 
• Synovial cavity ® subsynovium through the full thickness of the synovial lining and 
• Superficial plasma ® synovial cavity through ultrafiltration by the capillary wall and 
overlying synovial interstitium [29, 30] 
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This turnover flow is the trans-synovial flow and depends on local intra-extravascular pressures  
[4]. By this, most of the proteins and the water in the synovial fluid are changed approximately 




The synovium, the membrane surrounding the synovial fluid, is comprised of two layers. The 
deep layer consists of adipose, fibrous or areolar tissue and an ECM with main contents being 
collagen (e.g. types I, III, V, VI), proteoglycans (eg. decorin, biglycan), HA and fibronectin [1, 
4]. The second and superficial part of the synovium contains type A and type B synoviocyte 
cells [1]. Type A synoviocytes act as macrophages which consist ~30% of the intima and 
subintima cells [31] and type B synoviocytes, which appear more frequently and act similarly 
to fibroblasts [1]. These similarities between the synoviocytes and the mentioned cells, mean 
that type A synoviocytes express specific markers with a haematopoietic origin and type B 
synoviocytes secrete specific collagens, vimentin and Cluster Differentiation (CD) 90 [32]. 
Both type of synoviocytes are important in creating the joint’s immune system and in helping 
with the clearance of waste products. The synovium has several major roles, including: 
§ Playing the role of a diffusion membrane for solutes between the synovial fluid solution 
and the fenestrated microvessels and lymphatic vessels 
§ Providing a large proportion of filtration to the plasma (mostly with the ECM and type 
B synoviocytes) for passing the capillary walls and into the joint cavity 
§ Removing (through type A synoviocytes) the foreign fragments from the synovial fluid, 
with type A synoviocytes also producing chemokines 
§ Synthesis of HA and lubricin (through type B synoviocytes) 
§ Generation of the synovial fluid [4] 
	
Finally, outside of the ECM (consisting the synovium) there is a fenestrated capillary network 
with lymphatic vessels and loose areolar connective tissue, the subsynovium [1, 33]. 
1.2. Pathophysiology of the joint in Osteoarthritis and Rheumatic Arthritis 
	
IA drug delivery is useful for treating symptoms such as pain and inflammation in the joint 
while it is effective against a range of diseases such as arthritic disorders (OA and RA). OA 
has a prevalence of about 7% [1] and after the age of 65 years it appears in 60% of men and 
70% of women [4] while in the US it is the cause of more than 500,000 total joint replacements 
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every year [1]. RA has a prevalence of 1% in the population and affects, in average, 1.5 men 
and 3.6 women per 10,000 people each year [34]. 
The arthritic joint, involved in conditions such as OA or RA, has several differences to a healthy 
state joint (Fig. 1.2. A) associated with the articular cartilage, the components of the synovial 
fluid and the synovium [35]. The volume of the synovial fluid increases while the synovial 
tissue becomes enlarged due to a different balance between intravascular pressure and synovial 
interstitial pressure. An increased amount of proteins appears in the synovial fluid, reaching 
the amount present in the blood plasma (Table 1.1.) [2]. 
OA is mainly described as a disease where degeneration and loss of articular cartilage takes 
place while the synovium cells become enlarged (Fig. 1.2. B). Bone remodelling and new bone 
formation takes place in the degenerated articular cartilage due to the local presence of 
osteophytes in the cartilage and the bone [4]. In patients with OA, one of the first differences 
observed in the joint are fissures on the surface of the articular cartilage, which may then spread 
and penetrate into the cartilage and then enter the bone [4]. While degeneration expands in the 
articular cartilage, numerous results take place such as loss of collagen and proteoglycans (the 
main components of the articular cartilage), production of specific cytokines (eg. IL-1), growth 
factors (eg. IGF-1, TGFb) and proteases, leading to impairment of the collagen network. This 
means that the thickness of the articular cartilage is slowly lost, with the growth factors playing, 
most likely, a major role in the synthetic processes of OA [4]. The loss of collagen and 
proteoglycans and the production of cytokines, growth factors and proteases are mainly caused 
by the matrix metalloproteinases (MMP’s), which lead to the cleavage of macromolecules 
belonging to the articular cartilage such as type II collagen and the proteoglycan aggrecan [35]. 
The products of macromolecule degradation (involving the cytokines mentioned) also cause 
the degradation of the articular cartilage creating a positive feedback loop. 
RA is a chronic inflammatory disease which is mainly caused from interactions between cells 
starting with interactions between the antigen presenting cells and the CD4 + T cells (Fig. 1.2. 
C) [2]. The synovial joint becomes damaged and many cell types appear within it, such as T 
cells, B cells, dendritic cells, macrophages, fibroblasts, mast cells and neutrophils. The 
physiology of the joint is changed due to the appearance of the mentioned cells, with an 
increase in the volume of the synovial fluid, the temperature and the inner pressure. The activity 
arising from the inflammation present is considered to be a chain event, as the T cells activated 
are responsible for producing interferon c and specific cytokines (TNF and interleukins) [2] 
that activate synovial macrophages, fibroblasts, chondrocytes and osteoclasts, causing the 
inflammation of synovial tissues [35]. The macrophages and fibroblasts then, produce TNF-a 
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and IL-1, IL-6, IL-15, IL-18. The TNF-a and Interleukin cytokines, together with specific 
growth factors, are responsible for the activation of B cells and neutrophils. The neutrophils, 
that also play a role in the articular cartilage degradation, accumulate in the synovial fluid. The 
articular cartilage is then impaired by the MMP’s similarly to the events taking place in OA 
[2]. The B cells and the dendritic cells together with the T cells and tissue macrophages, form 
aggregates. The synovial lining (synovium) becomes enlarged from 1-20 cells in depth due to 
a large amount of type A and B synoviocytes present, leading to an increase in molecule 
transportation from the subsynovium to the synovium and synovial fluid [1, 32] The synovium 
also becomes pannus tissue at the cartilage-bone interface (an abnormal layer of fibrovascular 
tissue) containing mainly macrophages and osteoclasts. While the panus tissue continues its 




Fig. 1.2. Representation of a) healthy state joint, b) Osteoarthritis joint, c) Rheumatic arthritis 
joint. Reproduced with kind permission from [35] 
	
1.3. Physicochemical properties of synovial fluid in the healthy, OA and RA 
synovial joint 
	
1.3.1. pH of synovial fluid 
	
The pH value of the synovial fluid may have a significant effect on the dissolution of the drug 
administered through the joint as it affects the solubility of weak acidic and basic drugs. In 
literature, the pH of human synovial fluid (normal and disease state) is measured directly from 
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the samples collected with pH electrodes. More specifically, measurements were performed 
with a pH meter [36, 37] or radiometer [38], with a specific pH electrode made from antimony 
also been used in combination with a radiometer pH meter [39], while in another study a 
McInnis glass electrode applied [7].  
1.3.1.1. Healthy state 
	
Considering that synovial fluid is a dialysate of blood with the addition of HA and lubricin, the 
pH is near the physiological value (~7.4) [38] agreeing to previous animal studies and post 
mortem samples [7]. Results from one study that shows a mean value of 7.7 for healthy adult 
subjects (Table 1.2.). The same paper explains that an important factor affecting the pH, is the 
age of the subjects. At a young age of 7-19 the mean value of the pH was at 8.1 while from 20 
years and onwards the pH stabilises at around 7.7 (Fig. 1.3.) [36].  
1.3.1.2. Osteoarthritis 
	
The OA synovial fluid pH, seems to be lower than the healthy state synovial fluid pH in 
between the ages of 30-78 with a mean of 7.5 [36]. No test was performed on early age patients 
while only 3 patients were aged 30-49 years out of the 41 OA patients that were tested. In 
another study the mean synovial fluid pH of 16 OA patients tested was relatively higher than 
that noted as the value was 7.9 (Table 1.2.) [36, 37]. A higher pH may be estimated due the 
hydrogen ion concentration measurement technique, as oxygenation may take place when 
samples are withdrawn from the synovial cavity, increasing the hydrogen ion concentration 
[39]. 
1.3.1.3. Rheumatoid arthritis 
	
Tests on patients with RA have shown that the pH of their synovial fluid is lower than healthy 
and OA values. A mean value of 7.22 was measured which can be attributed to a topical lactic-
acid acidosis taking place due to the inflammation of the joint. The synovial membrane in this 
condition has acid producing villi formed in its surface that may entrap synovial fluid in its 
folds; if synovial fluid is withdrawn from that area the pH will be lower than the actual value 
[38]. It was also noticed that the position of the needle when withdrawing fluid was important 
for maintaining similar readings, which was not an issue for healthy state joints. Other 
measurements showed a lower mean value of 6.61 explained by the acidity present in inflamed 
joints [39] while in another study, the mean pH value was measured at 7.5 which was higher 
than studies conducted before [37] due to the possible oxygenation of the withdrawn samples 
(Table 1.2.) [39].  
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Table 1.2. pH values of synovial fluid in healthy and disease state 
Mean value Range Subjects Age State Reference  
7.39 7.29-7.45 6 - Healthy [7] 
7.7 6.5-8.9 91 7-78 Healthy [36] 
7.43 7.31-7.64 5 - Healthy [38] 
7.3 7.1-7.4 10 23-73 Healthy [39] 
      
7.55 7.49-7.6 41 30-78 OA [36] 
7.9 7.4-8.1 16 - OA [37] 
      
7.22 7.08-7.28 6 - RA [38] 
6.61 6-7.3 10 48-74 RA [39] 
7.5 7.4-.76 6 - RA [37] 
 
 









7-19 20-29 30-39 40-49 50-59 60-59 70-78
pH
Age
Healthy Rheumatoid arthritis Osteoarthritis
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1.3.2. Osmolality of synovial fluid 
	
Osmolality is a percentage (%) of the total number of particles dissolved per kilogram of 
solvent which can affect the osmotic pressure that shows how possible it is for the solvent 
molecules to pass through a semipermeable membrane, such as the one involved in a synovial 
joint [40]. Osmolality is usually measured by a freezing point depression osmometer or a 
vapour pressure depression osmometer [40-42]. The freezing point depression is considered 
more accurate, as the vapour pressure method is more useful for viscous and non-volatile 
solutions [41, 42].  
1.3.2.1. Healthy state 
 
One of the first studies conducted for measuring osmolality from healthy patients showed that 
the range changed over time, with the first measurement giving a mean value of 404 ± 57 
mmol/kg and after twenty minutes the same samples gave a mean value of 369 ± 50 mmol/kg 
[41]. This difference in osmolality over time may be explained by the conformational changes 
of HA due to entropy, influence the amount of bound water, which can be released in exchange 
for salt particles. In addition, stress conditions in the joint can affect the conformational state 
of HA. Another study showed slightly lower values in a range of 295-340 mmol/kg, which was 
justified by the technique used to measure osmolality, as a freezing point was used instead of 
vapour pressure (Table 1.3.) [42].  
1.3.2.2. Osteoarthritis 
	
The osmolality measured in synovial fluid from OA patients is significantly lower than that of 
healthy subjects. The first explanation as to why this occurs, focused on the change of HA in 
the diseased state synovial fluid. Due to the conformational changes and the difference in 
molecular weight of the HA there is an increase of bound water instead of salt and so the 
osmolality decreases [40, 41]. Secondly, the chondrocytes present in the articular cartilage 
seem to be affected by osmolarity difference and regulate gene expression of chondrogenic 
transcription factors together with ECM constituents [42].  
1.3.2.3. Rheumatoid arthritis 
	
The osmolality of the synovial fluid of patients with RA is also lower than that of healthy 
subjects. From the studies conducted it is shown that the values are slightly lower than those 
of the OA patients due to the change of the constituent concentrations through the disease, such 
as total protein which is lower in OA and also due to lytic enzymes and cell debris in RA [40]. 
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Subjects Age State Reference  
404 +/- 57 
369 +/- 50 
N/A 15 22-35 healthy [41] 
- 295–340 N/A >30 healthy [42] 
      
297 +/- 16.9 270-334 15 38-74 OA [40] 
- 249-277 3 >30 OA [42] 
      
280 +/- 7.7 265-290 15 55-86 RA [40] 
- 273-283 3 >30 RA [42] 
 
1.3.3. Surface tension of synovial fluid 
	
The surface tension shows the resistance of a liquid surface to an external force and affects the 
wetting of drug particles and consequently the surface area for drug dissolution [43]. 
Components such as phospholipids [44] and HA [43] are mainly responsible for changing the 
surface tension of the synovial fluid. There is limited data for the surface tension of the synovial 
fluid, with one study showing the values measured in healthy subjects and one more for patients 
with RA, with no measurements found for OA. The surface was measured by a Wilhelmy plate 
method [43] or a tensiometer [45].  
1.3.3.1. Healthy state 
	
When the amount of phospholipids present in synovial fluid are in healthy state levels, the 
surface tension is approx. 50 mN/m (Table 1.4.).   
1.3.3.2. Rheumatoid arthritis 
	
In RA, the composition of the synovial fluid is altered and the synovium is degenerated which 
can affect the presence of bound surface active phospholipids. The surface tension is affected 
by these changes [46] which means that the dissolution rate of poor soluble drugs could also 





Table 1.4. Surface tension of healthy and disease state synovial fluid 
Mean 
value(mN/m) 
Range  (mN/m) Subjects Age State Reference 
50.6 48-52 5 - Healthy [45] 
      
47.99 +/- 4.59  31.15–52.61 19 - RA  [43] 
	
1.3.4. Viscosity of synovial fluid 
	
As healthy synovial fluid has non-Newtonian shear thinning properties with viscosity 
decreasing as the shear rate becomes higher [9, 45, 47, 48], it is common in the literature to 
present figures with viscosity values against shear rates, as a specific viscosity or values over 
time, are difficult to interpret [49]. The viscosity of synovial fluid has been measured with a 
rotational cone in cone viscometer [47, 50, 51], a low shear rotational viscometer  [52, 53], a 
Weissenberg  rheogoniometer [48] and also a capillary tube method [49]. 
1.3.4.1. Healthy state 
	
The viscosity of synovial fluid at a shear rate of 0.1 s-1 is approx. 100 Pa s (Table 1.5.). With 
the shear rate decreasing, due to non-Newtonian behaviour, viscosity reaches a value of approx. 
0.1 Pa s with 0.001 s-1 [48-53]. The presence of the HA protein complex with its high molecular 
weight (107 Da) is responsible for maintaining the viscosity of synovial fluid [9, 52].  
1.3.4.2. Osteoarthritis 
	
OA synovial fluid has shear-thinning behaviour in accordance with synovial fluid from a 
healthy subject, but with lower viscosity at the same shear rates [47, 48, 53] (Table 1.5.). This 
is attributed to the decreased HA concentration due to dilution (higher volume of synovial 
fluid) and its lower molecular weight (106 Da) due to depolymerisation in OA [9]. 
Depolymerisation is caused by specific components present in blood, such as ascorbic acid, 
produced by the increased amount of leukocytes in the diseased synovial joint [54]. With lower 
viscosity, the synovial fluid is no longer able to provide lubrication and protection of the bone 
[9].  
1.3.4.3. Rheumatoid arthritis 
	
The synovial fluid in RA contains a smaller amount of HA compared to the OA fluid, with the 
molecular weight of HA in RA synovial fluid being higher (compared to OA), but still lower 
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than in healthy state synovial fluid (Table 5) [9]. This can explain its Newtonian properties 
(shear thinning behaviour) in comparison with the non-Newtonian properties of healthy and 
OA synovial fluids [50], resulting to the viscosity not being highly affected by the changing 
shear rate [48, 53]. The components of synovial fluid change similarly to OA due to the disease 
state affecting the concentration and molecular weight of HA [9].  
	
Table 1.5. Viscosity vs. shear rate of healthy and disease state synovial fluid  
Shear rate (1/s) Mean (Pa s) 
Viscosity 
Range (Pa s) 
Subjects Age State Reference  
0-5 - 0-0.5 6 <40 healthy [49] 
0.1-1000 - 0.1-100 3 43-48 healthy [48] 
0.001-1000 - 1-40 200 - healthy [53] 
0.001-1000 - 6-175 7 ~60 healthy [51] 
0.001-1000 - 0-10 4 - healthy [52] 
0.01-100 - 0.01-10 4 40-48 healthy [50] 
       
0.1-1000 - 0.01-0.5 4 - OA [48] 
0.001-1000 - 0.1-1 200 - OA [53] 
0.01-1000 - 0.01-10 22 - OA [47] 
       
0.1-1000 - 0.01-0.05 4 - RA [48] 
0.001-1000 - 0.004-0.007 200 - RA [53] 
	
1.4. Intra-Articular injection pathways  
When drug molecules are administered into the synovial fluid via IA injection, they follow 
specific pathways through the joint as shown in Fig. 1.4. 
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Fig. 1.4. Drug transport and distribution through synovial joint. Reproduced with kind 
permission from [1] 
The drug molecules can, simultaneously, bind to components of the synovial fluid, spread to 
the synovium and articular cartilage or be uptaken by the chondrocytes and synoviocytes 
present in the articular cartilage and synovium respectively [1]. 
In summary, the pathways followed by the drug after IA delivery according to the size of the 
drug molecules are [3, 55]:  
Less than 60 nm: The first pathway (Fig. 1.5. B) is through convective transport between the 
liquid articular cartilage matrix and the nanoparticulates containing the drug. This takes place 
during the dynamic compression of the cartilage (due to applied pressure through movement) 
where the nanoparticulates are integrated between the collagen fibres of the extracellular matrix 
or they can also be integrated within the chondrocytes of the articular cartilage [56]. Studies 
have shown that nanoparticles with a mean volume diameter of 31 and 38 nm were able to 
enter the articular cartilage ECM, whereas larger nanoparticles with a mean volume diameter 
of 96 nm could not. This was attributed to the 60 nm pore size of the dense collagen network 
[57].  
Between 1-10 µm: The second pathway (Fig. 1.5. A) is through phagocytosis by type A 
synoviocytes (macrophages) located in the synovium. In this pathway, the drug entrapped in 
the formulation can either be released within the targeted type A synoviocytes or transferred 
through the cell junction into the subsynovium. In this case, particles of size < 250 nm can 
escape freely from the joint cavity, whereas those with a diameter between 1-10 µm are 
effectively phagocytosed by the synovial macrophages [55, 58-60]. 
Between 35-105 µm: The third pathway (Fig. 1.5. C) involves the synovial fluid at which the 
formulation (microparticulates) either adhere to the articular cartilage and synovium or 
becomes entrapped inside the synovial folds. The drug is then dissolved into the synovial fluid 
and transfers via passive diffusion to the tissues, lymphatic system and capillaries of the joint, 
being cleared into the systemic circulation due to the transynovial flow [61-63]. The 
appropriate size of microspheres without causing harmful effects has been tested in rats and 
was 35-105 µm [64].  
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Fig. 1.5. Pathways followed by drug molecules after IA injection: A. Phagocytosis by Type A 
synoviocytes. B. Convective transport of drug nanoparticulates into the cartilage matrix. C. 
Microparticulates in synovial fluid adhering to the articular cartilage and synovium   
Reproduced with kind permission from [2]. 
1.5. Advantages and disadvantages of Intra-Articular drug administration 
	
The IA drug delivery has a vast number of advantages and disadvantages which define its 
effectiveness and safety. This type of delivery is localised, performed directly into the site of 
action (joint) and so systemic exposure is minimised which means that side effects of the drug 
distributed are also reduced [3, 4]. Due to the direct delivery, the amount of drug needed to 
achieve high concentrations in the joint is quite low which means lower toxicity and fewer side 
effects. Furthermore, due to the high concentration of the drug localised in the joint, there is a 
high efficacy, so drugs developed for IA delivery may have a low bioavailability [4]. 
	
Despite these advantages, there are still drawbacks associated with IA delivery. The most 
common ones are pain caused by administration and the discomfort caused by needle 
placement, reducing patient compliance. The cost and time needed to perform IA injections 
also provide a negative aspect [4, 65] as they might be quite challenging and a specialist may 
be needed to perform the injection correctly [66]. Another issue is the possible risk of infection 
and induction of septic arthritis [67], as during administration bacteria may contaminate the 
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joint space leading to the number of IA injections per year reduced to the minimum possible 
(every 3-4 months) [68, 69]. One of the most significant challenges met in IA delivery is the 
residence time of the drug, which can be quite short and the efflux is rapid, due to the quick 
uptake of the drugs through blood circulation [4, 70]. The clearance is rapid as the direct 
equilibrium between the synovial fluid and the blood circulation is regenerated very fast, even 
though, it is falsely considered that the synovial fluid is “entrapped” by the synovium. This is 
due to a discontinuous layer of synoviocytes on the synovial surface, with no presence of a 
basement membrane and with intercellular gaps of 0.1-5.5 µm, allowing a more direct 
continuity between the synovial cavity and the intercellular spaces of the synovium. The 
synovial joint is in direct equilibrium with the rest of the circulation, so absorption and re-
distribution is about the same between IA delivery and other non-intravenous parenteral routes 
[69, 71]. 
	
1.6. Current available IA drugs/formulations and future research 
	
A vast amount of studies have been done to develop IA formulations with a continuous 
controlled release and sufficient drug retention in the joint cavity for a prolonged period of 
time. The “ideal” formulation should have [2]: 
• Particle size according to the tissue targeted in the joint 
• Particles with good drug loading capacity 
• Biocompatible drug carrier which when degraded will not be toxic 
• Sterility 
The available drugs for IA administration are specific corticosteroids, HA and topical 
anaesthetic drugs given in combination with corticosteroids [72] (Table 1.6.). Corticosteroids 
provide anti-inflammatory, immunosuppressive action that can increase mobility and reduce 
joint deformity [73], while HA is an effective lubricant providing anti-inflammatory activity 
and also relieves pain [74]. The local anaesthetic provides an additional temporary analgesic 
effect and is administered in combination with the corticosteroid. The formulation containing 
the anaesthetic is Depo-Medrol® with lidocaine (Pfizer), containing methylprednisolone 
acetate (40 mg/mL) and lidocaine hydrochloride (10 mg/mL). 
For the IA drug delivery to be more efficient, several delivery systems such as 
micro/nanoparticles, liposomes and hydrogels are in pharmaceutical development to offer a 
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prolonged release of the drug over a period of time (weeks/months), which may also reduce 
the number of injections. The formulations available in the market for IA, are solutions, 
suspensions, hydrogels, and a liposome formulation (Lipotalonâ) licensed only in Germany. 
The active ingredient of Lipotalonâ (Merckle Recordati) is dexamethasone 21-palmitate, 
encapsulated in lecithin coated vesicles with a particle size of  ~200 nm [75]. In some 
occasions, the formulations are available in dry powder form re-suspended with sterile water, 
mostly due to stability issues [4].  Comparing the residence time in the joint of poorly soluble 
glucocorticoids administered in suspension or solution, suspensions tend to stay longer in the 
joint, as molecules already dissolved are easily cleared from the synovial cavity in comparison 
to suspended particles which dissolve in the joint before exiting via lymphatic clearance [76, 
77]. Other studies show that when a steroid is used via IA delivery in its crystalline form 
compared to a non-salt form, the drug retention is increased, as the drug is complexed with the 
salt and so isolated from the synovial fluid which leads to a slower clearance from the synovial 
cavity. This might not reduce the side effects of corticosteroid injections but it may provide 
increased anti-inflammatory potential [78-81]. 
1.6.1. Liposomes 
	
Promising formulations under development, for increased drug retention in the joint include 
liposomes, with drug activity potentially extending and due to encapsulation, the formulation 
may become more biocompatible [35]. The potential use of liposomes for increasing drug 
retention time was first studied in the late 70’s, showing promising results with an increase in 
cortisol palmitate efficacy compared to free cortisol [82]. A liposomal formulation of 
triamcinolone also showed that encapsulated triamcinolone had better efficacy than free 
triamcinolone due to the extended residence time of the drug delivery system after the IA 
injection in rabbits, while similar results were shown with clodronate compared to the free drug 
[83, 84]. Other studies involving radio-labelled methotrexate showed that the liposomes used, 
accumulate in the synovial membrane, where they slowly dissolve releasing the drug [85, 86]. 
Another study showed that liposomes can reduce inflammatory reactions that can be 
experienced with crystalline suspension formulations of glucocorticoids, highlighting the 
biocompatibility of this formulation [87]. Drawbacks of liposomes include the osmolarity and 
surface charge inside the formulation interfering with stability, reducing the effectiveness of 
the drug and its delivery [84].  
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1.6.2. Nano and Microparticles 
	
Nano- and micro-particles have been developed mostly targeting the articular cartilage (Fig. 
1.5. B). The efficacy of microparticles is shown with studies such as the reported prolonged 
half-life of triamcinolone and prednisolone when encapsulated with albumin microspheres (23 
µm) and also in studies with albumin microspheres loaded with diclofenac sodium, which 
provided an extended release of drug in the joint [88]. The most suitable size of microparticles 
used for IA delivery is proven to be 1-10 µm as they become captured by the synovial 
macrophages (similar action as phagocytosis) increasing their residence time in the joint [55]. 
Encapsulating iodide into albumin microspheres of a size lower than 6 µm, leads to a slower 
drug clearance in rabbit joints due to the uptake by synovial macrophages [89-92]. Smaller 
particles have been shown to be phagocytosed more easily. Comparing PLGA nanospheres 
(265 nm) and microparticles (26 µm) encapsulating betamethasone sodium phosphate, showed 
that the nanoparticles have a more potent action (increased drug concentration in damaged 
cells, drug stayed longer in the joint and side effects were reduced) [59]. With even smaller 
nanoparticles, a study in which collagen II binding peptides were used for coating, showed that 
nanoparticles lower than 60 nm would enter the cartilage matrix through convective transport 
and use it as a reservoir, but larger nanoparticles due to the dense collagen II network would 
not be able to access the matrix.  (Fig. 1.5. B). [56, 90]. Extended retention in the joint has also 
been shown with encapsulation material such as gelatin microspheres which contained 
flubiprofen, showing that the drug may stay for more than 24-h in the joint compared to injected 
flubiprofen with a retention time of 8-h [93]; chitosan microspheres containing celecoxib, 
where the drug release and the entrapment efficiency was shown to be dependent on the 
concentration of chitosan and other factors such as SPAN-85 and glutarldehyde which were 
part of the microspheres [94]; calcium alginate encapsulating TGF-β growth factor, that was 
released in a slow and steady rate (~0.3% per hour) in the target area improving the repair rate 
of the articular cartilage [95]; poly (l-lactic acid) microspheres encapsulating methotrexate 
compared to methotrexate solution (both through IA injection), showing a higher concentration 
in the synovial tissues and a higher retention time [96] and PLGA [poly(lactic-co-glycolic 
acid)], which were compared with Bovine Serum Albumin (BSA) loaded microspheres (both 
with Naproxen Sodium) showing that PLGA was more promising for a longer retention time 
in the joint [97, 98]. One of the problems with nanoparticles and microparticles is the burst 
release effect, during which the drug release is not in a slowly controlled manner. This leads to 
a higher concentration present in the joint after the burst release, creating problems such as 
	 38	
increased side effects for drugs administered frequently. In addition, developing 
macromolecules, peptides, proteins and generally soluble materials for drug encapsulation (e.g. 
by using a mixture of gelatine and chondroitine sulphate) is far more complex compared to the 
manufacturing of PLGA coated particles that require usage of organic solvents and increase in 
temperature [99] leading to albumin or PLGA being the most commonly used, also due to their 
biocompatibility and biodegradability. 
1.6.3. Hydrogels 
	
Hydrogels are insoluble colloidal dispersions that can swell in water mainly due to their 
macromolecular chains. Swelling seems to minimize non-wanted particles entering the joint 
through the injection and it can also provide a higher biocompatibility to the formulation [97]. 
Hydrogels mainly contain hydrophilic chains of homopolymers or copolymers which are 
connected via cross-linking [100]. Because of their semi-solid structure, hydrophilic 
environment and ability to increase retention time of the encapsulated drug, they show 
significant potential in IA drug delivery [101-103]. The hydrogel formulation may be available 
for corticosteroids and also for encapsulating HA [4]. An important type of hydrogel studied, 
is the stimuli-responsive polymers [poly(ethylene oxide) based photo-polymerising hydrogel 
and sodium alginate gels] which are made after phase transition under external factors (e.g. 
temperature and light) and were used to deliver growth factors TGF-b1 and IGF-I [103-106]. 
The examination of synthetic acrylic hydrogel microspheres for IA delivery was also 
performed to show whether it would provide improved residence time in the joint and reduced 
side effects with results being positive as the hydrogels were present in the synovial membrane 
and fluid degrading in a slow manner, increasing the retention time with less side effects [97]. 
Hydrogels also have certain drawbacks influencing their effectiveness, such as the potential 
cytotoxicity of the chemically cross-linked hydrogel which may cause problems in the in-vivo 
applications [107, 108]. 
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1.7. In-vitro dissolution testing for intra-articular formulations 
	
1.7.1. Compendial dissolution 
	
In the pharmaceutical industry, in-vitro drug dissolution testing is an important tool for 
evaluating and demonstrating product performance and product control. More specifically:  
• Quality control for assuring consistent batch to batch release and conformance to 
product specifications as a discriminating tool 
• Indirect measurement of drug availability, release, stability and effectiveness in 
formulation and drug development 
• Biopharmaceutical characterisation of product (chemical elucidation, physical 
characterisation, pre-formulation data) 
• Substantiation of label claim of product (showing product efficacy) 
• Assess critical manufacturing and formulation variables that might influence 
bioavailability 
• Compedial testing 
• Biorelevant testing with in-vitro in-vivo correlation (IVIVC) (reducing the regulatory 
burden of bioequivalence testing)  
[1, 31, 109-111] 
As parenteral formulations include solutions, suspensions, emulsions, sterile powders for 
solutions and suspensions, developing a single compendial dissolution method to determine 
quality control and product performance for such various types of parenteral drug products 
becomes challenging [112]. Compendial dissolution tests will offer the possibility to optimise 
the therapeutic effectiveness of the product during development, with limited ability to assess 
biopharmaceutical properties and predict results of in-vivo bioavailability and behaviour [111]. 
Until today, there is a lack of regulatory standards available for testing in-vitro drug dissolution 
from parenteral formulations, including IA formulations[1, 31, 112, 113]. The methods 
currently studied and used for this type of products are divided into three categories which are 
briefly described below (in detail, Chapter 2 Introduction): 
• Sample and separate method 
• Continuous flow through method 
• Dialysis membrane technique 
[31, 110, 114]. 
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1.7.1.1. Sample and separate method 
	
The sample and separate method (Fig. 1.6.) involves the drug being placed in a flask (or vial) 
containing the dissolution medium, usually positioned in a water bath. Drug release from the 
formulation is measured in specific time intervals. After sampling, centrifugation and filtration 
of the supernatant takes place to remove any undissolved drug [115]. 
    
Fig. 1.6. Sample and separate methodology. Reproduced with kind permission from [116] 
	
1.7.1.2. Continuous flow through (USP apparatus IV) method 
	
The continuous flow through method with the USP apparatus IV, consists of the medium flown 
through a pump and into the flow through cell (Fig. 1.7.), causing elution, while containing 
mainly glass beads and the drug formulation. A filter is placed in the top (“filter head”) of the 
cell, above the existing sieve, in order to avoid removal of undissolved drug from the cell, with 
the dissolved drug eluate filtered through and collected for analysis [117, 118]. 
 
Fig. 1.7. Open system setup with USP apparatus IV. Reproduced with kind permission from 
[118] 
 
The amount of glass beads and type of filter with adequate loading capacity should be carefully 
chosen as obstructions in the flow through cell may cause back-pressure against the desired 
flow [31, 119]. 
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1.7.1.3. Dialysis membrane technique 
	
A basic setup of the dialysis bag technique consists of the drug formulation being placed into 
the bag which is then placed in a vessel containing buffer (Fig. 1.8.). The drug dissolves inside 
the bag and diffuses from the dialysis bag into the receptor phase [115]. Agitation in the vessels 
eliminates the unstirred water layer, leading to a homogeneous sample with a faster diffusion 
rate through the membrane and into the receptor phase. The commonly used types of membrane 
include regenerated cellulose [113, 115], microporous cellulose [120] or cellulose acetate 
[121]. For sink conditions to be present, the volume of the media should be at least three times 
higher than the volume in which the drug would saturate according to the USP guidelines [116]. 
A more advanced model of dialysis used for IA dissolution testing, is shown through a three-
compartment oil/water model in Fig. 1.9. [122, 123]. The oil drug solution ([X]o) is placed in 
the aqueous donor compartment ([X]Dw) and the dialysis membrane separates it from the 
aqueous acceptor compartment ([X]A). The drug, after dissolving, diffuses through the dialysis 
membrane due to the concentration gradient between the two compartments as drug molecules 
transfer from areas of higher to lower concentration [124]. This continues until an equilibrium 
of drug molecules will be present between both phases.  
 




Fig. 1.9. Three compartment model (due to oil-water separation). [X]o is the oil drug solution, 
[X]Dw is the aqueous donor compartment and [X]A is the aqueous acceptor compartment. 
Reproduced with kind permission from [122] 
	
1.7.2. Biorelevant dissolution 
	
In summary (Chapter 4 Introduction, in detail), it is vital to design biorelevant dissolution tests 
for parenteral drugs, performed under simulated in-vivo conditions, mimicking in detail how 
the drug dissolves in the body. Biorelevant dissolution tests may reduce the amount of 
bioequivalence studies performed in various stages of the drug/formulation approval process, 
improve product quality and reduce relevant regulatory procedures [125]. The choice of 
apparatus is also important in order to resemble with more precision in-vivo conditions, with 
specifically designed setups or modifications of already established apparatus. Importance is 
also given to establishing suitable instrument parameters and appropriate biorelevant media 
(Chapter 3 Introduction, in detail).  
At the moment, validated biorelevant dissolution methods for parenteral formulations, 
including IA, do not exist. For IA formulations, biorelevant dissolution would be performed 
under simulated in-vivo conditions for predicting the dissolution of drugs administered into the 
joint and subsequently the synovial fluid, for providing a more accurate prediction of in-vivo 
behaviour. Artificial synovial fluids have been previously developed, mostly for tribological 
and rheological testing purposes [12, 45, 126, 127] and so may not contain all appropriate 
components that would affect the dissolution of the drug inside the synovial cavity with a result 
of not effectively predicting in-vivo performance. 
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1.8. Thesis aims and objectives 
This project aims at developing compendial and biorelevant in-vitro dissolution studies for IA 
formulations. The main target is to evaluate the applicability of setups such as USP apparatus 
and UV imaging on the dissolution of IA drug formulations. A vital part is to evaluate the 
parameters of the tested systems such as hydrodynamics and formulation variables that would 
affect drug dissolution of IA formulations, to design a refined compendial method, used for 
characterising the drug product and ensuring reproducible product quality. Our approach was 
to test methods currently studied such as USP apparatus I, II, III, IV, the dialysis membrane 
and the bi-phasic system, with the discriminatory ability of the most suitable system being 
evaluated (Chapter 2). An important aspect we aimed for was to develop biorelevant synovial 
fluid in different states, to simulate the conditions found in the joint, according to in-vivo 
measurements of physicochemical properties and solubility measurements of Triamcinolone 
Acetonide (TA). By developing biorelevant synovial fluid media in three states (healthy state, 
OA and RA) reflecting changes in composition during the disease states and by choosing 
components according to the significance of their effect in the dissolution of the drug in the 
media, would lead to prediction of in-vivo performance (Chapter 3) through appropriate 
biorelevant tests (Chapter 4). The amounts of components added, were chosen according to the 
average amounts found in literature, while measurements of physicochemical properties of in-
vivo disease state synovial fluid (OA and RA) would guide the development of the biorelevant 
synovial fluid (BSF). Developing biorelevant dissolution tests for IA formulations involved 
the evaluation of the side-Bi-side diffusion cell in different setups mimicking the conditions of 
the joint and also a bi-phasic dissolution setup in which the organic phase is used as the 
reservoir of the dissolved drug transferred from the aqueous phase, simulating the diffusion of 
the dissolved drug from the synovial joint into the blood circulation. Variables of these setups 
are evaluated towards their effect in drug dissolution, while the developed biorelevant synovial 
fluids are applied to simulate in-vivo behavior and improve the biorelevance of the tested 
system (Chapter 4). Finally, to fully investigate the drug dissolution process and to have a better 
understanding of the events taking place near the surface of the IA drug under test, the use of 
UV imaging as a dissolution test for IA formulation is described, with parameters of the sample 
preparation process optimised. The application of the UV imaging system for artificial synovial 
fluids in healthy and disease state is also described, evaluating the effect of the viscosity of the 
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Purpose: To develop appropriate compendial dissolution tests for IA formulations and 
investigate the effect of various dissolution method parameters on drug dissolution. 
Methods: Different setups of dissolution tests and apparatus accepted by the Pharmacopoeia 
were evaluated such as the USP apparatus I, II, III and IV, a dialysis membrane setup, a 
monophasic and bi-phasic setup. For each method, several factors were tested involving the 
hydrodynamics of the system, the formulation type and various dissolution media, to establish 
their impact on drug dissolution. Drug quantification was done with the HPLC and drug 
dissolution over time was measured.  
Results: Testing the USP apparatus I and III with the use of float-A-lyzers (ready to use 
dialysis membranes), generally did not lead to drug permeation through the membrane. The 
dissolution method designed with the USP apparatus IV in open system discriminated between 
particle sizes of TA, with all factors tested showing significant effect on drug dissolution. The 
results with the bi-phasic setup dissolution method with the USP apparatus IV in closed system, 
showed that most of the examined factors would affect mostly the partitioning of the drug 
rather than the dissolution rate. Changing the aqueous and organic phase ratio in the system or 
the size of the oil/water interface area between the two phases, resulted in a dissolution rate 
faster than the partitioning rate. Regarding the dialysis studies performed in glass bottles, 
having a high difference of osmolality between the aqueous and organic phase (due to the 
presence of methanol in the receptor phase), a larger dialysis membrane surface area or an 
increase in the temperature of the dissolution medium, would lead to the drug dissolving and 
permeating through the membrane in a significant rate. Results were consistent with the 
hypothesis that the osmolality gradient drives dissolution from IA formulations and permeation 
through the dialysis membrane faster than permeation due to the concentration gradient. 
Conclusions: A better understanding of the factors involved in the performed dissolution tests 
provides higher feasibility to develop a compendial dissolution method for IA formulations. 
The promising results from the continuous flow through cell method (USP apparatus IV) may 





IA administration is a type of parenteral injection taking place in the synovial joint [1-3]. Long 
acting corticosteroid and HA formulations [4, 5] are used today in diseases such as OA and RA 
as they provide anti-inflammatory effects in the joint cavity. IA injections are administered in 
patients with moderate to severe pain and inflammation, who do not respond appropriately to 
oral analgesic and anti-inflammatory agents [3, 6]. The IA injection leads to a localised delivery 
of the drug, reducing side effects as systemic exposure is minimised [4, 7]. With a lower dose 
administered, appropriate concentrations of the drug can be present in the joint. Based on this 
fact, there are better efficacy drugs with low bioavailability that can have a potentially more 
significant effect [4]. By considering the structure of the synovial joint, when an IA formulation 
is injected in the synovial cavity, it can be retained due to the synovial membrane lining that 
separates the internal part of the cavity from the external blood and lymph vessels [8, 9]. The 
drug can then follow different pathways, primarily according to its particle size, following IA 
injection: i) Phagocytosis and transfer of the drug molecules to the synovial membrane or 
subsynovium [10, 11], ii) convection of drug molecules with the articular cartilage or ECM 
[12] and iii) dissolution of drug molecules in the synovial fluid and transfer to the articular 
cartilage and synovium, or entrapment inside synovial folds [13, 14]. 
	
To demonstrate the rate with which the tested drug will dissolve in the joint, it is of vital 
importance to have a suitable in-vitro dissolution model that can also provide an appropriate 
characterisation and evaluation of the IA formulation under test [15]. Currently, there is no 
regulatory approved, standard compendial method for assessing drug dissolution from 
parenteral formulations, including IA formulations [16]. To develop an appropriate dissolution 
method, it is essential to study and define the effect of various factors of different dissolution 
methods on drug dissolution. Dissolution can be affected by drug substance factors, dosage 
form factors and may vary according to the methods used for its assessment [17]. The 
dissolution method development consists of the selection of appropriate media and suitable 
hydrodynamics and also the understanding of their effect on the drug dissolution. By having a 
better understanding of these factors, it becomes more feasible to develop a compendial 
dissolution method for IA formulations. 
Dissolution testing is an important tool in the pharmaceutical industry as it has primary 
significance in drug/formulation development and quality control [18]. An official compendial 
dissolution method would be used to set specification criteria for ensuring product quality 
	 61	
(batch-to-batch consistency), while providing a biopharmaceutical characterisation of the 
product and so defining critical formulation variables of dissolution [16, 19]. Since there are 
significant differences in the formulation design between dosage forms, leading to different 
physicochemical and dissolution characteristics, a single dissolution method cannot be a good 
fit for all. A suitable dissolution technique and an apparatus with appropriate hydrodynamic 
conditions should be used to accommodate the dosage form in test. 
	
For formulation development and quality control testing of parenteral (including IA) 
administered drugs, the in-vitro dissolution methods that are widely used according to literature 
are: i) sample and separate methods [20, 21], ii) continuous flow methods [22] and iii) dialysis 
techniques [23].  
The sample and separate method has been a widely used technique for testing drug dissolution 
from parenteral systems [24]. This method involves the drug formulation being placed into a 
vessel which contains the media and samples taken over time to assess drug dissolution. 
Centrifugation or filtration of the sample is an important step, to remove any undissolved drug 
before measuring dissolution [25]. Parameters that can affect the amount of drug dissolved 
include the container size, the type of agitation and the methods of sampling [24].  
The dialysis membrane method seems to be an interesting option for the dissolution testing of 
parenteral formulations (including IA). A small volume drug-donor phase is present in a 
membrane, separated from the larger volume receptor phase containing the buffer [26]. In the 
dialysis method, there are three steps that may be rate limiting to the dissolution/permeation of 
the drug: i) the dissolution of the drug in the donor phase, ii) the migration of the drug to the 
membrane and iii) the permeation of the drug through the membrane and into the receptor 
phase [27]. As the dissolution of the drug and its permeation through the membrane can take a 
long time [16] accelerated dissolution techniques may be appropriate for providing a rapid 
evaluation of the dissolution method in test [26]. It is suggested that the receptor phase volume 
should be at least 6- to 10-fold higher than the volume present in the dialysis membrane in 
order to have a driving force present for drug diffusion [24] or the saturation solubility of the 
drug tested should be at least three times above the drug concentration in the system [28] for 
appropriate sink conditions to be present in the receptor phase. 
The continuous flow cell method has been mostly suggested for dissolution testing of 
parenteral formulations, with the drug placed on glass beads in an appropriate cell according 
to the formulation type [25, 29]. Two setups can be used, an open system with the medium 
flowing through the cell and then being collected, or in a closed system where the medium is 
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circulated through the cell and back to the medium reservoir [30]. A combination of a bi-phasic 
method with the use of the flow through cell method (USP apparatus IV) could also provide 
meaningful results, by taking into account that low solubility drugs would lead to non-sink 
conditions in the closed-monophasic system setup (one aqueous phase) [24]. The use of a bi-
phasic dissolution model (aqueous and organic phase in equilibrium) can be used to facilitate 
the achievement of sink conditions with a smaller volume of medium in use compared to an 
open system. The setup involves an aqueous medium and an immiscible organic solvent, with 
the drug being dissolved in the aqueous phase and then partitioning into the organic layer. The 
organic phase in this setup acts as a reservoir in which the dissolved drug can diffuse, allowing 
more drug to dissolve in the aqueous medium [28]. The dissolution of the drug in the aqueous 
layer and then the partition to the organic phase takes place by exploiting the lipophilicity 
(logP) of the drug. In  a bi-phasic system, it is important for the aqueous layer not to be saturated 
and also for the total dose of drug studied to be less than 20% of its solubility, in the volume 
of organic phase in the bi-phasic system [28, 31], for sink conditions to be maintained.  
	
In the present study, the aim of our research was to design a developed and refined compendial 
method, used for characterising the drug product and ensuring reproducible product quality. 
Various parameters of the dialysis membrane method were assessed, such as the effect of 
surfactant, increase in osmolality in each phase, membrane length and dissolution medium 
temperature, addition of medium in donor phase and addition of organic solvent in the receptor 
phase in order to find appropriate method conditions and also to determine their effect in drug 
dissolution. Furthermore, different parameters of the USP apparatus IV affecting the 
hydrodynamics of the system were also evaluated according to their effect on drug dissolution, 
such as the effect of flow rate, cell size and different surfactant type added to the dissolution 
medium. The effect of the formulation type tested and the cell setup involving the placement 
of the drug in the USP apparatus IV cell were also investigated as they may have a vital part in 
drug dissolution [25]. The bi-phasic setup was combined with the continuous flow cell method 
for assessing parameters that would affect drug dissolution and partitioning to the organic 
phase such as the addition of surfactant in the aqueous phase, flow rate, cell size, volume of 
the phases, organic solvent and oil/water interface area. The synthetic corticosteroid TA has 
been chosen as a model drug due to its physical properties. A weak base with a pKa of 11.75 
and a low solubility of 17.5 µg/mL in water [32] and 5.2 mg/mL in octanol [11], it has similar 
values to the remaining corticosteroids administered through the IA route. TA has been used 
to evaluate different dissolution setups, intended for IA formulations. The tested suspensions 
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are Kenalog 40® (TA, 40 mg/mL) and Adcortyl® (TA, 10 mg/mL), while a microparticle 
formulation in two sizes containing TA was also developed for testing dissolution method 




































TA (98+%, fine chemical) was purchased from Alfa Aesar (UK), Kenalog 40® (40 mg/mL) 
and Adcortyl® (10 mg/mL), both IA suspensions of TA, were purchased from Bristol-Myers 
Squibb (UK). For all experiments, ultra-pure (Milli-Q purification device) water was used. The 
composition of PBS included sodium chloride (≥ 99.9%), potassium dihydrogen 
orthophosphate (≥ 99.5%), di-sodium hydrogen orthophosphate, anhydrous dried (≥ 99.5%) 
and potassium chloride (≥ 99.5%) purchased from Sigma-Aldrich (UK). Tween 80 
(polysorbate) was bought from VWR (UK) and sodium dodecyl sulphate (SDS/SLS) (≥ 99.0%) 
and CTAB (≥ 99.0%) were purchased from Sigma-Aldrich (UK). For the experiments with 
alterations in osmolality, sucrose and di-potassium hydrogen orthophosphate (≥ 99.5%) were 
purchased from Sigma-Aldrich (UK). The organic solvents used, methanol (MeOH), ethanol 
(EtOH) and ethyl acetate (all HPLC grade), were also purchased from Sigma-Aldrich (UK) 
while 1-octanol (99%, pure) was purchased from Fisher Scientific (UK). Cellulose acetate 
dialysis membranes (MWCO: 14 kDa) were purchased from Sigma-Aldrich (UK) while the 
pre-assembled dialysis tubes, Spectra/Por Float-A-lyzer, (MWCO: 25 kDa, volume size 1 mL) 
cellulose ester dialysis membranes were kindly donated from Agilent (US). Whatman glass 
fibre filters (GF/F 0.7 µm pore size, GF/D: 2.7 µm pore size) and hydrophilic polysulfone 
membrane disc filter (HT Tuffryn, 0.2 µm, Sigma-Aldrich, UK) were used in the USP 
apparatus IV experiments. For the development of nanoparticles poly-(l-lactide) (PLA) with 
inherent viscosity of ~1 dL/g, 0.1 % (w/v) in chloroform (25 oC), dichloromethane and poly 
(vinyl alcohol) (MW: 30,000-70,000) were purchased from Sigma-Aldrich (UK). 
	
2.2.2. Solubility studies 
	
The solubility of TA in PBS, PBS with methanol (50% v/v) and PBS with surfactants [PBS 
with Tween 80 (1% v/v), PBS with SLS (1% w/v) and PBS with CTAB (1% w/v)] was 
determined at 37 oC. The shake-flask method was used with an excess amount of TA added to 
the medium in test (n=3). The suspensions were then shaken in a water bath at 37 ± 0.5 oC 
(Grant SBB Aqua Plus, UK) for 24-h. Samples were then withdrawn, filtered with 0.45 µm RC 
filters and diluted with the corresponding medium where appropriate before analysis, with the 
amount of TA then quantified in the HPLC. 
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2.2.3. Measurement of osmolality 
	
Osmolality values were measured in triplicate by freezing-point depression of the media using 
an Advanced Micro-Osmometer Model 3300 (Advanced Instruments Inc.)  
	
2.2.4. Development of Triamcinolone Acetonide loaded microparticles 
	
2.2.4.1. Preparation of microparticles 
	
Microparticles were developed according to a modification of a published o/w emulsion-
solvent evaporation method [33, 34] with the modification related to the sonication power and 
sonication duration. PLA polymer (200 mg) was dissolved in 5 mL dichloromethane and was 
then added to a 1 mL suspension of TA (100 mg) in dichloromethane. The drug polymer 
solution was then transferred to 30 mL of pre-chilled aqueous polyvinyl alcohol (2% w/v), 
acting as the emulsifier, in an ice bath under sonication to prepare an o/w emulsion. The 
sonication took place with the use of a probe sonicator (Branson, Digital Sonifier, US) with a 
power of 10 W for 1 min (Microparticles b, MPb) and at 20 W for 2 min (Microparticles a, 
MPa). The primary o/w emulsion obtained after the sonication was then transferred to 100 mL 
of chilled aqueous polyvinyl alcohol solution (2% w/v) in an ice bath under probe sonication. 
The sonication was done at 30 W for 3 min for both size microparticles to stabilise the 
emulsion. Afterwards, the emulsion obtained was stirred for 3-h in room temperature on a 
magnetic stirrer (to evaporate the organic solvent and harden the microparticles). The 
microparticles formed were then centrifuged for 20 min at 28,000 x g at 4 oC using a centrifuge 
(Beckman Coulter, J2-MC High Speed Centrifuge, UK) to obtain a pellet of microparticles. 
The microparticle pellet was then washed twice with 30 mL distilled, de-ionized water for 
further removal of any free drug present or other additives. The final pellet was then re-
dispersed in 10 mL distilled, de-ionized water and frozen by storing at -80 oC for 30 min. 
Finally, after freezing, the microparticles were lyophilized in a freeze dryer (Labfreez FD-10 
Series, UK) at -40 oC and at a pressure of 0.1 mBar for 24-h. 
	
2.2.4.2. Characterisation of microparticles 
	
2.2.4.2.1. Particle size 
	
Lyophilized particles (1 mg) were re-suspended in 5 mL of distilled, de-ionized water for 
measuring particle size and size distribution with the use of a Mastersizer X standard bench 
and a Small Volume Sample Dispersion Unit (MAM 5000, Malvern Inc., US). The particle 
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size and size distribution for Adcortyl® and TA powder in PBS (10 mg/mL) was measured with 
the same equipment. 
	
2.2.4.2.2. Surface morphology of particles 
	
The surface morphology was examined with a scanning electron microscope (Jeol, SEM 
6480LV, UK). The particles were mounted on a piece of carbon sticky aluminium stubs and 
stored in a desiccator overnight to remove the residual moisture. Following this, they were 
sputter coated with a thin layer of gold (SC7620 sputter coater, Quorum Technologies Ltd., 
UK) to reduce charging and improve image quality. Images of TA microparticles were then 
collected. 
	
2.2.4.2.3. Drug content of particles 
	
5 mg of lyophilized TA loaded microparticles were dissolved in 25 mL dichloromethane and 
the solution was stirred for 1-h at room temperature. From this solution, 1 mL was mixed with 
50 mL of methanol, in order to measure TA content with the HPLC. TA amounts were 
calculated according to a calibration curve (range 2-10 µm/mL) in methanol. Calibration curves 
were prepared with the use of a stock solution of TA in methanol (100 µg/mL). The working 
calibration standards were prepared by diluting the stock solution accordingly with the selected 
medium [35]. All measurements were performed in triplicates. Drug loading (%) and the 
encapsulation efficacy (%) were calculated based on: 
	!"#$	&'()*+$	 % = 	./00	12	3456	78	.7941:/4;79<=0./00	12	.7941:/4;79<=0 	×	100     (Eq. 1) A+B(CD#&(E*'+	FGG*B*F+BH	 % = 	 =I:=47.=8;/<	3456	<1/3786;J=14=;79/<	3456	<1/3786 	×	100   (Eq. 2) 
 
2.2.5. In-vitro dissolution studies 
	
2.2.5.1. In-vitro dissolution studies with USP apparatus I 
	
Dissolution experiments were performed with a USP apparatus I (Agilent 708-DS Dissolution 
Apparatus, UK) with the use of a dialysis membrane instead of the cylindrical baskets. The 
modification was designed in co-operation with Agilent and consisted of a special adjustment 
of the metal probe, with a specially designed plastic part placed instead of the basket, which 
on its end part, would fit the upper plastic cap of the Float-A-lyzer (ready-to-use lab dialysis 
membrane, volume: 1 mL) and would hold it in position. The Float-A-lyzers were pre-wetted 
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and treated for use according to the manufacturer (Spectrum, US). The dose used was 1 mL of 
TA suspension 40 mg/mL (Kenalog 40®). The Float-A-lyzer height in the USP apparatus I was 
adjusted according to the <711> Dissolution General Chapter of the US Pharmacopoeia which 
suggests that the bottom of the basket and the inside bottom part of the vessel should be in a 
constant distance of 25 ± 2 mm during the test. The volume of the dissolution medium [PBS 
or PBS with Tween 80 (0.5% v/v)], was 900 mL at 37 ± 0.5 oC and the rotational speed was 
set at 150 rotations per minute (rpm). At appropriate time intervals (every 30 min for 8-h) 5 
mL samples were withdrawn from the vessel with a glass syringe attached to a cannula, set at 
a specific height in the apparatus (half distance from the bottom of the vessel to the surface of 
the medium). 5 mL of fresh buffer was then replaced in the vessel and samples were then 
analysed with HPLC. The experiment was done in triplicate and results after the analysis of 
TA are presented as Mean (% dissolved over time) ± S.D. 
	
2.2.5.2. In-vitro dissolution studies with USP apparatus II 
 
A dissolution experiment was performed with the USP apparatus II (Agilent 708-DS 
Dissolution Apparatus, UK). The paddle height in the USP apparatus II was adjusted according 
to the <711> Dissolution General Chapter of the US Pharmacopoeia. The volume of the 
dissolution medium, PBS, was 900 mL, at 37 ± 0.5 oC and the rotational speed was set at 100 
rpm. A dose of 1 mL of TA suspension 40 mg/mL (Kenalog 40®) was placed into the vessel 
and at specific time intervals (every 10 min for 1-h and then every 30 min for 2-h) 5 mL samples 
were withdrawn from the vessel with a glass syringe attached to a cannula which was set at a 
specific height in the apparatus (half distance from the bottom of the vessel to the buffer 
surface). 5 mL of fresh buffer was then replaced in the vessel and all samples were diluted with 
PBS before analysis with the HPLC. The experiment was done in triplicate and results after 
the analysis of TA are presented as Mean (% dissolved over time) ± S.D. 
	
2.2.5.3. In-vitro dissolution studies with USP apparatus III 
	
Dissolution experiments were performed with a USP apparatus III (Agilent Bio-Dis 
Reciprocating cylinder apparatus, UK). The glass reciprocating cylinders commonly used were 
replaced with Float-A-lyzers. The modification was designed in co-operation with Agilent and 
consisted of a special adjustment to the inert fittings of the evaporation cap, which on its end 
part, would fit the upper plastic cap of the Float-A-lyzer (Ready-to-use lab dialysis membranes, 
volume: 1 mL) and would hold it in position. The Float-A-lyzers were pre-wetted and treated 
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for use, according to the manufacturer (Spectrum, US).  The dose used was 1 mL of TA 
suspension 40 mg/mL (Kenalog 40®) and the volume of PBS or PBS with Tween 80 (1% v/v) 
was 200 mL in each of the vessels, at 37 ± 0.5 oC and dip rates were set at 30 and 60 dips per 
minute (DPS). Samples were collected at appropriate time intervals (every 30 min for 5-h, 7-h 
and 72-h). The samples were analysed with HPLC. The experiment was done in triplicate and 
results after the analysis of TA are presented as Mean (% dissolved over time) ± S.D. 
	
2.2.5.4. In-vitro dissolution studies with USP apparatus IV  
	
Dissolution experiments were performed with the USP apparatus IV (Flow-through cell 
system) (Erweka DFZ 720, UK) connected with a piston pump (Erweka, HKP720). The small 
and large cells for tablets and capsules used in the experiments have three parts, the lower cone, 
the middle cylindrical portion and the filter head on top. A glass bead of 6 mm is positioned in 
the tip of each cell for tablets and capsules and on top, glass beads are added, to fill the cell up 
to the score of the tablet holder. The medium flows in tubes and enters the cell from the lower 
cone towards the filter head top. The cone and filter head are separated by a #40 mesh screen 
and added filter(s). The USP apparatus IV was used in two modes: open and closed. In the 
open system, fresh medium would flow continuously through the cell and would then be 
collected, while in the closed system, a specific volume of medium is recycled through the 
system [30]. The drug suspension was loaded onto the glass beads with a disposable dropping 
pipette. Samples for all experiments were collected with glass volumetric cylinders in specific 
time points, then were diluted with the corresponding medium, where appropriate, before 
analysing with the HPLC to determine the amount of TA dissolved. The % dissolved was 
calculated according to a calibration curve (2-10 µm) in the corresponding medium [35]. The 
experiments were performed at 37 ± 0.5 oC in triplicate and results are presented as Mean (% 
dissolved over time) ± S.D. 
	
2.2.5.4.1. Open Mode Setup 
	
2.2.5.4.1.1. Flow rate 
	
The flow rate (4, 8, 16 mL/min) was evaluated with the large cell and the small cell for tablets 
and capsules filled up to the score of the tablet holder with 1 mm glass beads. The filter top of 
the cell contained two glass fibre filters (GF/F: 0.7 µm pore size and GF/D 2.7 µm pore size). 
The dose used was 1 mL of TA suspension 40 mg/mL (Kenalog 40®) and the medium used 
was PBS. Samples were collected with glass volumetric cylinders every 15 min. 
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2.2.5.4.1.2. Cell size 
	
The cell size of the cell for tablets and capsules [internal diameter: 12 mm (small cell), 22.6 
mm (large cell)] was evaluated with the cell filled up to the score of the tablet holder with 1 
mm glass beads. The filter top of the cell contained two glass fibre filters (GF/F: 0.7 µm pore 
size and GF/D 2.7 µm pore size). The dose used was 1 mL of TA suspension 40 mg/mL 
(Kenalog 40®) and the medium used was PBS with a flow of 4 and 8 mL/mL. Samples were 
collected with glass volumetric cylinders every 15 min. 
	
2.2.5.4.1.3. Glass bead size 
 
The glass bead size (1 and 2 mm) was evaluated with the large cell and the small cell for tablets 
and capsules filled up to the score of the tablet holder with the glass beads. The filter top of the 
cell contained two glass fibre filters (GF/F: 0.7 µm pore size and GF/D: 2.7 µm pore size). The 
dose used was 1 mL of TA suspension 40 mg/mL (Kenalog 40®) and the medium used was 
PBS with a flow of 4 mL/min. Samples were collected with glass volumetric cylinders every 
15 min. 
 
2.2.5.4.1.4. Sample position 
 
The positioning of the sample was evaluated with three different cell setups (Fig. 2.1.). Fig. 
2.1. A is the setup described in 2.2.5.4.1.1. with the large cell for tablets and capsules in use. 
Fig. 2.1. B is the setup described in 2.2.5.4.1.1. with the large cell for tablets and capsules in 
use, with the difference of the filter head top part of the cell being replaced by the semisolid 
cell (an accessory part, set in the filter head instead of the sieve), with GF/F and GF/D filters 
placed above the sieve of the semisolid cell. The drug suspension in this occasion was placed 
inside the compartment of the semisolid cell, below the sieve. Fig. 2.1. C is the setup described 
in 2.2.5.4.1.1. with the large cell for tablets and capsules in use with the difference of a GF/F 
filter placed on the 1 mm glass beads and the suspension placed on top of that filter. The dose 
used was 1 mL of TA suspension 40 mg/mL (Kenalog 40®) and the medium used was PBS 
with Tween 80 (1% v/v) with a flow of 4 mL/mL. Samples were collected with glass volumetric 
cylinders every 15 min. 
 
2.2.5.4.1.5. Filter type 
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The filter type (GF/F + GF/D, HT Tuffryn) on the filter head top of the cell for tablets and 
suspensions was evaluated with the large cell for tablets and capsules filled up to the score of 
the tablet holder with 1 mm glass beads. The dose used was 1 mL of TA suspension 10 mg/mL 
(Adcortyl®) and the medium used was PBS with a flow of 4 mL/min. Samples were collected 
with glass volumetric cylinders every 30 min up to 1-h and the every 1-h up to 6-h. 
	
2.2.5.4.1.6. Surfactant type added to the dissolution medium 
 
The effect of the dissolution medium containing surfactant was evaluated, involving different 
types and concentrations of surfactants in PBS [Tween 80 (0.5, 1% v/v), SLS (1% w/v) or 
CTAB (1% w/v)] with the large cell for tablets and capsules filled up to the score of the tablet 
holder with 1 mm glass beads. The filter top of the cell contained two glass fibre filters (GF/F: 
0.7 µm pore size and GF/D 2.7 µm pore size). The dose used was 1 mL of TA suspension 40 
mg/mL (Kenalog 40®) and the medium had a flow of 4 mL/min. Samples were collected with 
glass volumetric cylinders every 15 min for 6-h. 
 
2.2.5.4.1.7. Drug concentration in the suspension 
 
The drug concentration in the suspension [TA suspension 40 mg/mL (Kenalog 40®) and TA 
suspension 10 mg/mL (Adcortyl®)] was evaluated with the large cell for tablets and capsules 
filled up to the score of the tablet holder, with 1 mm glass beads. The filter top of the cell 
contained two glass fibre filters (GF/F: 0.7 µm pore size and GF/D 2.7 µm pore size). The dose 
used was 1 mL and the dissolution medium was PBS with Tween 80 (1% v/v) with a flow of 
4 mL/mL. Samples were collected with glass volumetric cylinders every 15 min for 6-h. 
 
2.2.5.4.1.8. Particle size 
 
The particle size of the suspension [developed microparticle powder of small vs. large size re-
suspended in PBS, TA suspension 10 mg/mL (Adcortyl®) vs. TA powder in PBS 10 mg/mL] 
was evaluated in different conditions. Developed microparticle powder or small and large size 
were tested with the small cell for tablets and capsules filled up to the score of the tablet holder, 
with 1 mm glass beads. The filter top of the cell contained a HT Tuffryn filter. The amount of 
PLA-TA microparticle powder corresponding to 0.1 mg TA was suspended in 1 mL of PBS 
and the suspension was loaded on top of 1 mm glass beads in the small cell. The dissolution 
medium used was PBS with a flow of 4 mL/mL. TA suspension 10 mg/mL (Adcortyl®) vs. TA 
powder in PBS (10 mg/mL) were tested with the large cell for tablets and capsules filled up to 
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the score of the tablet holder, with 1 mm glass beads. The filter top of the cell contained two 
Whatman glass fibre filters (GF/F: 0.7 µm pore size and GF/D 2.7 µm pore size). The dose 
used was 1 mL of TA suspension 10 mg/mL (Adcortyl®) and 1 mL of PBS containing 10 mg 
of TA powder. The dissolution medium used was PBS with a flow of 4 mL/min. Samples were 
collected with glass volumetric cylinders every 15 min for 6-h. 
	
 
            A          B       C 
Fig. 2.1. Schematic diagrams showing the setup of the cell: A. Large cell with glass beads. B. 
Large cell with glass beads with semisolid cell in placed in filter top. C. Large cell with glass 
beads and GF/F filter placed on top of glass beads.  Modified from [29] 
	
2.2.5.4.2. Closed Mode Setup 
 
2.2.5.4.2.1. Monophasic dissolution setup 
	
The monophasic dissolution system experiments were performed with the use of a USP 
apparatus IV (Erweka, DFZ 720, UK) connected to a piston pump (Erweka, HKP720) in a 
closed system setup. The medium flows in tubes and into the cell from the lower cone towards 
the filter head top. In the closed system bi-phasic setup, the aqueous medium is pumped through 
tubing, circulating for each cell. An agitation of 300 rpm with a magnet in the bi-phasic system 
of the glass bottle was present. The volume used for the monophasic closed system was 60 mL 
of PBS with Tween 80 (1% v/v) and the dose used was 1 mL of TA suspension 40 mg/mL 
(Kenalog 40®) and the medium had a flow of 8 mL/min. The experiments were performed at 
37 ± 0.5 oC in triplicate and 1 mL samples were collected from both phases every 30 minutes 
for 1-h and then each hour until 6-h (with replacement of the corresponding medium). 
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2.2.5.4.2.2. Biphasic dissolution setup 
 
The two-phase dissolution system experiments were performed with the use of a USP apparatus 
IV (Erweka, DFZ 720, UK) in a closed system setup, with the dissolution medium placed in a 
glass bottle (Volume area of bottle for the small volumes used: 16.6 cm2 and for the larger 
volumes used: 58.1 cm2). The medium flows in tubes and into the cell from the lower cone 
towards the filter head top. In the closed system bi-phasic setup, the aqueous medium (saturated 
with the organic solvent) is pumped through tubing, circulating for each cell. An agitation of 
300 rpm with a magnet in the bi-phasic system of the glass bottle was present. The experiments 
were performed at 37 ± 0.5 oC in triplicate and 1 mL samples were collected from both phases 
every 30 minutes for 1-h and then each hour until 6-h (with replacement of the corresponding 
medium). Samples from the aqueous phase would be used to measure the amount of TA 
dissolved and samples from the organic phase would be used to measure the amount that 
partitions from the aqueous phase. Samples for all experiments were collected with glass 
syringes attached to a cannula which was set at a specific height in the glass bottle (half distance 
from the bottom of the vessel to the aqueous medium surface, for aqueous phase samples and 
half distance from the top of the aqueous medium surface to the top of the organic medium 
surface, for organic phase samples) every 30 min for 1-h and then every hour for 6-h, then were 
diluted with the corresponding medium, where appropriate, before analysing with the HPLC. 
The % dissolved and partitioned was calculated according to calibration curves (2-10 µm) in 
the corresponding medium [35]. The experiments were performed at 37 ± 0.5 oC in triplicate 
and results are presented as Mean (% dissolved over time) ± S.D. 
 
2.2.5.4.2.2.1. Surfactant in aqueous phase 
	
The effect of the dissolution medium containing surfactant was evaluated, involving different 
types of surfactants in PBS [Tween 80 (1% v/v) and SLS (1% w/v)] with the small cell for 
tablets and capsules filled up to the score of the tablet holder with 1 mm glass beads. The 
organic solvent used was 1-octanol. The filter top of the cell contained two glass fibre filters 
(GF/F: 0.7 µm pore size and GF/D 2.7 µm pore size). The volumes used in the glass bottle were 
for the aqueous phase 40 mL and the organic phase 10 mL or for the aqueous phase 300 mL 
and for the organic phase 200 mL. The dose used was 1 mL of TA suspension 10 mg/mL 
(Adcortyl®) and the medium had a flow of 8 mL/min. 
 
2.2.5.4.2.2.2. Flow rate 
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The flow rate (2 and 8 mL/min) was evaluated with the small cell for tablets and capsules filled 
up to the score of the tablet holder with 1 mm glass beads. The aqueous medium used was PBS 
with Tween 80 (1% v/v) and the organic medium used was 1-octanol. The filter top of the cell 
contained two glass fibre filters (GF/F: 0.7 µm pore size and GF/D 2.7 µm pore size). The 
volumes used in the glass bottle were for the aqueous phase 40 mL and the organic phase 10 
mL. The dose used was 1 mL of TA suspension 10 mg/mL (Adcortyl®). 
 
2.2.5.4.2.2.3. Cell size 
 
The cell size of the tablets and capsules (small and large) filled up to the score of the tablet 
holder with 1 mm glass beads was evaluated. The aqueous medium used was PBS with Tween 
80 (1% v/v) and the organic medium used was 1-octanol. The filter top of the cell contained 
two glass fibre filters (GF/F: 0.7 µm pore size and GF/D 2.7 µm pore size). The volumes used 
in the glass bottle were for the aqueous phase 40 mL and the organic phase 10 mL. The dose 
used was 1 mL of TA suspension 10 mg/mL (Adcortyl®) and the medium had a flow of 8 
mL/min. 
 
2.2.5.4.2.2.4. Organic phase/aqueous phase interface area 
 
The effect of the organic phase/aqueous phase interface area (58.1 cm2 and 145.2 cm2) on the 
dissolution of TA from the formulation was evaluated with the small cell for tablets and 
capsules filled up to the score of the tablet holder with 1 mm glass beads. The aqueous medium 
used was PBS with Tween 80 (1% v/v) and the organic medium used was 1-octanol. The filter 
top of the cell contained two glass fibre filters (GF/F: 0.7 µm pore size and GF/D 2.7 µm pore 
size). The volumes used in the glass bottle were for the aqueous phase 300 mL and the organic 
phase 200 mL. The dose used was 1 mL of TA suspension 10 mg/mL (Adcortyl®) and the 
medium had a flow of 8 mL/min. 
 
2.2.5.5. In-vitro dissolution with dialysis membrane method in glass bottles 
 
A cellulose acetate dialysis membrane with a MWCO of 14 kDa (Sigma-Aldrich, UK) was 
chosen for the permeation of TA (according to the drug’s molecular weight of 434.5 g/mol). 
The dialysis membrane was then securely sealed with membrane clips. The system was agitated 
on a magnetic stirrer (300 rpm) and held at 37 oC. At selected time intervals (30 min, 1-h, 2-h 
and then every 2-h up to 12-h and then at 24-h), 1 mL samples were collected from the receptor 
compartment and replaced with fresh corresponding medium. Samples were then diluted with 
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the corresponding medium where appropriate, before analysing with the HPLC to determine 
the amount of TA dissolved. The % dissolved was calculated according to a calibration curve 
(2-10 µm) in the corresponding medium [35]. The experiments were performed in triplicate 
and results are presented as Mean (% dissolved over time) ± S.D. Sink conditions were 
maintained throughout the experiments as the saturation solubility of TA was at least three 
times above the drug concentration in the system [28]. 
 
2.2.5.5.1. Effect of surfactant 
 
The effect of the surfactant added to the receptor phase [PBS, PBS with SLS (1% w/v)] was 
evaluated with a volume of 100 mL in the glass bottle with a dose of 1 mL or 0.1 mL of TA 
suspension 10 mg/mL (Adcortyl®). The dose was placed in a 1.5-cm length dialysis membrane.  
The effect of surfactant was also tested with a similar setup containing with a dose of 1 mL of 
TA suspension 10 mg/mL (Adcortyl®) and containing a different surfactant (PBS, PBS with 
Tween 80 (1 and 10% v/v)]. 
 
2.2.5.5.2. Effect of increased osmolality in the donor phase 
 
The effect of increased osmolality resulting by the addition of sodium chloride (from 382 to 
500 mOsm) in the donor phase was evaluated with a volume of 100 mL PBS with Tween 80 
(1% v/v) in the glass bottle with a dose of 1 mL or 0.1 mL of TA suspension 10 mg/mL 
(Adcortyl®). The dose was placed in a 1.5-cm length dialysis membrane.  
The effect of increased osmolality resulting by the addition of a higher amount of sodium 
chloride (from 382 to 2000 mOsm) in the donor phase was also tested with a similar setup 
containing a volume of 1000 mL of PBS with Tween 80 (1% v/v) and the dose of the drug 
being placed in a 20-cm length dialysis.  
 
2.2.5.5.3. Effect of increased osmolality in the receptor phase 
	
The effect of increased osmolality resulting by the addition of di-potassium hydrogen 
orthophosphate (from 382 to 1000 mOsm) or sucrose (from 382 to 500, 1000 and 1500 mOsm) 
in the receptor phase of PBS with Tween 80 (1% v/v) was evaluated with a volume of 1000 
mL in the glass bottle with a dose of 1 mL of TA suspension 10 mg/mL (Adcortyl®). The dose 
was placed in a 1.5-cm length dialysis membrane.  
 
2.2.5.5.4. Effect of dialysis membrane length 
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The effect of the dialysis membrane length (1.5, 10 and 20 cm) was evaluated with the receptor 
phase containing 1000 mL of PBS with Tween 80 (1% v/v) in the glass bottle with a dose of 1 
mL of TA suspension 10 mg/mL (Adcortyl®).  
The effect of the dialysis membrane length between 10- and 20-cm was also evaluated with the 
receptor phase containing 1000 mL of PBS with Tween 80 (1% v/v) in the glass bottle and the 
donor phase containing 1 mL of TA suspension 10 mg/mL (Adcortyl®) with an additional 
volume of medium added [total volume in donor phase: 1 mL Adcortyl® + 9 mL of PBS with 
Tween 80 (1% v/v)]. 
	
2.2.5.5.5. Effect of temperature  
 
The effect of temperature (37 oC and 60 oC ) was evaluated with the receptor phase containing 
1000 mL of PBS with Tween 80 (1% v/v) in the glass bottle with a dose of 1 mL of TA 
suspension 10 mg/mL (Adcortyl®). The dose was placed in dialysis membranes with lengths 
of 1.5-, 10- and 20-cm. 
	
2.2.5.5.6. Effect of additional volume of the donor phase (additional medium added) 
 
The effect of the additional medium in the donor phase (addition of 9 mL of PBS with Tween 
80 (1% v/v)] containing a dose of 1 mL of TA suspension 10 mg/mL (Adcortyl®) was evaluated 
with a volume of 1000 mL PBS with Tween 80 (1% v/v) in the glass bottle. The dose was 
placed in 10- and 20-cm length dialysis membranes. 
 
2.2.5.5.7. Organic solvent in receptor phase 
	
2.2.5.5.7.1. Drug concentration in the suspension 
 
The effect of the drug concentration in the suspension [TA suspension 10 mg/mL (Adcortyl®) 
and 40 mg/mL (Kenalog 40®)] was evaluated with a volume of 100 mL of PBS with MeOH 
(50% v/v) in the glass bottle. The dose of 1 mL was placed in a 1.5-cm length dialysis 
membrane. 
	
2.2.5.5.7.2. Formulation type (solution, suspension and suspension developed with the 
addition of different volumes of methanol) 
 
The effect of the formulation type, with a suspension [0.5 mL of TA suspension 10 mg/mL 
(Adcortyl®) compared to 1 mL of TA solution 5 mg/mL (TA powder in MeOH) and TA 
	 76	
suspensions (TA 10 mg/mL) with different volumes of methanol [TA powder in 1 mL PBS 
with MeoH (90% v/v) and TA powder in 1 mL PBS with MeOH (50% v/v)] was evaluated 
with a volume of 100 mL of PBS with MeOH (50% v/v) in the glass bottle. The dose was 
placed in a 1.5-cm length dialysis membrane. 
	
2.2.5.5.7.3. Organic solvent type 
 
The effect of the organic solvent type in the receptor phase [PBS with MeOH (50% v/v), PBS 
with Ethanol (1% v/v) and (10% v/v)] was evaluated with a volume of 100 mL in the glass 
bottle. The dose of 1 mL of TA suspension 10 mg/mL (Adcortyl®) was placed in a 1.5-cm 
length dialysis membrane. 
	
2.2.6. Triamcinolone Acetonide HPLC Analysis 
 
The samples obtained from the in-vitro dissolution experiments and standard solutions were 
analysed using an Agilent 1100 series HPLC system (Agilent, UK) consisting of a G1329A 
autosampler, a G1330A ALS thermostat, a G1316A thermostatted column compartment, a 
G1315A DAD, a G1322A degasser and a G1311A quaternary pump. A modification of a 
published method was used [64]. Reversed phase chromatography was performed using an 
Agilent Eclipse XDB-C18 column (2.6 x 250 mm, 5µm pore size) (Agilent, UK). The flow rate 
was set at 1 mL/min, temperature at 25 oC, the UV detection signal was set at 240 nm, run time 
for 8 min and injection volume 20 µL. The mobile phase was run at an isocratic mode with 
65:35 (methanol/water). Samples were diluted with the corresponding medium where 
appropriate, before analysing with the HPLC to determine the amount of TA dissolved. The % 
dissolved was calculated according to a calibration curve (2-10 µm) in the corresponding 
medium [35]. Calibration curves were prepared with the use of a stock solution of TA (100 
µg/mL) in methanol. The working calibration standards were composed after diluting the stock 
solution accordingly with the selected medium.  
 
2.2.7. Dissolution profile comparisons 
 
The use of f2 similarity factor was chosen for comparing dissolution profiles. [36]. The 
percentages of dissolution for all time points were considered until the drug reached 85% 
dissolution of the plateau value; in this occasion one time point after the 85% dissolution was 
taken into account [37]. The similarity factor f2 from 50-100 showed similarity of the compared 
dissolution profiles. 
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The equation used was: GK = 50	× log 1 + 1 + Q; −	S;K;TUV WX.Z×	100 		    (Eq. 3)  
where: 
n is the number of time points 
Rt is the dissolution value of the reference at time t  
Tt is the dissolution value of the test at time t. 
	
The calculations were done with the DDsolver Add-In (DDsolver, Add-In, Microsoft Excel) 



























2.3. Results and Discussion	
 
2.3.1. Solubility studies 
 
The equilibrium solubility of TA after 24-h is shown in Fig. 2.2. The addition of surfactants to 
the medium shows a significant increase in the solubility of TA as confirmed from the 
experimental data [solubility value of TA in PBS: 28.5 ± 0.7 µg/mL (n=3); solubility value of 
TA in PBS with Tween 80 (1% v/v): 91.6 ± 9.65 µg/mL (n=3); solubility value of TA in PBS 
with SLS (1% w/v): 478 ± 8.3 µg/mL (n=3); solubility value of TA in PBS with CTAB (1% 
w/v): 1041.2 ± 6.9 µg/mL (n=3)]. Similar results have been observed in the literature for TA 
[39]. The molecular weight of Tween 80 is larger compared to the anionic surfactants used [40] 
and so with similar surfactant molar concentrations, more drug molecules will be encapsulated 
in the SLS micelles, leading to lower diffusivity of the drug-micelle complex and so less drug 
will be dissolved from the formulation. Furthermore, ionic surfactants such as SLS and CTAB 
have higher surface activities with a stronger solubilising effect than non-ionic surfactants such 
as Tween 80 leading to higher drug solubilisation [39]. In addition, considering the critical 
micelle concentration values of the surfactants used in PBS (Tween 0.05 mM, CTAB: 1 mM 
and SLS: 1.1 M) [41], Tween 80 (and non-ionic surfactants) has a much lower CMC value and 
higher aggregation numbers than its ionic counterparts with similar hydrocarbon chains leading 
to less drug encapsulated and so a smaller solubilization capacity. The addition of organic 
solvent to the medium also leads to a significant increase in the solubility of TA, confirmed 
from the experimental data [solubility value of TA in PBS with MeOH (50% v/v): 536.7 ± 63.5 
µg/mL (n=3)]. Adding methanol to the aqueous PBS medium leads to a reduction of water-to-
water interactions due to the presence of hydrogen bond donating or accepting regions and also 
hydrocarbon regions. This leads to the system being more beneficial for non-polar solutes [42] 





Fig. 2.2. Solubility of TA samples in several media (n=3) 
	
2.3.2. In-vitro dissolution studies with USP apparatus I 
	
There was no significant drug dissolution noted in PBS or in PBS with Tween 80 (0.5% v/v) 
(data not shown). As Adcortyl® is an aqueous suspension, after a short amount of time it seems 
to sediment and form particle aggregates in the float-A-lyzer setup [43]. Particle aggregation 
took place due to the lack of agitation within the membrane which caused problems to the 
diffusion of the drug [26]. 
	
2.3.3. In-vitro dissolution studies with USP apparatus II 
 
Dissolution studies with the USP apparatus II showed that due to non-sink conditions (40 mg 
of TA in 900 mL PBS) the % of drug dissolution reached a plateau from the first sampling 
point at 10 minutes, as the suspension would dissolve rapidly when in contact with PBS (results 
not shown). The percentage of the drug dissolved is approx. 40% due to the solubility of TA 
in PBS (28.5 µg/mL) (Fig. 2.2.). 
	
2.3.4. In-vitro dissolution studies with USP apparatus III 
	
Dissolution of TA in PBS was negligible in the modified USP apparatus III at 30 and 60 dpm 
as the drug did not permeate through the dialysis membrane (data not shown). Adding 0.5% 
v/v of Tween 80 into PBS, at 30 dpm, similarly did not lead to significant dissolution from the 
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dialysis membrane (data not shown). The reasoning for the drug not exiting the dialysis 
membrane in all conditions tested [30 and 60 dpm in PBS, 30 dpm in PBS with Tween 80 
(0.5% v/v), 60 dpm in PBS with Tween 80 (1% v/v) for 72-h] was due to the lack of agitation 
within the membrane [26]. 
	
2.3.5. In-vitro dissolution with USP apparatus IV 
 
2.3.5.1. Open system setup 
	
2.3.5.1.1. Effect of flow rate  
 
Results with the large cell showed that an increase in the flow rate from 4 to 8 mL/min, to 16 
mL/min had an effect on the dissolution of TA from Kenalog 40® in PBS (GK[\] =	56.34 and GK[\^_ =	52.18 respectively and GK]\^_ = 79.09) (Fig. 2.3) [44]. With the use of the small cell, 
increasing the flow rate from 4 to 8 mL/min increased the TA dissolution significantly (GK[\] =	30.07) (Fig. 2.3). The increase in drug dissolution relates to the increased hydration of the 
material in test, as a higher volume of medium is flown through the cell [45, 46].  
 
2.3.5.1.2. Effect of cell size  
	
The effect of the cell size on the TA dissolution from Kenalog 40® was more significant at 8 
mL/min reaching a difference of approx. 30% in the dissolution between the small and large 
cell in 6-h (GK^b\bb._ =	32.03). At 4 mL/min the difference in dissolved drug between the small 
and large cell was @ 10% (GK^b\bb._ = 63.6) in 6-h (Fig. 2.3). Using a smaller diameter cell size 
and increasing the flow rate, leads to the medium being flown through the cell with a higher 
pressure [47, 48]. Consequently, the medium will flow through the cell with a higher linear 
velocity related to the volumetric rate, through the cross-sectional area of the two size cells. As 
the linear velocity is inversely related through the ratio of the squared radii, at a specific 
volumetric flow, the linear velocity of the small cell will be greater than that of the large cell, 




Fig. 2.3. Mean ± SD of TA dissolved from Kenalog 40® in PBS with different flow rates in the 
USP apparatus IV in open mode [Glass bead size: 1 mm, Cell size: large (solid lines), 12 mm 
(dashed lines)] 
 
2.3.5.1.3. Effect of cell setup 
 
2.3.5.1.3.1. Effect of glass bead size 
 
In both cells, changing the glass bead size, from 1 to 2 mm, did not affect the dissolution of 
TA significantly. At 4 mL/min, the TA dissolution profiles from the dissolution of TA with the 
use of 1 mm and 2mm glass beads were similar in the large cell (GK^\b = 94.16) and in the 
small cell (GK^\b = 63.63) (Fig. 2.4). The use of glass beads results in a flow closer to a 
“laminar” type (fluid particles moving in parallel to the direction of flow), with the fluid 
entering the cell with a relatively faster speed in comparison to a “jet” type (fluid particles 
moving rapidly in all direction within the direction of the flow) with no glass beads present in 
the cell [44, 48]. A “jet” flow type of hydrodynamics leads to a more turbulent agitation of the 
sample. With glass beads in the cell, the fluid particles move close to parallel with each other 
and to the direction of the flow [30]. In both cells, increasing the size of the glass beads results 
in more space available in the cell due to bigger gaps present in the packed column, allowing 
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Fig. 2.4. Mean ± SD of TA dissolved from Kenalog 40® in PBS with different glass bead sizes 
in the USP apparatus IV in open system [Flow rate: 4 mL/min, Cell size: large (solid line), 12 
mm (dashed line)] 
	
2.3.5.1.3.2. Effect of sample position 
 
TA dissolution from the formulation was significantly different with the sample placed on the 
glass beads directly compared to the sample placed on the GF/F filter on top of the glass beads, 
(GKcdefgh\bb._	ii = 46) (Fig. 2.5). The dissolution of TA from Kenalog 40® in the tested setups 
revealed a high variation, indicating low reproducibility. When the sample was placed in the 
semisolid cell, in 6-h there was a significant difference observed in TA dissolved from the 
formulation compared to the setup involving the placement of the suspension on the glass beads 
(GKjgidjkedl\bb._	ii = 18.46). The time it takes for the medium to reach the suspension and for 
the dissolution to take place when the drug is placed on the glass beads is shorter, might have 




















Fig. 2.5. Mean ± SD of TA dissolved from Kenalog 40® in PBS with Tween 80 (1% v/v) with 
different sample positions and different concentrations used in the USP apparatus IV in open 
system (Flow rate: 4 mL/min, Glass bead: 1 mm, Cell size: large) 
	
2.3.5.1.3.3. Effect of filter type 
 
Comparing the dissolution of TA from Adcortyl® with the glass microfiber filters [(GF/D + 
GF/F) with pore sizes of 2.7 µm and 0.7 µm respectively], and the Hydrophilic Polysulfone 
membrane disc filters [0.2 µm], showed that a filter with a smaller pore size and drug loading 
capacity will allow less amount of dissolved drug to diffuse through the filter used in the setup 
(GKmnnomnp\qr	rscchtV = 19.28). In a USP apparatus IV setup, the use of a durable filter in the 
filter head is vital, in order to avoid collecting undissolved drug material [46]. As the drug 
material starts to disintegrate into finer particles due to the contact with the medium [51], it 
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Fig. 2.6. Mean ± SD of TA dissolved from Adcortyl® in PBS with different filters in the filter 
head in different drug amounts in the USP apparatus IV in open system. (Flow rate: 4 mL/min, 
Glass bead: 1 mm, Cell size: large) 
 
2.3.5.1.4. Effect of dissolution medium: surfactant type and concentration 
 
The addition of cationic surfactant (CTAB) aids the system to reach complete dissolution of 
TA from the suspension after 1-h, while with the anionic surfactant (SLS), complete dissolution 
is reached at approx. 4-h. With the non-ionic surfactant (Tween 80), approx. 95% of total TA 
dissolution from the formulation is reached after 6-h. The TA dissolution profiles with all 
surfactants seems to follow a pattern of first order release. The media containing ionic 
surfactants (1% w/v) showed a higher % of TA dissolution from Kenalog 40® than the non-
ionic Tween 80 (1% v/v) (GKruggV	]v\wxw =20.95 and GKruggV	]v\yrz{ = 3.66). Similarity was 
noted between TA dissolution profiles in media with CTAB and SLS (GKwxw\yrz{  = 29.14). A 
faster initial dissolution from the suspension is shown with the use of CTAB (1% w/v) and 
SLS (1% w/v) compared to Tween 80 (1% v/v) (Fig. 2.7). Similar results have been observed 
in the literature [39]. The molecular weight of Tween 80 is larger compared to the molecular 
weight of the anionic surfactants used [40] and so with similar surfactant molar concentrations, 
more drug molecules will be encapsulated in the SLS micelles, leading to lower diffusivity of 
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ionic surfactants such as SLS and CTAB have higher surface activities with a stronger 
solubilising effect than non-ionic surfactants such as Tween 80, leading to higher drug 
solubilisation [39]. 
The effect of the concentration of surfactant in the medium [PBS with Tween 80 (0.5% v/v and 
1% v/v)] on the dissolution of the drug from the formulation has a significant effect [52] on the 
dissolution of TA from the formulation (GKv\v.| = 28.7 and GKv.|\^  = 48.61 respectively). Adding 
surfactant to the medium, reduces the surface tension due to adsorption at the liquid-air 
interface and improves the wetting properties of the drug. The addition of surfactant also 
increases the amount of drug encapsulated in the created micelles, and subsequently increases 
the dissolution rate of the drug (Fig. 2.7) [53]. 
 
Fig. 2.7. Mean ± SD of TA dissolved from Kenalog 40® with different types of surfactant and 
in different amounts in the USP apparatus IV in open system (Flow rate: 4 mL/min, Glass bead: 
1 mm, Cell size: large). 
 
2.3.5.1.5. Effect of formulation factors 
 
2.3.5.1.5.1. Effect of drug concentration in the suspension 
 
Changing the concentration of the formulation placed on the glass beads had a significant effect 
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faster. Results show that the % of drug dissolved with the use of 1 mL Adcortyl® (TA 10 
mg/mL) seems to reach completion faster than 1mL Kenalog 40® (TA 40 mg/mL) (Fig. 2.8). 
In terms of absolute amounts of TA dissolved at 6-h, 37.6 mg were dissolved from the Kenalog 
40 and 9.9 mg from Adcortyl. 
 
Fig. 2.8. Mean ± SD of TA dissolved in PBS with Tween 80 (1% v/v) from suspensions with 
different concentrations of TA, in the USP apparatus IV in open system (Flow rate: 4 mL/min, 
Glass bead: 1 mm, Cell size: large mm, Membrane: GF/F + GF/D) 
	
2.3.5.1.5.2. Effect of formulation type: suspension vs. microparticles 
 
2.3.5.1.5.2.1. Preparation and characterisation of microparticles 
 
The loading of TA was 13.6 and 28.53% for the small and large microparticles developed, 
respectively, while the particle size was respectively 3.46 and 85.92 µm, with the particle size 
distribution analysis presented in Table 2.1. Scanning electron microscopy (SEM) revealed that 
the particles were spherical in shape and mostly appeared in aggregates in both MPa (Fig. 2.9) 























Fig. 2.9. SEM micrographs of the size and surface morphology of MPa 
 
   
 
Fig. 2.10. SEM micrographs of the size and surface morphology of MPb 
 
Table 2.1. Physicochemical Characterisation of TA loaded PLA microparticles 
Batch 
D (v, 0.1) 
(µm) 
D (v, 0.5) 
(µm) 







efficiency (% w/w) 
MPa  3.09 3.46 3.94 13.6 +/- 5.36 41.3 +/- 16.25 
MPb  38.42 85.92 141.38 28.53 +/- 1.68 86.45 +/- 5.09 
Adcortyl® 4.26 8.45 13.65 - - 
TA powder 82.11 171.43 263.55 - - 
 
2.3.5.1.5.2.2.  In-vitro drug release 
 
The difference in TA release between the suspensions of different particle size (MPa and MPb) 
was highly significant showing that the dissolution from the large microparticles (MPb) was 
faster than the small ones (MPa) over a period of 6-h (GKji}ee\e}h~g= 5.02) (Fig. 2.11). Even 
though, according the Noyes-Whitney equation [49], increasing the particle size should lead to 
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decreased dissolution as lower drug diffusion rates result from a smaller particle surface area, 
here we notice the opposite 
The rationale behind the obtained results can be attributed to the properties of the MP 
suspension in PBS. The formulation containing the MPb powder [D (v, 0.5: 85.92)] has a much 
higher encapsulation efficacy compared to the formulation containing the MPa powder [D (v, 
0.5: 3.46)], meaning that the amount of the poly-lactic acid (PLA) in the MPb powder, for 
encapsulating the same drug amount (0.1 mg/mL), is lower, affecting wettability (Table 2.1). 
Poor wettability leads to poor dissolution of the particles and hence drug dissolution from the 
suspension does not follow the Noyes-Whitney equation [49]. It was also noticeable that the 
MPa did not dissolve in a similar way with the MPb powder. The small microparticles form a 
uniformed homogenous milky white suspension in PBS, in comparison with the large 
microparticles that wouldn’t seem to mix properly in the PBS, with the suspension drug 
particles being visible.  
	
The discriminating ability of the method used with the open system USP apparatus IV, can also 
be shown when comparing the Adcortyl® suspension (10 mg/mL) with a suspension of TA 
powder in PBS (10 mg/mL) (GKzlkhfte\rz	Äkulgh = 19.9) (Fig. 2.12). Measuring the particle 
sizes showed that the TA particles in Adcortyl® are approx. 20x smaller than in the TA powder 
(Table 2.1). The TA dissolution from the suspensions in this case follow the Noyes-Whitney 
equation, as increased particle size leads to decreased dissolution, showing that the TA from 
the Adcortyl® suspension has a faster dissolution rate than the TA powder suspension.  
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Fig. 2.11. Mean ± SD of TA released from PLA-TA microparticle suspensions in PBS with 
different particle sizes (Flow rate: 4 mL/min, Glass bead: 1 mm, Cell size: small, filter: 
Polysulfone 0.2 µm)  
 
Fig. 2.12. Mean ± SD of TA dissolved from different suspensions in PBS (Flow rate: 4 mL/min, 
































2.3.5.2. Closed mode setup  
 
2.3.5.2.1. Monophasic dissolution setup  
 
Results in the monophasic setup with the closed system of the USP apparatus IV with 60 mL 
of PBS with Tween 80 (1% v/v) and a dose of 1 mL of TA suspension 40 mg/mL (Kenalog 
40®), showed that with no sink conditions present, the % of drug dissolution reached a plateau 
from the first sampling point and onwards. In order to have had sink conditions for 1 mL of 
Kenalog 40®, a volume of ~ 9 L of PBS with Tween 80 (1% v/v) is needed, according to the 
solubility of TA in this medium (91.6 µg/mL) which should be at least 3 times surpassed with 
the volume of the medium in the receptor phase (Fig. 2.2). 
2.3.5.2.2. Bi-phasic dissolution setup 
 
2.3.5.2.2.1. In low volumes (aqueous phase: 40 mL, organic phase: 10 mL) 
 
2.3.5.2.2.1.1. Effect of surfactant in aqueous phase 
 
Using low volumes for the organic (10 mL) and the aqueous phase (40 mL) and ensuring sink 
conditions as the total dose of drug (10 mg TA) is less than 20% of its solubility in the volume 
of organic phase (5.2 mg/mL) [28, 31, 54] the partitioning of the drug to the organic phase is 
significantly higher when the surfactant in the aqueous phase is SLS (1% w/v) compared to 
Tween 80 (1% v/v) with a difference in dissolution of 20% in 6-h (GKwxw\ruggV	]v = 33.38) (Fig. 
2.13). In the aqueous layer with Tween 80 (1% v/v), the % of TA dissolved reaches a plateau, 
showing that the drug in the aqueous phase is saturated in the setup, while with the use of SLS 
(1% w/v) in PBS, the % of TA dissolved does not reach a plateau, rather reaches a peak at 30 
min and decreases (Fig. 2.13). The partition kinetics of the drug from the aqueous to the organic 
phase is described by Eq. 4 [55]: 
3Åu3; = ÇÉK( + ÇÉb + f         (Eq. 4) 
where: 
( = ÑÖk ÜáàÅwà − ÜàáÅwá   
â = ä ÜàáÅwáÖà ãvÖk − Çåç − ÜáàÅwàÖk ãvÖà − Çåé   
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G = äèçé ãvÖàÖk  
and ÇÉ is the drug concentration in the water phase E is the time ä is the oil-water interface area ê1 is the oil phase volume èçé  is the oil-water rate partition constant Çåéis the drug solubility in the water phase èéç  is the water-oil rate partition constant Çåç is the drug solubility in the oil phase êé is the water phase volume ëX is the total drug amount present in the two-phases system 
 
A higher amount of drug is dissolved in the aqueous phase when containing PBS with SLS 
(1% w/v) compared to PBS with Tween 80 (1% v/v) as the solubility of TA is higher in the 
first compared to the latter (478.01 µg/mL and 91.6 µg/mL respectively) (Fig. 2.2), and 
subsequently, with a higher drug concentration in the water phase (ÇÉ), partitioning of TA to 
the organic phase is higher [55]. As the ÇÉ increases (drug dissolution increasing from 56.1 to 
70.6%), the rate of partitioning becomes faster than the rate of dissolution, reducing the % of 
drug dissolved over time in the aqueous phase rather than the plateau previously noticed in 
PBS with Tween 80 (1% v/v). As the lipophilicity of the drug is exploited in a biphasic system, 
using different surfactants (anionic, SLS and non-ionic, Tween 80) could influence 
partitioning; the rate of the partition constant between the aqueous and organic phase (èçé and èéç) changes and so does the partition coefficient, as the solubility of TA in PBS with SLS 
(1% v/v) is different than in PBS with Tween (1% v/v) (Fig. 2.14) [55, 56]. In addition, due to 
the ability of the surfactant to increase the hydrophilicity of the suspension [as the non-polar 
(hydrophobic) region of the created micelles have minimised contact with the aqueous 
medium], drug partitioning to the organic phase will be reduced [28]. Mixed micelles created 
by 1-octanol and ionic surfactants can affect drug partitioning, as their relative concentrations 
may lead to 1-octanol decreasing the critical micelle concentration of the ionic surfactant, 
leading to increased ionisation of the micelles and changes into the micellar size and structure 
[55]. 
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2.3.5.2.2.1.2. Effect of flow rate 
 
TA dissolution results with different flow rates showed that sink conditions in the aqueous 
phase were not maintained in both setups as the % of TA dissolved reaches a plateau from the 
first sampling point at approximately 20% [according to the solubility of TA in PBS with 
Tween 80 (1% v/v) being 91.6 µg/mL, Fig. 2.2.] (Fig. 2.13). Dissolution takes place faster than 
the partitioning of the drug leading to the non-sink conditions in the aqueous phase [31]. 
Different flow rates (2 and 8 mL/min) showed that by increasing the flow, partitioning to the 
organic phase increases; with ~55% TA dissolved compared to 40% TA dissolved respectively 
in the aqueous phase [PBS with Tween 80 (1% v/v)] from the Adcortyl® formulation (GKb\] = 
47.29). (Fig. 2.13). Considering the increased partition of TA with the increasing flow rate in 
the method, the drug can be dissolved faster in the aqueous phase, which consequently can 
have an effect on partitioning, as there will be an increase in the total drug present in the system 
(ëX) [56].  
 
2.3.5.2.2.1.3. Effect of cell size 
 
With both the cells tested (large compared to small), the % of TA dissolved from Adcortyl® in 
the aqueous phase reached a plateau. In the organic solvent, the % of TA dissolved from 
Adcortyl® with the use of the large cell was 33% in 6-h compared to 18.7% with the use of the 
small cell (GK^b\bb._ = 52.46) (Fig. 2.13). By using a large cell in the USP apparatus IV, the 
interface of the suspension in contact with the aqueous media is increased meaning that there 
is a higher amount of drug dissolved over time and so a higher concentration of drug present (ÇÉ) [30]. The partitioning kinetics suggest that by increasing the drug dissolved in the 
aqueous phase (ÇÉ), the total amount present in the system (ëX) increases [56]. This leads to 
the partitioning of the drug also increasing, resulting in a higher % of TA partitioned to the 
organic phase [56].  
 
2.3.5.2.2.2. In high volumes (aqueous phase: 300 mL, organic phase: 200 mL) 
 
2.3.5.2.2.2.1. Effect of the presence of surfactant 
 
Results showed that with no surfactant present in the aqueous phase, the % of drug dissolved 
in PBS reaches a lower plateau at compared to PBS with Tween 80 (1% v/v), which can be 
explained from the solubility of TA in these media (Fig. 2.14). It is also shown that the % of 
TA dissolved in the aqueous layer without surfactant (PBS), although reaches a plateau from 
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1- to 3-h, it seems to reduce and at 6-h it is approximately 10% lesser. This indicates that 
although the drug present in the aqueous phase was saturated for a 2-h period, drug partitioning 
then becomes faster than drug dissolution. This does not seem to take place with the presence 
of a surfactant in the aqueous phase [PBS with Tween 80 (1% v/v) and PBS with SLS (1% 
v/v)] which increases the hydrophilicity of the suspension [28] that leads to less drug being 
partitioned into the organic phase.  In the organic phase, results confirmed that the amount of 
drug being partitioned is higher when no surfactant is present with Tween 80 
(GKVk	jshc}f}Vf\ruggV	]v  = 62.07) and with SLS (GKVk	jshc}f}Vf\wxw  = 69.16) (Fig. 2.14).  
2.3.5.2.2.2.2. Effect of volume and surface area in the aqueous and organic phase 
	
By increasing the volume (High volume, aqueous phase: 300 mL, organic phase: 200 mL) and 
surface area (High volume in 145.2 cm2 and low volume in of 58.1 cm2) in both phases the 
amount of drug dissolved in the aqueous phase is increased compared to lower volumes (Low 
volume, aqueous phase: 40 mL, organic phase: 10 mL), with a plateau reached at a higher % 
of TA dissolved (Fig. 2.13, 2.14). Partitioning takes place in a slower rate than dissolution, 
which is the reason the plateau is reached. In the organic phase, the partitioning in the lower 
volume is higher than the partitioning in the high volume (GKeku\îd~î = 40) (Fig. 2.13). This can 
be explained as the TA concentration in the aqueous phase (ÇÉ) is higher in the small volume 
(0.06 mg/mL) compared to the concentration of TA present in the high volume, (0.02 mg/mL.) 
(Fig. 2.14) and so with a higher ÇÉ there is higher partitioning to the organic phase [55, 56]. 
	
2.3.5.2.2.2.3. Oil-water interface area (ä) 
 
The dissolution of TA in the aqueous phase from Adcortyl® in the setup with an oil-water 
interface area of 145.2 cm2 compared to the setup with an oil-water interface area of 58.1 cm2 
seems to take place in a slower rate compared to the partitioning of the drug into the organic 
phase. In the beginning of the experiment TA dissolves faster than it partitions to the organic 
phase which can explain the peak of the % of TA dissolved in the aqueous phase in 1-h. The 
increased oil-water interface area (ä) (Eq. 4) leads to a faster partitioning rate than dissolution 
as indicated by the reducing percentage of the drug dissolved in the aqueous phase after 1-h 
(Fig. 2.14). The % of TA partitioning into the organic phase, happens faster with the use a 
higher surface area (57%) compared to 13% with the use of a lower surface area (GK|].^\^[|.b = 




Fig. 2.13. Mean ± SD of % TA dissolved from Adcortyl® in aqueous phase 40 mL (dotted line) and in organic phase (solid line) 10 mL 
(cell size: small, flow rate 8 mL/min), with the USP apparatus IV in closed system. 
 
Fig. 2.14. Mean ± SD of % TA dissolved from Adcortyl® in aqueous phase 300 mL (dotted line) and in organic phase (solid line) 200 
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2.3.6. In-vitro dissolution studies with the dialysis membrane method in glass bottles 
 
2.3.6.1. Effect of type and amount of surfactant 
 
With 1 mL of Adcortyl® placed in a 1.5 cm length dialysis membrane (donor phase) in 100 mL 
of PBS with SLS (1% w/v) (receptor phase), there was no significant permeation measured up 
to 12-h (data not shown). This could be explained from the length of the dialysis membrane, 
as a small surface-area-to-volume ratio leads to a slower dialysis. Also, as drug dissolution is 
rapid when the drug is in medium, there are no sink conditions within the membrane, making 
the diffusion through the membrane, the rate limiting step [26, 46]. As Adcortyl® is an aqueous 
suspension, after a short amount of time, the drug seems to sediment and form particle 
aggregates in the dialysis membrane [43]. This happened due to the lack of agitation within the 
membrane causing problems to the diffusion of the drug [26]. No significant drug dissolution 
from the formulation was also noted by reducing the amount of drug in the donor phase (from 
1 mL [(10 mg TA) to 0.1 mL (1 mg TA)] showing that the amount of drug present in the system 
is not the primary cause of the method not providing significant results (data not shown), as 
lack of agitation would still be the key issue. Increasing the volume of medium in the receptor 
phase and using a different surfactant, [1000 mL of PBS with Tween 80 (1% v/v)] also did not 
provide significant results (data not shown). By increasing the amount of Tween 80 in the 
medium, from 1% to 10%, results were not as expected; increasing the amount of surfactant, 
theoretically, increases the solubility of TA in the medium and so more drug should be 
dissolved [39, 40]. Results showed that in PBS with Tween 80 (1% v/v), the dissolution is 5% 
in 12-h compared to TA dissolution in PBS with Tween 80 (10% v/v), where at the same time 
point it is 0.5%. A higher amount of Tween 80 seems to lead to an increase of the medium 
viscosity, by forming a barrier on the membrane, decreasing the rate of drug diffusion [22, 27, 
57, 58]. 
 
2.3.6.2. Effect of increased osmolality in the donor phase 
 
The addition of 400 mg of NaCl to 1 mL of Adcortyl® in the donor phase increases the osmotic 
pressure in the membrane (from 382 to 500 mOsm) and water diffusion from the lower 
concentration to the higher concentration through the semi permeable membrane would be 
expected [59]. According to the phase in which the osmolality will be higher and following the 
net movement of water, the membrane will swell or shrink. Based on osmosis, where increase 
of the osmotic pressure occurs inside the membrane, dissolved drug will be diffused to the 
receptor phase [59-61]. Despite this theoretical reasoning, the dissolved drug measured in the 
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receptor phase was not significant (data not shown). In order to test if results were influence 
by the significance of the increase in osmolality, a study was performed with a higher increase 
in osmolality (from 382 to 2000 mOsm) in the Adcortyl® suspension and a higher receptor 
volume [PBS with Tween 80 (1% v/v), from 100 to 1000 mL) and an increase in the dialysis 
membrane length, resulting in an increased surface area (from 1.5 to 20 cm). Results showed 
that the % of TA dissolved in 8-h was similar (9.3 to 9.7%) showing that the increase in 
osmolality in the donor phase, does not have a significant effect in TA dissolution from the 
formulation.  
	
2.3.6.3. Effect of increased osmolality in the receptor phase 
 
Theoretically, increasing the osmolality in the receptor phase would cause the net movement 
of water from inside the membrane towards the outer part and thus the osmosis of the solvent 
in the dialysis sac towards the receptor phase. Visually the membrane would shrink due to the 
movement of the solvent towards the outside compared to increased osmolality inside the 
membrane, which would cause it to “balloon” and potentially burst or collapse if too much 
water migrated across it (due to osmotic pressure drawing water in the tubing) [59, 61]. These 
experiments showed that in a receptor phase of PBS with Tween 80 (1% v/v) with the addition 
of 6% Potassium Phosphate Dibasic (K2HPO4), leading to an osmolality of 1000 mOsm, did 
not results in significant TA dissolution, while the addition of sucrose in PBS with Tween 80 
(1% v/v) (calculated according to the calibration curve presented in Fig. 2.16) led to slightly 
higher, yet non-significant TA dissolution from the formulation (Fig. 2.15). Addition of 
different amounts of sucrose [6.4% (500 mOsm) compared to 17% (1000 mOsm)] led to similar 
non-significant dissolution results with 1% difference at 12-h between the TA dissolved from 
the formulation (Fig. 2.15). The addition of 28% sucrose (1500 mOsm) gave lower dissolution 
results than with the lower concentrations of sucrose added to the receptor phase, at 12-h. It 
was visible that a high addition of sucrose leads to high medium viscosity, which affects the 




Fig. 2.15. Mean ± SD of TA dissolved from Adcortyl® (1 mL) in 1000 mL PBS with Tween 
80 (1% v/v) with different osmolality due to the addition of sucrose 
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2.3.6.4. Effect of dialysis membrane length  
 
At 8-h, the dissolution of TA from the formulation with the 1.5 cm membrane was 4% 
compared to 7% from the 10 cm (!"#.%&#' = 79.23) and 9% from the 20 cm (!"#.%&(' = 73.11) 
membrane (Fig. 2.17). The highest noticeable difference between the TA dissolution from the 
formulation with 10 and 20 cm membranes is at 24-h, as there is a TA dissolution from the 
formulation of 9 and 16% respectively (!"#'&(' = 74.71). Having a larger membrane contact 
surface area increased drug permeation, as it may be partially dependent on the contact area of 
the sample with the membrane [27, 62, 63]. Similar results were shown with added medium in 
the donor phase [1 mL Adcortyl® + 9 mL of PBS with Tween 80 (1% v/v)] comparing TA 
dissolution from the formulation with dialysis membrane lengths of 10 and 20 cm (!"#'&(' = 
82.49) (Fig. 2.17).  
2.3.6.5. Effect of temperature of medium 
 
Increasing the temperature of the medium to 60 oC, at 24-h shows a clear difference in % of 
drug dissolved comparing the methods with increasing surface area. In the 1.5 cm membrane, 
there was a 12.5% of TA dissolved, compared to 23% from the 10 cm (!"#.%&#' = 59.98) and 
34.5% from the 20 cm (!"#.%&(' = 44.34) (Fig. 2.17) proving that an increase in the temperature 
of the setup leads to a more accelerated dissolution of TA from the formulation and diffusion 
through the membrane as high temperature increases molecular mobility and subsequently drug 




Fig. 2.17. Mean ± SD of TA dissolved from Adcortyl® (1 mL) in 1000 mL PBS with Tween 
80 (1% v/v) with different lengths of dialysis membrane at 37 oC (solid lines) and at 60 oC 
(dashed lines) 
 
2.3.6.6. Effect of increased volume of the donor phase (medium added to donor phase) 
 
Comparing TA dissolution between the donor phase containing Adcortyl® (1 mL) or Adcortyl® 
with the addition of PBS with Tween 80 (1% v/v) (1 + 9 mL), showed TA dissolution of 16% 
and 13% respectively in 24-h (!"#&#)* = 85.92) (Fig. 2.18). Theoretically, as medium is added 
in the donor phase, more drug can dissolve from the suspension and permeate through the 
membrane to the receptor phase. As a higher amount of drug is dissolved with Adcortyl® (1 
mL) compared to Adcortyl® with additional medium (1 + 9 mL), adding medium inside the 
dialysis membrane did not lead to higher TA dissolution and diffusion through the membrane 






















Fig. 2.18. Mean ± SD of TA dissolved from Adcortyl® with additional medium in the donor 
phase (1 mL + 9 mL) (solid lines), Adcortyl® (1mL) (dotted line) and Adcortyl® (1 mL with 
2000 mOsm) (dashed lines) in 1000 mL PBS with Tween 80 (1% v/v) with different length of 
dialysis membrane 
	
2.3.6.7. Organic solvent in receptor phase 
	
2.3.6.7.1. Effect of drug concentration in the suspension 
 
Comparing the amount of drug dissolved from a dose of 1 mL of TA suspension [10 mg/mL 
(Adcortyl®) and 40 mg/mL (Kenalog 40®)] and diffused from the dialysis membrane in PBS 
with methanol (50% v/v) became evident after 2-h (!"+,-./012&34562.7	9' = 35.01) (Fig. 2.19). In 
order to accelerate drug dissolution, adding an organic solvent in the aqueous buffer medium 
has proven to be advantageous [26]. With the 1 mL dose containing Kenalog 40® compared to 
Adcortyl®, drug permeation rate increased indicating a passive diffusion process, with the 
concentration driving force playing the important role, following the 1st Fick’s law [27]. 
	
2.3.6.7.2. Effect of formulation type 
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Comparing TA dissolution from a dose of 1 mL solution of 5 mg/mL TA in MeOH with a dose 
of 0.5 mL of suspension [Adcortyl® (5 mg TA)] showed that the dissolved drug compared to 
the drug in suspension, permeates through the semi-permeable membrane faster 
(!":.2;0<.5&:;:=45:<.5 = 18.72) (Fig. 2.19). This can be explained as the drug in solution is already 
dissolved and able to permeate through the membrane, while the drug in suspension as will 
have to first dissolve and then permeate through the membrane [27, 65].  
 
2.3.6.7.2.2. TA suspension with different volume of methanol 
 
Results between TA suspensions of 10 mg/mL with a different methanol volume, [TA powder 
in 1 mL PBS with MeoH (90% v/v) and TA powder in 1 mL PBS with MeOH (50%) v/v], 
showed that the suspension with a higher amount led to higher percentages of drug dissolved 
at the end of 12-h (!"#'/*'&%'/%'  = 27.16) (Fig. 2.19). This can be explained as the suspension 
with a higher amount of methanol contains a higher amount of dissolved drug which can 
permeate through the membrane more rapidly [27, 65].  
 
Fig. 2.19. Mean ± SD of TA % dissolved from formulations with the dialysis membrane 
method [100 mL PBS with MeOH (50% v/v), membrane length: 1.5 cm, volume: 1 mL (solid 
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2.3.6.7.3. Effect of organic solvent type 
 
Increasing the % of ethanol added to PBS leads to slightly higher amounts of TA diffused from 
the dialysis membrane although results is of non-significance (data not shown). The dissolution 
of TA is significantly higher with the use of methanol in the medium, as a co-solvent system 
has a reduction of water-to-water interactions due to the presence of hydrogen bond donating 
or accepting regions and also hydrocarbon regions. This leads to the system being more 





















The effect of various factors on drug dissolution from parenteral suspensions was successfully 
evaluated with the selected dissolution methods. Using the USP apparatus II revealed that 
placing the suspension directly in PBS will lead to a plateau in dissolution after the first 10 min 
according to the solubility of the drug in the medium. In the USP apparatus I and III, with the 
use of float-A-lyzers, there was no drug dissolution from the formulation measured. With the 
use of the USP apparatus IV open system, the parameters tested, including hydrodynamics 
(flow rate and cell size), sample position, different type and amount of surfactants added to the 
medium, the type of filter used and the concentration of TA in the suspension had a significant 
effect on drug dissolution from the formulation. The discrimination power of the USP 
apparatus IV method was also shown by testing dissolution profiles of different microparticle 
sizes. The effect of glass bead size on the dissolution of TA was not significant. In the closed 
system, with the use of a bi-phasic setup, the factors tested seem to affect the partitioning of 
the drug to the organic phase without affecting the plateau reached in the aqueous phase. The 
change in the oil-water interface area compared to all the factors tested, seemed to lead to faster 
partitioning rather than dissolution of the drug. Using the dialysis membrane methodology, 
with PBS in the receptor phase and the donor phase of a short dialysis membrane length, the 
drug did not migrate through the membrane. Also, with increased surfactant in the receptor 
phase, increase osmolality in the donor phase and additional volume in the donor phase 
(addition of medium), there was no drug dissolution from the formulation. Results were 
promising when a significantly high difference of osmolality was present with the use of 
methanol in the receptor phase, with an increase in dialysis surface area and by accelerating 
the dissolution by increasing the temperature of the medium. The flow-through cell dissolution 
method provided an appropriate method to characterise parenteral formulations and set 
specifications, that could be used for the development of a compendial dissolution method for 
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Chapter 3: Characterisation of in-vivo disease state synovial fluid 




Purpose: To develop and characterise biorelevant media that simulate the environment of 
healthy and disease state synovial fluid, based on the physicochemical properties of the 
corresponding in-vivo fluids and reveal the similarity of drug solubilisation in the in-vivo and 
biorelevant synovial fluids.  
Methods: The characterisation of in-vivo Osteoarthritis (OA) and Rheumatoid Arthritis (RA) 
synovial fluids and developed Biorelevant Synovial Fluids (BSFs) took place by measuring 
their physicochemical properties (pH, viscosity, surface tension, osmolality). Viscosity was 
measured against shear rate using a cone and plate viscometer, pH was measured with a pH/Ion 
meter, surface tension with the Du Nouy ring method and osmolality by freezing-point 
depression. Based on the properties of the in-vivo fluids, biorelevant media were designed to 
reflect conditions in the synovial joint cavity during healthy state, OA and RA. Solubility 
studies of Triamcinolone Acetonide (TA) were also performed in the in-vivo and in-vitro 
synovial fluid with the shake flask method in a temperature controlled water bath. 
Results: Measurements of OA and RA in-vivo synovial fluids formed the basis for the 
development of the three BSFs (healthy state, OA and RA), with solubility studies performed 
to show biorelevance between in-vivo and in-vitro synovial fluid. Viscosity of the biorelevant 
media was not in accordance to the in-vivo measurements with the use of the average amounts 
of HA, and so Carboxymethylcellulose (CMC) or an increased amount of HA were used as 
viscosity enhancers. Solubility of TA in the in-vivo and in-vitro synovial fluid were increased 
with the addition of phospholipids in the developed media. Comparing solubility results of the 
in-vivo and in-vitro disease state (OA and RA) revealed that the latter were slightly lower. 
Conclusions: The developed media with the addition of a viscosity enhancer, reflect the 
physicochemical properties of the in-vivo fluids, and present a higher physiological relevance 






In recent years, there has been a strong interest in the pharmaceutical industry for the 
development of parenteral formulations. Their various advantages, compared to the oral 
administration route that is mostly preferred due to its convenience in drug delivery, have 
resulted in a high number of marketed products [1]. A vital part in the development of these 
drugs and formulations is assessing their dissolution behaviour in an environment simulating 
in-vivo conditions, such as conditions in the joint cavity. The physiological environment of 
synovial fluid determines significantly the in-vivo performance of the drug administered 
through the IA route with factors such as pH, osmolality, surface tension and especially 
viscosity being of primary importance [2].  
	
The lubricating and viscoelastic ability of HA has been determined from a variety of studies 
[3-8]. Viscosity has an important effect on dissolution rate and by following the Noyes–
Whitney equation (Eq. 1) where the diffusion coefficient, D, is partly related to the solvent 
viscosity, the dissolution rate will decrease with the increasing viscosity of the medium; as D 
is inversely proportional to the viscosity [9]. This is shown in the Stokes–Einstein equation 
(Eq. 2), as the viscosity of the medium, among other parameters affects the diffusion coefficient 
D and consequently the dissolution rate with an inverse proportional correlation: 
?@?A = C D? EF − EH           (Eq. 1) 
where 
dm/dt = solute dissolution rate (kg x s-1) 
m = mass of dissolved material (kg) 
t = time (s) 
A = surface area of the solute particle (m2) 
D = diffusion coefficient (m x s-1) 
d = thickness of the concentration gradient (m) 
Cs = particle surface (saturation) concentration (kg or moles/L) 






I = JKLMNO           (Eq. 2) 
where 
D = diffusion coefficient of the solute in solution 
k = Boltzmann constant 
T = absolute temperature 
η = viscosity of the solvent 
r = radius of the solute molecule 
 
Proteins such as albumin and γ-globulin in synovial fluid have been a subject of discussion on 
how they affect viscosity and dissolution as the presence of the HA-protein complex has not 
been fully understood. There have been different opinions expressed in various studies on the 
bounding of HA with proteins and how this HA protein complex affects the non-Newtonian or 
Newtonian character of the synovial fluid. Fam, in his review [5], explains that initial studies 
[10-12] showed that hydrolysing the proteins in the complex, with the use of papain, would 
lead to a reduced viscosity of the modified synovial fluid. A later study though [13] revealed 
that ethylenediaminetetraacetic acid (EDTA) (used for producing papain) could be the 
responsible component for degrading the complex and leading to the reduced viscosity. Results 
from that study showed that the physicochemical properties of the complex are not dependent 
on the protein content and so it would not influence the complex viscosity, which was apparent 
in other studies as well [14, 15]. Further research [16] suggests that while plasma proteins were 
considered to bind to HA irreversibly forming a complex, albumin binds to HA in pH lower 
than 5 and so in the pH of physiological conditions there will be no binding present. A later 
study suggested that albumin may self-bind leading to multi-protein polymeric aggregates, 
while HA entangles in the protein aggregate [17, 18] proving that the proteins are important 
for the synovial fluid mechanical properties [19]. Further research has shown that components 
such as synthetic HA and proteins in BSF have a strong effect in increasing viscosity at low 
shear rates which would have an effect on the dissolution of drugs [20]. From these studies it 
is understood that the formation of HA-protein complexes takes place either because of protein 
aggregates or due to the complex between proteins and HA, without yet having an extended 
knowledge of the macromolecules involved [17]. The presence of proteins has also proven to 




The presence of lipids in the synovial fluid can be essential, as it is proven that they form multi-
bilayers [22, 23] that affect surface tension while offering improvement in wetting 
characteristics. These components manage to transform a hydrophobic surface into a 
hydrophilic one by an aggregation process. The lipids are arranged into energetically 
favourable vesicles and lamellar spheres, to form a type of reservoir for surfactants in the 
lubrication process [22, 23]. Lipids also act as the body’s natural surfactants and so may 
substantially contribute to the enhancement of the solubility and dissolution of poorly soluble 
drugs in the fluid.  
 
There has been a small number of artificial synovial fluids developed (containing mainly HA), 
mostly used for viscosity, tribological and rheological testing purposes [17, 24-26], with some 
additional studies assessing dosage form performance [27-30]. Artificial synovial fluid has 
been developed [30] in order to investigate the influence of specific components present in the 
synovial fluid (HA and albumin) on the dissolution characteristics of crystal suspensions. 
Results showed that these components do influence drug dissolution and that an artificial 
synovial fluid may be able to provide similar dissolution characteristics in comparison with 
bovine synovial fluid. A review by Marques [29] has highlighted the use of a simulated 
synovial fluid with PBS and HA which has been used in the following in-vitro studies: 
dysprosium borate glass microspheres in-vitro were immersed in the mentioned simulated 
synovial fluid for up to 64 days at 37 oC [27], while in another study [28], bilayered chitosan 
based scaffolds were developed to investigate the cytotoxicity of composite scaffolds using 
unsintered hydroxyapatite. The mentioned simulated synovial fluid was also used in bioactivity 
studies for examining the possibility of the polymeric component for the chondrogenic part, to 
not mineralize in various immersion periods. In all occasions, the amount of the components 
added, would be chosen according to the average values present in synovial fluid found in 
literature, for a healthy individual. The components chosen for addition would be the HA, BSA 
and in some occasions γ-globulin.  
	
Up to date there is no proposed BSF media reflecting the physiological parameters of the 
synovial fluid composition in healthy and disease state for assessing dissolution behaviour in 
the synovial joint. To develop these media and to be able to predict drug dissolution and 
solubility, it is vital to consider the physiological components that may affect the process of 
dissolution while evaluating physiologically relevant concentrations. In this study the 
physicochemical properties of the in-vivo disease state (OA and RA) synovial fluid were 
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characterised in terms of the pH, osmolality, surface tension, viscosity vs. shear rate, in order 
to obtain data that would be useful for the development of BSF. As several media would need 
to be developed in order to reflect changes in composition during disease stages, two disease 
states, OA and RA were taken into account in this study. A healthy state (HS) BSF was also 
developed according to the values reported in the literature. With the measurements performed 
on the disease state in-vivo synovial fluid, we were able to establish the values of the 
physicochemical properties, by considering how they affect the dissolution of the drug in the 
joint. In addition, the solubility of a model drug for IA use, TA, in the in-vivo pathogenic (OA 
and RA) synovial fluid was measured to show biorelevance with respect to how the drug would 






















TA (98+%, fine chemical) was purchased from Alfa Aesar (UK). For the development of the 
BSFs, Hank’s Balanced Salt Solution (HBSS), 1X, without calcium, magnesium, phenol red 
Thermo Scientific HyClone was purchased from Fisher Scientific (UK), the 0.1 M phosphate 
buffer contained 0.1 M Na2HPO4, 0.1 M HCl, bovine serum albumin powder, fraction V and 
sodium hyaluronate 95% were purchased from Fisher Scientific (UK), γ-globulin from bovine 
blood was purchased from Sigma-Aldrich (UK), phosphatidylcholine (PC) from egg was 
purchased from Lipoid (Germany) and carboxymethylcellulose (CMC) sodium salt was 
purchased from Fisons (Fisons Scientific Equipment, UK). Hyaluronidase from bovine tests, 
Type VIII, lyophilized powder (300-1000 U/mg) was purchased from Sigma-Aldrich (UK).  
For all media, ultra-pure water was obtained from a Milli-Q purification device. 
	
3.2.2. Collection and handling of synovial fluid samples from patients with OA and RA  
	
OA and RA synovial fluid was collected from volunteers through aspiration of excess synovial 
fluid present in the affected joint at the Orthopaedic centre, Attikon University Hospital, 
Athens, Greece. Fourteen volunteers (from three of which double samples were withdrawn) 
with OA aged 50-86 years old and ten volunteers with RA were included in the study. The 
volunteers all gave their written informed consent for being part of the experimental procedure. 
The study was approved by the Ethics Committee of the Attikon University Hospital, Athens, 
Greece. The aspirated synovial fluid samples, were kept in a freezer at -80 oC. Before 
measuring physicochemical properties and performing the solubility studies, the samples were 
left to reach room temperature. For the OA synovial fluid experiments, 14 samples were used 
for the pH, osmolality measurements and solubility studies, 13 for the surface tension 
measurements as for one sample there was not enough volume to perform the measurement 
and for the viscosity measurements 10 samples were used for the similar reason. For the RA 
synovial fluid experiments, 10 samples were used for all measurements and solubility studies 
(Table 3.1). 
	
Table 3.1. OA and RA synovial fluid samples used for each study 
Physicochemical Study No. of OA samples No. of RA samples 
pH 14 10 
Osmolality 14 10 
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Surface Tension 13 10 
Viscosity 10 10 
Solubility 14 10 
 




The pH values were measured by a freshly calibrated pH electrode connected to a S220 Seven 
Compact pH/Ion pH meter (Mettler-Toledo) at room temperature (25 oC). The measurements 




Osmolality values were measured by freezing-point depression of the media using an 
Advanced Micro-Osmometer Model 3300 (Advanced Instruments Inc.). The measurements 
were performed in triplicates. 
	
3.2.3.3. Surface Tension 
 
The surface tension was determined with the Du Nouy ring method by using a Force 
Tensiometer – Sigma 700/701 (Dyne Testing) at room temperature (25 oC). A standard Du 
Nouy Ring was used while the medium was placed in a small vessel with a diameter of 46 mm. 
The measurement lasted for 5 minutes or until a stable surface tension was indicated. The 
measurements were performed in triplicates. 
	
3.2.3.4. Shear Rheometry (Viscosity) 
 
The rheological properties of the in-vivo samples and the developed in-vitro BSFs were 
measured using a Bohlin C-VOR rheometer (Malvern Instruments Ltd, UK) at 25 oC with a 
stainless-steel cone and plate geometry technique (40 mm diameter cone with a 4o cone angle) 
due to small volumes. Shear rates ranging from 0.07 to 1000 s-1 were applied for each 
measurement. The measurements were performed in triplicates with three measurements made 
for each sample. 
	
3.2.4. Development of Healthy and Disease State Biorelevant Synovial Fluids 
 
Biorelevant healthy and disease state synovial fluids were prepared with the addition of main 
components affecting dissolution, according to average values found in the literature. The 
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addition of CMC sodium salt or an increased amount of HA was used to enhance the viscosity 
value of the developed media. The buffers were chosen according to their ability to maintain 
the aimed pH value while providing osmolality values close to the measured in-vivo values. 
The biorelevant media were prepared according to the method proposed by Jantratid et al. [31]. 
The HBSS buffer was adjusted to a pH of 6.8 by adding 0.1 M of HCl before the addition of 
further components while the phosphate buffers for the OA and RA BSFs were made by adding 
0.1 M Na2HPO4 (955.1 mL/L) and 0.1 M HCl (44.9 mL/L) for 1 L of a 0.1 M buffer. The 
phosphate buffer was then adjusted to pH 8.1 (for OA) and 8 (for RA) with addition of 0.1 M 
HCl to result to the targeted pH.  
To prepare all three biorelevant media (HS, OA and RA), the following procedure was 
followed with different amounts added, according to the media developed (Table 3.2) 
1) The buffer was prepared and adjusted to the appropriate pH 
2) HA is added under continuous stirring and then the viscous solution is transferred to a 
round-bottom flask with the appropriate amount of PC (Stock solution: 100 mg/mL PC 
in dichloromethane) added 
3) The dichloromethane is driven off by using a rotary evaporator (Buchi Rotovapor R-
114 and Buchi Waterbath B-480, Buchi Labotechnik, Flawil, Switzerland) and vacuum 
(PC 2001 Vario and control system CVC 2II, Vacuubrand GMBH, Wertheim, 
Germany) at 40 oC for 15 min starting at 650 mbar and decreasing the pressure 
gradually to 100 mbar which is then maintained for a further 15 min. This led to a 
slightly cloudy micellar solution having no odour of dichloromethane 
4) The γ-globulin and BSA are then added under continuous stirring 
5) Finally, additional buffer is used to adjust the volume 
6) The medium is stored at 5 oC until used (within 3 days) 
	
3.2.5. Importance of components in the Biorelevant Synovial Fluid development 
 
3.2.5.1. Selection of buffer species 
 
During the development of the media, the PBS was found to be commonly used for simulating 
synovial fluid [29] as the ion concentrations are close to the literature data [32] leading to 
values of osmolality close to the in-vivo measurements. Alternatively, the HBSS was found to 
have salts very similar to those present in the plasma and also contained sodium bicarbonate, 
which is the body’s original buffer (together with carbonic acid) and that is why it was chosen 
for the development of the HS synovial fluid [33, 34]. The pH of the HBSS was altered in the 
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beginning of the development with the addition of 0.1 M hydrochloric acid for the final pH of 
the medium to be 7.4. The same buffer (HBSS) was initially tested for developing the disease 
state BSFs (OA and RA) but due to the additions, the buffer solution would “break” and lose 
its properties. Thus, a different phosphate buffer was chosen according to the final pH of the 
disease state media (OA and RA) (Table 3.2). The selection was made according to the ability 
of the buffer to combine the targeted pH and osmolality instead of physiological relevance 
[35]. 
	
3.2.5.2. Hyaluronic acid 
 
The lubricating and viscoelastic ability of HA has been determined from a variety of studies 
[3-8] and so its presence in the BSF is vital as a primary determinant for viscosity. Considering 
that the molecular weight and concentration would affect the viscosity of the medium [5, 24], 
as the HA used during the development has a molecular weight of 1.5-2.2 M Da, different 
amounts than the physiological should be used to have the appropriate viscosity according to 
the in-vivo measurements (Healthy: 8.1 mg/mL, OA: 4.8 mg/mL and RA: 3.5 mg/mL, 
compared to in-vivo amounts (Healthy: 3 mg/mL, OA: 1.5 mg/mL and RA: 1.3 mg/mL, Table 
3.2).  
	
3.2.5.3. Proteins (Bovine Serum Albumin and γ-globulin) 
 
As proteins seem essential components of synovial fluid, γ-globulin and bovine serum albumin 
(BSA) due to their potential effect in viscosity, they were included into the medium. The 
presence of proteins has also proven to affect the surface tension of synovial fluid [21]. 
	
3.2.5.4. Phospholipid PC 
	
The presence of lipids in the synovial fluid can be essential as they can act as the body’s natural 
surfactants, although there have not been any previously reported studies involving this 
component in the development of artificial synovial fluid. The addition of phospholipid PC 
would also improve the biorelevance of the media. 
 
Based on the decision to include these components, a HS BSF and two disease state (RA and 
OA) BSFs were developed with amounts added according to the average findings in the 
literature for each, as several media were needed to be developed in order to reflect changes in 




3.2.6. Composition of healthy state biorelevant medium 
	
The amounts of the components and the ranges of the physicochemical measurements reported 
in the literature seem to have a high variability. This may be explained by the variability in 
measuring techniques, aspiration techniques (leading to oxygenation of samples) [36] and 
biological variation, as different volunteers included in studies may differ in data involving 
age, disease progression and treatment during the time of aspiration, as injections in synovial 
fluid may affect the measurements performed. The average amounts of components added in 
the HS BSF shown in the “IN-VIVO” section of Table 3.2, were according to documented 
measurements found in the literature, with Version 1 (Table 3.2, orange) developed according 
to these average values of chosen components. The pH of HBSS had to be reduced to 6.8 
instead of its initial value of 7.4, before the addition of components, in order for the developed 
final product to acquire the targeted pH value. The adjustment took place with the addition of 
0.1 M HCl to the buffer, before the addition of any further components, as proteins precipitated 
from the added acid. In Version 2 (Table 3.2, orange), CMC sodium, a viscosity enhancer, was 
chosen to be added to the medium to reflect the effect of a viscosity enhancer, while 
measurements with the removal of HA (containing only CMC as the viscosity enhancer) were 
also performed. Different concentrations of CMC sodium were tested in order to find the 
appropriate amount, with 25 mg/mL chosen for further testing (Fig. 3.1). Regarding the HA 
used in this study, it has a molecular weight of 1.5 to 2.2 million Da with the HA contained in 
HS synovial fluid being 6.3 to 7.6 million Da [5]. Version 3 (Table 3.2, orange) shows the 
addition of HA in an appropriate amount according to the equation derived from the 
exponential fitting from the viscosity measurements with different HA amounts added to the 
buffer [Data fitted with Eq. Y=0.03947 * exp (0.6348*X)] (Prism Version 7, GraphPad) (Fig. 
3.2), as the molecular weight of HA plays a significant role in the effect it has on the viscosity 




Fig. 3.1. HS BSF viscosity measurements with the addition of CMC in HBSS 
 
3.2.7. Composition of OA biorelevant medium 
 
Table 3.2 (In-vivo OA, green) summarizes the average values of the in-vivo components found 
from the literature. Starting with measurements in each step addition of a component, in order 
to see their effect on the physicochemical properties, Version 1 was developed with a 
phosphate buffer of 0.05 M (Table 3.2, green). The phosphate buffer also includes the addition 
of salts according to the ion concentrations of the initial buffer (0.05 M) and the ion 
concentrations of the synovial fluid from the literature data, to increase osmolality to the aimed 
value [32]. In Version 2 (Table 3.2, green), the effect of CMC sodium as a viscosity enhancer 
was tested (Fig. 3.2) similarly to the HS BSF. As both osmolality and ionic strength have a 
strong impact on drug release, it is of importance to investigate the effect of different strengths 
of Molar concentration of the buffer, for concluding to the optimal level (Table 3.2, green, 
Version 2). 0.05 M was tested with the addition of salts and in versions without HA or without 
CMC or without both; 0.06 and 0.07 M were tested with or without salts and 0.1, 0.12 and 0.13 
M were tested without salts. In Version 3 (Table 3.2, green), the addition of HA is considered 
for increasing viscosity according to the equation derived from the exponential fitting of 
viscosity measurements with different HA amounts added to the buffer [Data fitted with Eq. 
Y=0.03947 * exp (0.6348*X)] (Prism, Version 7, GraphPad) (Fig. 3.4). An increased Molarity 



















No CMC 20 mg/ml CMC 25 mg/ml CMC




Fig. 3.2. OA BSF viscosity measurements with the addition of CMC in Phosphate buffer 
3.2.8. Composition of RA biorelevant medium 
 
For the RA BSF development, as with the Healthy state and OA BSF, the in-vivo average 
amounts of components found in the literature were taken into account for the amounts of the 
components added in the developed biorelevant media. The similar buffer used for OA was 
chosen and in Version 1 (Table 3.2, purple), with the addition of salts, the presence of CMC 
sodium for increasing viscosity was evaluated (Fig. 3.3). Similarly with before, the addition of 
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Version 2 Version 3 
IN-VIVO 
(OA) 
Version 1 Version 2 Version 3 
IN-VIVO 
(RA) 
Version 1 Version 2 
Buffer - HBSS HBSS HBSS - 
0.05 M NaHPO4 + 
HCl 
(+salts) 
0.05, 0.06, 0.07, 
0.1, 0.12, 0.13 M 













HA 3 3 3 and 0 8.1 1.5 2 1.5 and 0 4.8 1.3 1.3 3.5 and 0 
BSA 11.5 11.5 11.5 11.5 11.5 11.5 11.5 11.5 20.25 20.25 20.25 
γ-globulin 1.7 1.7 1.7 1.7 1.7 1.7 1.7 1.7 24.75 24.75 24.75 
PC 0.15 0.15 0.15 0.15 0.25 0.25 0.25 0.25 0.9 0.9 0.9 
CMC sodium - - 25 - - - 
5, 7.5, 12.5, 15, 
17.5  
- - 10, 11 and 12 - 
Salts - - - - - 
2.9 mg/mL NaCl 
0.3 mg/mL KCl 
2.9 mg/mL NaCl 
0.3 mg/mL KCl 
- - 
2.9 mg/mL NaCl 





Fig. 3.4. Equation derived from exponential growth fitting of 8 samples of Phosphate buffer 
with HA.  
	
3.2.9. Solubility studies of TA in in-vivo disease state (OA and RA) and biorelevant synovial 
fluid in healthy state and disease state (OA and RA) 
 
The solubility of TA in the in-vivo disease state synovial fluid (OA and RA), the in-vitro 
developed BSFs (HS, OA and RA) and in the widely used artificial synovial fluid [PBS with 
HA (3 mg/mL) at pH 7.4] [29] was determined at 37 oC. The in-vitro BSFs that were tested to 
determine TA solubility, contained additional HA to reach the viscosity of the in-vivo results. 
In addition, the solubility of TA was determined in the in-vitro BSF of HS and OA with the 
average amounts of HA found from the literature, for the biorelevant medium after the addition 
of each component. The studies were performed with the shake flask method by adding an 
excess amount of TA to the medium in test. The suspensions were then shaken in a water bath 
at 37 ± 0.5 oC (Grant SBB Aqua Plus, UK) for 24-h (achieved equilibrium). Samples were then 
withdrawn, filtered with 2.7 µm GF filters, diluted with the corresponding medium where 
appropriate before analysis and then treated with hyaluronidase solution. The amount of TA 
was then quantified in the HPLC [37]. 
 






















Synovial fluid sample preparation took place according to the method described by Sottofattori 
et al. [38]. An amount of hyaluronidase solution prepared based on manufacturer (initial 
concentration of 300-1000 U/mg) were added to the in-vivo and in-vitro developed synovial 
fluid samples to reach a final concentration of 150 U/mL which degraded HA and decrease the 
viscosity of the sample leading to an easier filtration and analysis. Hyaluronidase was 
reconstituted at 1 mg/mL in 0.02 M sodium phosphate buffer, pH 7, containing 77 mM sodium 
chloride and 0.01 % BSA. 
	
3.2.11. Triamcinolone Acetonide HPLC Analysis 
 
The solubility samples and standard solutions were analysed using an Agilent 1100 series 
HPLC system (Agilent, UK) consisting of a G1329A autosampler, a G1330A ALS thermostat, 
a G1316A thermostatted column compartment, a G1315A DAD, a G1322A degasser and a 
G1311A quaternary pump. A modification of a published method was used [64]. Reversed 
phase chromatography was performed using an Agilent Eclipse XDB-C18 column (2.6 x 250 
mm, 5µm pore size) (Agilent, UK). The flow rate was set at 1 mL/min, temperature at 25 oC, 
the UV detection signal was set at 240 nm, stop time at 24 min and injection volume 20 µL. 
The HPLC method included a gradient with increased water % in the beginning of each run 
(methanol:water at 10:90 for 8 min and then at 65:35 for 16 min).  
Samples were diluted with the corresponding medium, where appropriate, before analysing 
with the HPLC to determine the amount of TA dissolved. Working calibration standards from 
a range of concentrations (2-10 µg/mL) were composed with a solution of hyaluronidase being 
added to the sample. The hyaluronidase solution was added to the sample and then a 20 µg/mL 
aqueous intermediate (PBS) of the stock solution of TA in methanol (5 mg/mL) was added to 
the synovial fluid-enzyme solution in appropriate volumes to prepare the spiked standards 
following the sample preparation technique. Adding the stock solution directly into the blank 
BSF caused protein precipitation due to the strong effect of the organic solvent. The drug 
amount was chosen to be included before the addition of the hyaluronidase, to follow the same 
process observed in the solubility studies; the sample including the drug and the addition of the 
degrading enzyme following afterwards. The % dissolved was calculated according to a 






3.3. Results and Discussion 
 
3.3.1 Physicochemical properties of in-vivo disease state Synovial Fluid (OA and RA) 
 
3.3.1.1. pH and osmolality 
 
The mean pH of the OA samples was at 8.04 ± 0.41 making it slightly basic. The pH of the RA 
samples was 7.56 ± 0.11 which is close to the value of the synovial fluid in physiological 
conditions. The osmolality of the RA and OA samples was similar and close to isosmotic values 
(299.5 ± 9.87 and 301.89 ± 9.55 mOsm/kg, respectively) (Table 3.4 and 3.5, IN-VIVO).  
The measurement of pH is of primary importance as it can have a significant effect on the 
dissolution of drug products. Comparing these results to literature data, the OA pH measured 
seems to be in accordance with most published data [40] but also slightly higher than other 
recorded results [41]. Studies conducted with different aspiration and measurement techniques 
may lead to non-correlating results [2] and so this difference in values may be explained by the 
variability in measuring techniques and aspiration techniques (leading to oxygenation of 
samples) [36]. Biological variation may also be the cause, as different volunteers included in 
studies may differ in data involving age, disease progression and treatment during the time of 
aspiration, as injections in synovial fluid may affect measurements performed [2, 40, 42, 43]. 
An explanation has also been given involving the measurement of the hydrogen ion 
concentration determining the pH value; as the samples are withdrawn from the synovial 
cavity, oxygenation may take place, changing the hydrogen ion concentration and showing 
higher pH values, as pH measurements involve the measurement of the hydrogen ions 
concentration in the solution [36]. This indicates that pH results should be closer to 
physiological values (pH: 7.5) as synovial fluid is an ultrafiltrate of the blood [7, 32, 44] and 
so values should be similar to the pH of blood. This was also suggested from the synovial fluid 
pH of RA patients, as measured results show a value close to physiological (7.56 ± 0.11) (Table 
3.5). Although previously documented results are in good correlation with these measurements 
from RA patients [40], data from other studies have shown lower values. A lower value of pH 
for RA synovial fluid was justified from a topical lactic-acid acidosis taking place in the joint 
due to the inflammation caused by the disease. In addition, the position of the needle while 
withdrawing fluid, has proven to be of importance for the reproducibility of readings in RA 
measurements, which was not an issue for normal joints. In RA, the synovial membrane has 
acid producing villi formed in its surface that may entrap synovial fluid in its folds and if 
synovial fluid is withdrawn from those positions, the pH will be lower than the actual value 
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[36, 45]. Similarly to the OA samples, oxygenation of the withdrawn samples can be the reason 
for the measurements being of a higher value [40]. 
Osmolality measurements showed isosmotic values of approximately 300 mOsm for OA and 
RA synovial fluids (Table 3.4 and 3.5, IN-VIVO). The principal cation affecting osmolality in 
synovial fluid is sodium (approx. 145 mM) and the principal anion is chloride (approx. 107.4 
mM) [32]. Results for the OA synovial fluid were consistent with earlier results [46] while 
another study showed lower values [47]. In disease state, the HA present in synovial fluid 
changes in amount and form. According to the progression of the disease, the conformation 
may be different and so patients may have differing values. Due to the conformational change 
and the difference in molecular weight of the HA (in HS: 6.3-7.6 MDa compared to 1.06-3.48 
MDa in OA and 3.2-6.8 MDa in RA [5]), there is an increase of bound water instead of salt 
leading to decreased osmolality [42, 46]. Differences in osmolality may also be explained by 
the presence of chondrocytes in the articular cartilage, as they seem to be affected by the 
difference in osmolarity while regulating the gene expression of chondrogenic transcription 
factors together with ECM constituents [47]. The osmolality of RA samples recorded in earlier 
studies are consistant with the measurements our group has recorded, with a mean value of 280 
±7.7 mOsm [46] and a range of 273-283 mOsm [47]. A slight difference which may be 
considered between the two disease states is explained by the change of the constituent 
concentrations through the disease, such as total protein being lower in OA and also due to the 
extra enzymes and debris present in the joint during RA [46]. 
	
3.3.1.2. Surface tension 
 
The surface tension of RA was 47.6 ± 2.2 mN/m and 45.4 ± 3.8 mN/m for OA (Table 3.4 and 
3.5, IN-VIVO). The value measured for the RA fluid was in accordance to previously recorded 
measurements in the literature [48]. Different amounts of phospholipids are present in OA and 
RA synovial fluids due to the degeneration of the synovium, on which the surface-active 
phospholipids are bound. Although the surface tension is primarily affected by their presence, 
the values measured seem to be similar in the OA and RA synovial fluids with no significant 
difference observed between the two disease states. The measurements are lower than healthy 
state synovial fluid values found in the literature [24] as disease state synovial fluids contain a 
higher amount of phospholipids [22, 23, 49, 50]. The RA synovial fluid contains larger amounts 
of immunoglobulin complexes, fibrin and fibrinogen than serum and healthy state synovial 




3.3.1.3. Viscosity vs. shear rate 
 
Our measurements showed that for shear rates from 0.07 to 1000 1/s the viscosity values for 
RA fluid had an average value of 0.36 to 0.01 Pa s and the OA fluid had an average value of 
0.88 to 0.01 Pa s while a higher variability was apparent in the lowest shear rates (Table 3.4 
and 3.5, IN-VIVO). OA synovial fluid has non-Newtonian shear thinning properties which 
means that the viscosity will decrease as the shear rate becomes higher [5, 24, 52, 53] compared 
to the Newtonian properties of the RA synovial fluid [54]. Hence, it is common in the literature 
to present viscosity values against shear rates, as a specific viscosity or values over time are 
difficult to interpret [55]. Studies comparing the viscosity of OA with RA synovial fluid 
showed lower viscosity at the same shear rates [52, 53, 56] for the latter.  
The primary component affecting viscosity in synovial fluid is the HA [7, 26, 32, 44, 50]. While 
a higher concentration or molecular weight of hyaluronic acid increases viscosity [5, 24], 
increasing the concentration in an aqueous solution above 1 mg/mL or by increasing the 
molecular weight from 0.15 x 106 Da to 1.2 x 106 Da [24, 57] leads to the formation of an 
entanglement network, enhancing the increase of viscosity [24]. The viscosity of OA and RA 
synovial fluids have been measured in earlier studies and are in accordance with the 
measurements performed; showing that the viscosity in OA samples is higher than in RA at the 
measured shear rates [5, 24, 41, 52, 58] although varying according to the type of rheometer 
used and shear rates chosen. From our results, it is noticeable that the difference in viscosity 
measurements between OA and RA synovial fluid is more significant in low shear rates while 
there is no difference in the highest shear rate tested due to shear-thinning abilities of the 
synovial fluid [5]. The importance of the leading effect of HA on viscosity was also shown in 
tests during which HA was degraded with the use of an enzyme, such as hyaluronidase [38], 
and showed a significant decrease in viscosity and elasticity [59]. As the concentration of HA 
affects viscosity, data from literature shows that the amount in OA synovial fluid is higher 
compared to RA, due to the damaged synovial membrane which produces HA, and also due to 
dilution with blood in the synovial cavity [5, 56, 60]. As for the molecular weight of HA, it has 
lower values for the disease states compared to the HS synovial fluid, due to depolymerisation 
[5]. More specifically this reaction is caused by certain components present in blood, such as 





3.3.2. Physicochemical properties of Biorelevant Synovial Fluid (Healthy state, OA and RA)  
 
3.3.2.1. Healthy state biorelevant synovial fluid (HS BSF) 
 
Table 3.3. Physicochemical properties of developed HS BSF  
Components 
HS BSF 
IN-VIVO Version 1 Version 2 Version 3 
  Buffer + HA + PC + BSA +g-glob +CMC +CMC 
 -HA 
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The amounts of the components and the ranges of the physicochemical measurements reported 
in the literature seem to have a high variability. This may be explained by the variability in 
measuring techniques, aspiration techniques (leading to oxygenation of samples) [36] and 
biological variation, as different volunteers included in studies may differ in data involving 
age, disease progression and treatment during the time of aspiration, as injections in synovial 
fluid may affect measurements performed. 
	
The physicochemical properties in Version 1 (Table 3.3) were measured in each addition step 
in order to see the effect each component may have. During the addition of each component, 
noticeably, the pH was more affected by the addition of HA and then PC, as the pH value 
increased by approximately 1 unit with each addition, while it reduced to the intended value 
with the addition of BSA and γ-globulin. The osmolality of the medium in Version 1 reflected 
the iso-osmolal values of the in-vivo literature data. Regarding the surface tension, although 
the addition of PC potentially reduces its value [22], the difference seen was not significant, 
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while the addition of proteins had a slightly stronger effect [21] resulting to the value of the 
literature. The viscosity, although increased with the addition of HA, does not seem to be 
significantly influenced by the addition of the extra components. While HA was added in the 
correct average amount, the viscosity did not seem to be close to the anticipated value. This is 
because the molecular weight of HA plays a significant role in the effect it has on the viscosity 
of the medium [5, 24]. Measurements in Version 2 (Table 3.3) show the effect of the addition 
of CMC in viscosity, while measurements with the removal of HA were also performed. 
Different concentrations of CMC sodium were tested in order to find the appropriate amount, 
with 25 mg/mL chosen for further testing (Fig. 3.1). Results showed that the addition of CMC 
sodium led to an exponential increase in viscosity [61-64]. Results with the addition of CMC 
sodium and removal of HA, showed that the presence of CMC sodium does affect the viscosity 
significantly, by enhancing rather than replacing the viscosity effect of HA. The addition of 
CMC in its sodium salt form also has a significant impact on the osmolality of the medium as 
it causes an increase while the surface tension seems to slightly reduce (Table 3.3). 
Version 3 (Table 3.3) shows the addition of HA in an appropriate amount according to the 
equation derived from the exponential fitting from the viscosity measurements with different 
HA amounts added to the buffer (Fig. 3.4) [5, 24]. In addition, the presence of HA as the 
viscosity enhancer compared to the use of CMC leads to the viscosity and surface tension 
values being of accordance with the in-vivo data with a slight decrease in osmolality which 
reached a value similar to Version 1 (Table 3.3), as the sodium salt of CMC, increasing the 
osmolality, is not present. Version 1 (Table 3.3) was chosen to test the solubility of TA and 
according to the relevance of the physicochemical property results with the in-vivo results from 
literature, Version 3 was tested as well. 
 
3.3.2.2. Osteoarthritis biorelevant synovial fluid (OA BSF) 
 
Table 3.4 summarizes the measured physicochemical properties used for the development of 
the OA BSF. Starting with measurements in each step addition of a component, in order to see 
their effect on the physicochemical properties, Version 1 with a phosphate buffer of 0.05 M 
was developed. The differences observed between the HS and OA BSF (Version 1, Table 3.4) 
seem to be significant in the way the components added affect the change in the pH. This can 
be explained due to the strength of the buffer used, as the HBSS is at 0.1X and the phosphate 
buffer is at 0.05 M and so a stronger buffer would be more resistant to changes in pH when 
small quantities of components which may affect it, are added. 
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In Version 2 (Table 3.4), the effect of CMC sodium as a viscosity enhancer was tested (Fig. 
3.2), showing that with this addition, the osmolality and viscosity increases while the pH and 
surface tension remains constant. Removing the HA shows that the effect of CMC sodium 
enhances rather than replaces the viscosity. This may be due to the different processes followed 
to increase viscosity. CMC sodium, compared to HA, when dissolved in the medium separates 
into sodium cations and a polymer anion due to an electrolytic process which then interact with 
each other through electrostatic forces. Also electrostatic interactions (hydrogen bonds) take 
place as the water molecule and OH groups on the CMC molecule exhibit electric dipole which 
have a vital importance in the viscosity effect [63].  
Having no presence of a component primarily affecting the viscosity (removal of CMC sodium 
and HA), led to a value close to the viscosity of the buffer although slightly increased due to 
the presence of proteins and their aggregation [65-68]. A difference in buffer Molarity did not 
seem to have a significant effect on the pH or the viscosity of the medium while with increasing 
Molarity, the surface tension  slightly rose (Version 2, Table 3.4). Changing the concentration 
of the solutes in the buffer, by increasing sodium and potassium ions, led to the increase of the 
buffer osmolality. This is shown as media with similar Molarities have different osmolality 
values with the addition or removal of salts and also by increasing the strength of the buffer 
(Version 2, Table 3.4). In Version 3 (Table 3.4), the addition of HA is considered for increasing 
viscosity according to the equation derived from the exponential fitting of viscosity 
measurements with different HA amounts added to the buffer (Table 3.4, Fig. 3.4). An 
increased Molarity was chosen without the addition of salts as the phosphate buffer (0.1 M) 
and all the physicochemical properties measured were of accordance with the in-vivo data. 
Version 1 (Table 3.4) was chosen to test the solubility of TA and according to the relevance of 
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3.3.2.3. Rheumatoid Arthritis biorelevant synovial fluid (RA BSF) 
 
In Version 1 (Table 3.5), the average component amounts together with added salts and the 
presence of CMC sodium for increasing viscosity, show that a small increase in CMC amount 
might affect the viscosity but the osmolality, pH and surface tension may stay unaffected. 
Similarly to before, the addition of HA (Fig. 3.4) was tested instead of CMC sodium (Version 
2, Table 3.5) with the final measurements being in accordance with the in-vivo data. According 
to the relevance of the physicochemical property results with the in-vivo fluid, Version 2 (Table 
3.5) was chosen for testing solubility with TA. 
 
Table 3.5. Physicochemical properties of developed RA state BSF 
Components 
RA BSF 
IN-VIVO Version 1 Version 2 
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3.3.3. Solubility studies  
 
The solubility studies of TA in the in-vivo disease states showed that, in RA, the drug has a 
solubility of 54.15 ± 19.1 µg/mL and in OA 29.84 ± 9.46 µg/mL (Fig. 3.5). The solubility of 
TA in RA synovial samples is higher suggesting that the amounts of components added to the 
two pathogenic synovial fluids affect the solubility and probably the dissolution rate of the 
drug in the joint [9]. The component most likely affecting solubility is the lipids present in 
different concentrations in the disease state media as they act as the body’s natural surfactants. 
The lipids manage to transform a hydrophobic surface into a hydrophilic one by an aggregation 
process. The molecules are arranged into energetically favourable vesicles and lamellar spheres 
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to form a type of reservoir for surfactants in the lubrication process [22, 23] leading to the fact 
that they may substantially contribute to the enhancement of the solubility and dissolution of 
poorly soluble drugs in the fluid. 
 
Fig. 3.5. Mean ± SEM solubility of TA in synovial fluid of OA and RA patients (OA, n=14, 
RA, n=10) 
 
Regarding studies with the in-vitro fluid, measuring the solubility of TA in each step addition 
of the components, in the HS and OA BSF, the addition of PC increased the solubility 
significantly compared to the addition of the proteins (Table 3.6). Comparing the TA solubility 
values in the in-vivo disease state results (Fig. 3.5) with the in-vitro disease state results (Table 
3.7) (OA 29.8 µg/mL to 17.4 µg/mL and for RA 54 µg/mL to 19.4 µg/mL respectively) in-vivo 
results were higher. Although the components added to the BSF and the physicochemical 
properties tested are similar, the solubility seems to differ. Comparing the developed BSFs 
between them and with the widely used artificial synovial fluid [PBS with HA (3 mg/mL)], 
showed slight differences. The solubility of the developed BSFs seems to be lower in 
HS<OA<RA which would be explained primarily by the amount of PC phospholipids 
contained in the media, following the same pattern. There does not seem to be a significant 
difference with the widely used artificial synovial fluid although it does not contain any of the 
physiological components present in the developed media apart from HA. Despite this, the 
developed media may well have a significant effect on the solubilisation and dissolution rate 
of drugs, as they have different viscosities. Considering the macroviscosity of the solution, a 
more viscous fluid will slow down the diffusional mass transport and according to 
microviscosity and the Stokes-Einstein equation, this parameter has vital importance in the 























Table 3.6. Solubility of TA in HS BSF (Version 1 Table 3.3) and OA BSF (Version 1 Table 
3.4) after each component addition 
Components added to BSF HBSS + HA (HS) or  
Phosphate Buffer + 
HA (OA) 
+ PC + BSA + γ-globulin 
(Completed 
BSF) 

















Table 3.7. Solubility of TA in in-vivo OA, RA synovial fluid and in in-vitro HS BSF (Version 
3 Table 3.3), OA BSF (Version 3 Table 3.4), RA BSF (Version 2 Table 3.5) and artificial 
synovial fluid [PBS + HA )3 mg/mL)]  
Synovial Fluid HS BSF OA BSF RA BSF PBS + HA 
Artificial 
Synovial Fluid 





























Three BSFs were developed (HS, OA and RA) with their physicochemical parameter values 
being in accordance with the in-vivo measurements of disease state synovial fluid by taking 
into consideration the average values of the component amounts found in literature. 
Development of the media was according to the components that would have a strong effect in 
drug dissolution in these media. As the molecular weight of HA has a significant importance 
in viscosity enhancement and each synovial fluid state has HA of different molecular weights, 
using the average amount found in literature, did not provide the expected viscosity according 
to the in-vivo study measurements. By testing viscosity enhancers such as CMC or with 
additional amounts of HA, the appropriate viscosity for the developed BSFs could be achieved. 
According to the solubility studies performed, TA solubility in the developed BSFs were 
slightly below the values of TA solubility in the in-vivo OA and RA synovial fluids. Comparing 
the developed media to the widely used artificial synovial fluid, showed that there are 
differences between disease and healthy state. The developed BSFs reflect the influence of the 
altered component amounts and the difference in viscosity. These media can be recommended 
for the prediction of drug dissolution from IA formulations in the healthy and diseased joints, 
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Purpose: To develop biorelevant drug dissolution tests for IA formulations and define the 
effect of setup parameters and hydrodynamics on drug dissolution and permeation. 
Methods: TA dissolution and permeation was investigated from an IA suspension using Side-
Bi-Side cells and a bi-phasic setup. The amount of drug applied to the methods was based on 
the in-vivo clinical dose. Side-Bi-Side cells were used in three different setups with a static 
flow simulating the permeation of the drug through the synovial membrane (Setup I), a flow 
through the receptor phase simulating the blood circulation on the outer part of the synovial 
cavity (Setup II) and a flow from the donor to the receptor simulating the transynovial flow 
(Setup III). In static flow, the simultaneous measurement of dissolution and permeation of the 
drug was enabled. With a flow present, the permeation of the drug through the membrane was 
assessed, mimicking the permeation of the drug from the synovial cavity to the blood 
circulation through the synovium. Parameters such as the membrane [GF/F, GF-6, GF-10, a 
combination of GF-6 and GF-10, Polytetrafluoroethylene (PTFE), cellulose acetate (CA) 
membrane], the medium [PBS with Tween 80 (1% v/v), organic solvent (methanol, 1-octanol), 
biphasic setup with PBS with Tween 80 (1% v/v) and 1-octanol and also biorelevant media 
such as healthy state BSF, PBS with HA and HS, OA and RA BSFs without HA], the flow rate 
(0.1 and 0.2 mL/min) and also the drug amount (0.3 and 1 mg TA) were tested in order to 
assess their effect on drug dissolution and permeation. In the bi-phasic setup, drug dissolution 
and permeation was also assessed with the use of developed BSFs without HA (HS, OA and 
RA), with 1-octanol as the organic phase, acting as the reservoir for the dissolved drug. 
Measurements took place from both phases. 
Results: Using the side-Bi-side setup, in Setup I, the PTFE membrane did not allow permeation 
of the drug compared to GF/F and CA, while the organic solvents tested showed no significant 
difference to the permeation of TA compared with PBS with Tween 80 (1% v/v), apart from 
methanol. With setup II, a flow present in the receptor phase showed a higher % of permeation 
of TA compared to the static flow in setup I. In setup III, less drug in the donor phase reached 
full permeation faster and a higher flow rate also led to increased permeation. Comparing 
media, the use of non-biorelevant PBS with Tween 80 (1% v/v) led to higher TA permeation. 
Membranes with higher pore size and loading capacity (GF-6 and GF-10) also led to a higher 
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amount of TA permeation. Between biorelevant media, there was no significant difference 
comparing HS BSF and PBS with HA. With BSF without HA, the HS and OA state led to 
higher TA permeation than with the use of RA state BSF. With the bi-phasic setup, 
discrimination in TA dissolution between the BSFs without HA tested, was not significant 
although difference in dissolution profiles was observed in comparison to testing TA 
dissolution in PBS. 
Conclusions: The tested systems allow better simulation of the physiological variables of the 
synovial cavity in comparison to compendial dissolution apparatus. This may become quite 
useful to predict in-vivo behaviour of IA formulations after joint injection while it can also 



























IA administration has proven to be a very attractive drug delivery approach for conditions 
affecting the joints, due to the multiple advantages offered and especially the direct application 
to the main site of the developed disease [1]. Compared to the delivery of conventional products 
such as tablets and capsules, this type of administration provides the possibility of high initial 
drug concentrations at the site of action with just a low amount of drug injected as exposure to 
non-related sites is minimised [2]. With limited systemic toxicity, this route is suitable for drugs 
with good efficacy but a low bioavailability, such as proteins or low solubility drugs [3]. Due 
to these advantages, there is a vast amount of IA formulations in the market, with an extensive 
number in the current pipeline of major pharmaceutical companies [2, 4, 5]. 
	
Drug dissolution testing is an important evaluation tool for measuring the rate and extent of 
drug dissolution from a dosage form. It has also been used for quality control evaluation during 
early and late stages of drug and formulation development, acting as a vital factor for the 
approval of newly marketed drug products [6, 7]. Standardised, official dissolution methods 
could be used for these purposes and for the optimization of therapeutic effectiveness during 
product development, but these compendial dissolution tests would not offer an assessment of 
biopharmaceutical properties, bioequivalence and predictive results of in-vivo bioavailability 
and behaviour due to their lack of biorelevance [6, 8]. Although there is a high unmet need for 
an official dissolution test in accordance with regulatory authorities, at the moment, there is no 
standardised official dissolution method for testing drug dissolution for parenteral and more 
specifically for IA products [9, 10]. Methodologies such as sample and separate, dialysis and 
continuous flow have been widely used conventional systems for parenteral formulations [11, 
12], but with no sufficient simulation of the physiological environment and hydrodynamics of 
the synovial cavity, providing a weak prediction of in-vivo behaviour. Biorelevant dissolution 
for IA drugs would be performed under simulated in-vivo conditions for predicting the 
dissolution of drugs administered into the joint and subsequently the synovial fluid. This 
research tool may be able to reduce the amount of bioequivalence studies performed in various 
stages of the drug/formulation approval process, improve product quality and reduce relevant 
regulatory procedures [6]. It is crucial for the dissolution tests to be performed under exact 
simulated conditions of the synovial fluid physiology, with the choice of media and suitable 
instrument parameters mimicking hydrodynamics being of vital importance to be able to 
predict in-vivo bioavailability [13]. As there is no compendial setup simulating hydrodynamics 
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and resembling in-vivo conditions, modified setups could be of better use. A combination of a 
widely acceptable apparatus simulating the hydrodynamics of the joint with an appropriate 
setup with a suitable dissolution method and a medium that would simulate the synovial fluid 
conditions, would have the potential to provide efficient in-vivo predictive biorelevance. 
	
For a more predictive biorelevant test of in-vivo conditions, a biorelevant fluid should simulate 
the synovial fluid in HS and in disease states, during which parameters affecting drug 
dissolution may change. Many of the biorelevant dissolution media used in various studies 
simulating the synovial fluid, may not be adequate for this purpose as they may not contain all 
the appropriate key components affecting drug dissolution and so being appropriate for 
predictive models [14-18]. Although several attempts have been made to simulate the 
conditions in the synovial cavity, in most media, attention is given to the addition of HA which 
provides viscoelastic properties to the fluid. Although viscosity does affect dissolution rate as 
it partly determines the diffusion coefficient in the Noyes-Whitney equation (Chapter 3) [19], 
there are components that provide solubilising effects to the tested drug such as phospholipids 
[20, 21] which have not been added to developed biorelevant fluid before. To have a better 
prediction of drug solubility and dissolution rate in the synovial cavity, an updated version of 
the widely used simulated synovial fluid [14] containing valuable components affecting 
solubilisation and dissolution was evaluated in Chapter 3, considering the missing 
physiological relevance of the composition. 
	
The volume of synovial fluid in the knee would be 0.5-2 mL for a HS individual and more than 
3.5 mL for a patient with OA [1]. The synovial fluid is an ultrafiltrate of the blood, being 
filtered from the blood circulation towards the inside of the synovial cavity through the 
synovial membrane; then the created synovial fluid is also filtered outside of the synovial cavity 
and again into the blood stream through the synovial membrane (transynovial flow). The 
synovial membrane (synovium) is quite thin (15-20 µm in the rabbit knee and 60 µm in the 
human knee [22]) and has an ECM of collagen and glycosaminoglycans [23] and the fluid 
flows through its 1-2 µm gaps between the synovial lining cells [24]. The aqueous transynovial 
flow is normally 5-10 µL/min for a flexed knee joint, with an IA pressure of approximately 2 
cmH2O inside the cavity [23]. With increased fluid volume inside the joint due to conditions 
such as chronic joint effusion, the IA pressure increases to approximately 20 cmH2O affecting 
the transynovial flow that also increases to 20-40 µL/min [25].  The flow causes the volume of 
the synovial fluid in the cavity to be replaced (refreshed) multiple times during the day with 
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water and proteins replaced in less than 2 hours and HA in 38 hours in a normal individual and 
in patients with OA [1, 26]. In patients with RA due to the extensive damage of the synovial 
membrane, the proteins that enter and are cleared from the synovial cavity is up to three times 
more than in healthy individuals [1].  
	
In order to evaluate permeation through membranes, in-vitro diffusion has been studied 
throughout the years, with setups involving the placement of the drug in the donor chamber, 
an artificial or biological membrane, a fluid passing through and the measurement of the flux 
from the receptor chamber. These type of configurations have been applied for the study of 
various drug delivery systems with a biorelevant approach depending on the type of membrane 
and type of medium used. Diffusion cells have been applied for studying diffusion in numerous 
delivery systems: for oral formulations, by measuring oral absorption from permeation across 
Caco-2 cell monolayers [27] and mimicking the physiological conditions of the human GI tract 
[28]; for drug delivery through the blood-brain barrier (BBB) by studying permeation effects 
through microvessel endothelial cells [29] and the involvement of the neurokinin (NK-1) 
receptor in the permeation of Substance P across the BBB with bovine brain microvessel 
endothelial cells (BBMEC) monolayers grown on polycarbonate membranes mounted on the 
diffusion apparatus [30]; for delivery through buccal absorption by studying the permeability 
characteristics of cultured buccal epithelial cells used as the membrane in the diffusion 
apparatus [31] and examining drug permeation across porcine buccal mucosa [32, 33]; and for 
pulmonary delivery by testing permeability through cystic fibrosis mucus solution for 
simulating disease state mucus [34] while the application of iontophoretic transport of drugs 
across a biological membrane has also been applied [35].  
	
The application of a bi-phasic setup has also been suggested for simulating biorelevance of 
drug partitioning through a membrane. The setup involves the use of an upper organic layer 
which would be in equilibrium with the aqueous layer in test [36]. The drug which would be 
placed in the aqueous layer, would dissolve and by exploiting its lipophilicity (logP) it would 
partition into the organic layer which would act as a reservoir for the dissolved drug. This way, 
sink conditions would be maintained in the system until complete dissolution. The biorelevance 
in this model was initially reported by Gibaldi and Feldman [37], who suggested that the 
partitioning of the drug after dissolving in the aqueous phase, would be analogous to the 
absorbance of the drug from the gastrointestinal (GI) tract during the dissolution rate-limited 
absorption. This setup has been used since in multiple studies and has also been considered for 
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coupling with USP apparatus such as the USP apparatus IV [38, 39] and the USP apparatus II 
[40, 41]. The biorelevance noted in this setup may also be considered for an IA drug delivery 
system as the removal of the drug from the GI tract may reflect the permeation of the drug 
through the synovial membrane and into the sub-synovium and the blood circulation. 
	
The aim of our research was to develop an in-vitro biorelevant dissolution test that can be used 
for the characterisation of drug dissolution and diffusion according to the physiological 
conditions present in the synovial joint. To achieve this aim, the objectives were to simulate 
the conditions in the synovial cavity by considering and evaluating the media used and the 
composition of the synovial fluid in healthy and disease state on drug dissolution, the 
hydrodynamics of the joint in terms of the volume of the fluid, the flow present in the synovial 
cavity in three membrane diffusion setups (static flow, blood circulation flow and transynovial 
flow), the effect of drug amount on the tested setups and the effect of the membrane applied. 
With a bi-phasic model we evaluated the effect of developed BSF in Chapter 3, on drug 

































TA (98+%, fine chemical) was purchased from Alfa Aesar (UK), Kenalog 40® (TA 40 mg/mL) 
and Adcortyl® (TA 10 mg/mL) were purchased from Bristol-Myers Squibb (UK). For all 
experiments, ultra-pure water was used obtained from a Milli-Q purification device. The 
phosphate buffers were made with sodium chloride (≥99.9%), potassium dihydrogen 
orthophosphate (≥99.5%), di-sodium hydrogen orthophosphate, anhydrous dried (≥99.5%) and 
potassium chloride (≥99.5%) which were purchased from Sigma-Aldrich (UK). The BSF 
produced, was made with HBSS 1X without calcium, magnesium, phenol red; bovine serum 
albumin powder, fraction V; sodium hyaluronate 95%, all purchased from Fisher Scientific 
(UK), γ-globulin from bovine blood purchase from Sigma-Aldrich (UK) and phospholipid PC 
from Egg purchased from Lipoid (Germany). Hyaluronidase from bovine tests, type VIII, 
lyophilized powder (300-1000 U/mg) was purchased from Sigma-Aldrich (UK). Tween 80 was 
bought from VWR (UK) and 1-Octanol (99%, pure) was purchased from Fisher Scientific 
(UK), while methanol was purchased from Sigma-Aldrich (UK). The membranes used, were 
ordered from Whatman (GE Healthcare Life Sciences) and include different types of glass 
microfiber filters (GF) GF/F, GF-6, GF-10 and membranes from CA (0.45 µm) and PTFE (0.45 




4.2.2.1. Media evaluated in biorelevant dissolution studies 
 
4.2.2.1.1. Non-biorelevant media 
 
In the setups involving the side-Bi-side cells, the media tested in the static flow (Setup I, Table 
4.1) were PBS with Tween 80 (1% v/v), methanol, 1-octanol and a biphasic system containing 
PBS with Tween 80 (1% v/v) and 1-octanol. In setup II and III (Table 4.1), the non-biorelevant 
medium tested was PBS with Tween 80 (1% v/v). 
	
4.2.2.1.2. Biorelevant media of Healthy and Disease State Synovial Fluid 
 
BSFs were tested with the side-Bi-side setup III (Table 4.1) in three states, healthy, OA and 
RA and also in the widely used artificial synovial fluid containing PBS with HA (3 mg/mL) 
[14]. The BSF media were prepared with the addition of main components affecting 
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dissolution, excluding HA, with average values found in the literature (Table 4.2) in accordance 
with Chapter 3. The healthy state BSF was also evaluated with the addition of HA according 
to the values found in the literature. In the monophasic and bi-phasic setups, the similar BSFs 
simulating the healthy state, OA and RA, excluding the component HA, were tested. To prepare 
the media, the procedure followed was according to the development of BSFs in Chapter 3, 






















































Flow rate 0 mL/min 0.2 mL/min 0.1 - 0.2 mL/min 
Membrane 







Glass microfiber (GF/F) 
Glass microfiber (GF/F, GF-





(donor and receptor 
compartment) 






Biphasic: PBS with Tween 
80 (1% v/v) and 1-octanol  
PBS + Tween 80 (1% v/v) 
PBS + Tween 80 (1% v/v) 
 
BSF with HA (Healthy 
state) 
 
BSF without HA (Healthy 
state, OA and RA) 
 
PBS + HA (3 mg/mL) 
Sampling times 
Every 30 min up to 1 hour, 
then every 2 hours up to 12 
hours and then 24 hours 
Every 30 min up to 1 hour, 
then every 2 hours up to 12 
hours 
Every 30 min up to 1 hour, 
then every 2 hours up to 8 or 
12 hours 
Sampling points Donor and receptor phase Receptor phase Receptor phase 
Volume of medium 
(Donor - Receptor) 
3.5 mL 1.5 mL 1.5 mL 
Amount of drug 
1 mL of TA suspension 10 
mg/mL (Adcortyl®) 
1 mL of TA suspension 10 
mg/mL (Adcortyl®) 
0.1 and 1 mL of TA 







Fig 4.1. Side-Bi-Side setups in this study. Setup I (above), setup II (bottom, left), setup III 
(bottom, right) 
 
Table 4.2. Composition of Biorelevant media simulating synovial fluid in healthy state, OA 
and RA 
Components (mg/mL) Healthy State Osteoarthritis (OA) Rheumatoid Arthritis (RA) 
Buffer HBSS 0.1 M NaHPO4 + HCl 0.1 M NaHPO4 + HCl 
HA 3 or 0 0 0 
BSA 11.5 11.5 20.25 
γ-globulin 1.7 1.7 24.75 
PC 0.15 0.25 0.9 
 
4.2.2.2. Solubility studies 
 
The solubility of TA in the developed biorelevant media (Healthy state, OA and RA) without 
HA, was determined at 37 oC. The study was performed with the shake-flask method by adding 
an excess amount of the drug to the medium in test. The suspensions were then shaken in a 
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water bath at 37 ± 0.5 oC (Grant SBB Aqua Plus, UK) for 24-h. Samples were then withdrawn, 
filtered with 0.45 µm RC filters, diluted with the corresponding medium where appropriate 
before analysis and then the TA amount was quantified in the HPLC. 
	
4.2.2.3. Biorelevant in-vitro dissolution/permeation testing 
	
4.2.2.3.1. In-vitro dissolution/permeation setups with Side-Bi-Side cells  
	
The dissolution and permeation of TA was studied from commercially available Side-Bi-Side 
diffusion cells (Permegear Inc., USA). A controlled stirring rate (300 rpm) was applied in both 
compartments with 7 mm stir bars (Sigma-Aldrich, UK) in each glass half cell and a 
temperature of 37 oC applied. The cells were placed on temperature controlled magnetic 
stirrers. A membrane or filter was then applied between the glass half cells, which were then 
tightened together with a cell clamp. The system mimics the structure of the joint [22, 43] 
which is represented by two cavities, the donor phase (synovial cavity) and receptor phase 
(subsynovial cavity – blood circulation) which are separated by the membrane/filter (synovial 
membrane). The donor compartment in the glass cell half, represents the synovial cavity in 
which the drug is administered, the membrane in the setup represents the synovial membrane, 
and the receptor compartment in the other glass cell half represents the sub-synovium cavity in 
which the blood circulation flows. The physiological environment is simulated with low 
volumes in each compartment and with an open system flow in the setup, mimicking the blood 
circulation (flow in receptor phase) or the transynovial flow (flow from donor to receptor 
phase). Fig. 4.1. illustrates the different setups of the Side-bi-Side cells tested according to the 
actions taking place in the synovial cavity during and after the IA injection process. 
	
4.2.2.3.1.1. Setup I. Static flow 
 
Setup I explores the dissolution and permeation of TA through the membrane with static 
medium flow; the parameters tested being described in Table 4.2. In this setup, sampling takes 
place in both compartments, measuring dissolution in the donor compartment, where the drug 
is placed and permeation through the examined membrane and at the other compartment 
(receptor). In Setup I, the effect of different membranes and media was evaluated. Glass 
microfiber filters (GF/F, GF-6, GF-10) were used as the membrane between the donor and 
receptor compartment, with CA and PTFE filters tested as well. The cells used in this setup did 
not have ports allowing a flow through the receptors (as in setups II and III) and the volume of 
medium in each compartment was 3.5 mL. 1 mL of the TA suspension 10 mg/mL (Adcortyl®) 
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with medium [PBS with Tween 80 (1% v/v)], organic solvent (methanol or 1-octanol) or a bi-
phasic setup [PBS with Tween 80 (1% v/v) and 1-octanol) was placed in the donor and receptor 
compartment. 100 µL samples were taken in multiple time points up to 24-h, from both 
compartments, with syringes from a zone midway between the surface of the medium and the 
bottom of the glass cell, with volume replacement with fresh medium. Samples from both 
compartments were injected in the HPLC, with measurements showing the amount of drug 
dissolved (donor compartment) and drug diffused through the membrane (receptor 
compartment). The % dissolved was calculated according to a calibration curve (2-10 µg/mL) 
in the corresponding medium [44]. Results are presented as Mean (% dissolved over time) ± 
S.D. 
 
4.2.2.3.1.2. Setup II. Flow of medium in receptor phase (Simulating blood circulation) 
 
In setup II (Fig. 4.1), there is a continuous flow through the receptor phase of the Side-bi-Side 
glass half cell, mimicking the permeation of the drug from the synovial cavity to the flowing 
blood circulation with the diffusion of TA measured over time. This setup considers the 
simulation of the blood flow outside of the synovial cavity and resembles the process following 
an IA injection, as part of the formulation slowly exits the joint and enters the flowing blood 
circulation [22, 26, 45]. The receptor phase simulates the subsynovium of the synovial joint 
(the outside part of the synovial cavity, separated by the synovial membrane) leading to the 
blood circulation [1, 22, 23]. Because of the flowing medium present, an open system flow is 
generated in the receptor compartment. 
	
The effect of flow present in the receptor phase was evaluated with this setup, in which sink 
conditions are present due to the existence of the open system in the receptor phase.  Stoppers 
were placed in the side portings of the donor Side-Bi-Side glass half cell phase (Fig 4.1, Setup 
II). A syringe pump (Fusion 200, Chemyx Ltd.) was used to flow the medium through the 
receptor compartment with tubing connected to one port flowing the medium in and a small 
part of tubing connected to the other port of the same glass cell for collecting the sample in 
volumetric cylinders, with stoppers placed in both ports of the donor compartment glass half 
cell. The cells with ports allowing a medium to flow through both phases, were different from 
the cells used for the static flow setup, with an initial volume of medium in each compartment, 
1.5 mL. 1 mL of TA suspension 10 mg/mL (Adcortyl®) with medium [PBS with Tween 80 
(1% v/v)] was placed in the donor and receptor compartment with a constant medium flowing 
through (flow: 0.2 mL/min) the receptor compartment. Samples were collected from the 
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receptor compartment in volumetric cylinders as the medium was flowing through, measuring 
drug permeation through the membrane every half hour for 1 hour and then every 2 hours for 
12 hours. Samples from the receptor compartment were injected in the HPLC, with 
measurements showing the amount of drug diffused through the membrane. The % dissolved 
and permeated was calculated according to a calibration curve (2-10 µm) in the corresponding 
medium [44]. Results are presented as Mean (% dissolved over time) ± S.D. 
 
4.2.2.3.1.3. Setup III. Flow of medium from donor to receptor phase (Simulating transynovial 
flow) 
 
The third setup (III) (Fig. 4.1) mimics the transynovial flow, as the medium in the cell flows 
from the compartment where the drug is placed, permeates through the membrane, and then 
exits through the compartment that mimics the exo-synovial space making the setup an open 
flow system. As the donor phase simulates the synovial cavity containing synovial fluid and 
the receptor phase simulates the subsynovium of the synovial joint connected to the blood 
circulation, the flow mimics the transynovial flow from the synovial cavity to the subsynovium 
through the synovial membrane [46, 47]. A syringe pump (Fusion 200, Chemyx Ltd.) was used 
to flow the medium from the donor phase through to the receptor phase with tubing connected 
to one port of the donor compartment and a small part of tubing connected to one port of the 
receptor compartment for collecting the sample in volumetric cylinders, with stoppers placed 
in the remaining ports of the donor and receptor compartment glass half cells. The cells with 
ports allowing a medium to flow through both phases, were different from the cells used for 
the static flow setup, with an initial volume of medium in each compartment, 1.5 mL. 
	
Parameters such as the effect of flow rate from the donor to the receptor phase (0.1 and 0.2 
mL/min), was tested on the diffusion of TA through the GF/F membrane, and PBS with Tween 
80 (1% v/v) as the medium placed in both receptors and a dose of 1 mL of TA suspension 10 
mg/mL (Adcortyl®) in the donor phase (Table 4.2) Also different membranes [Glass microfiber 
(GF/F, GF-6, GF-10, combination of GF-6 and GF-10), CA and PTFE] were tested in PBS 
with Tween 80 (1% v/v) and Healthy state BSF (with HA) in a flow of 0.1 mL/min and a dose 
of 1 mL of TA suspension 10 mg/mL (Adcortyl®) in the donor phase. In addition, the effect of 
different drug amounts (1 and 0.3 mg) of TA on the diffusion of the drug through the GF/F 
membrane was examined in PBS with Tween 80 (1% v/v) and a flow of 0.2 mL/min. The effect 
of different media [PBS with Tween 80 (1% v/v), Healthy state BSF (without HA) and the 
widely used dissolution medium PBS with HA (3 mg/mL) [14]) were also examined, with a 
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GF/F, GF-6, GF/10 and a combination of GF-6 + GF-10 membrane with a flow of 0.1 mL/min 
and a dose of 1 mL of TA suspension 10 mg/mL (Adcortyl®) in the donor phase. Finally, the 
effect of biorelevant media without HA (Healthy state, OA and RA) was evaluated with a flow 
of 0.1 mL/min, a combination of GF-6 + GF-10 membranes and a dose of 0.1 mL of TA 
suspension 10 mg/mL (Adcortyl®) in the donor phase. For the development of the BSF, the 
HA is responsible for the viscosity of the medium [48, 49]. BSFs were tested with and without 
HA as the addition of HA leads to a high viscosity which does not allow the medium to be used 
in this setup as the flow and permeation through the membrane is restricted. TA suspension 
was placed in the donor compartment together with the medium used, in volumes of 0.1 mL 
and 1.4 mL respectively or 1 mL and 0.5 mL medium respectively, with 1.5 mL of medium 
placed in the receptor phase. Samples were collected from the receptor compartment in 
volumetric cylinders as the medium was flowing through, measuring drug permeation through 
the membrane every half hour for 1 hour and then every 2 hours for 12 hours. Samples from 
the receptor compartment was injected in the HPLC directly or after treatment for BSF samples 
containing HA, with measurements showing the amount of drug diffused through the 
membrane. The % dissolved and permeated was calculated according to a calibration curve (2-
10 µm) in the corresponding medium [44]. Results are presented as Mean (% dissolved over 
time) ± S.D. 
	
4.2.2.3.2. In-vitro dissolution/permeation set ups with glass bottles 
 
The simulation of the synovial cavity from a biorelevant dissolution aspect can also be 
expressed with the use of a biphasic model. The monophasic and biphasic dissolution system 
experiments were performed with the use of glass bottles (Duran HPLC bottle, Fisher 
Scientific, UK). In both setups, there was an agitation of 300 rpm with the bottles placed on a 
magnetic hotplate stirrer. For the monophasic setup, 50 mL of PBS, HS and OA BSF (without 
HA) were tested and for the bi-phasic setup 50 mL of aqueous phase [(PBS, HS, OA and RA 
BSF (all BSFs without HA)] and 10 mL of organic phase (1-octanol). The experiments were 
performed at 37 ± 0.5 oC in triplicate. 1 mL samples were collected from a zone midway 
between the surface of the medium and the bottom of the glass bottle every 30 minutes for one 
hour and then each hour until 8 hours from the aqueous phase in the monophasic and from both 
phases in the biphasic setup (with volume replacement with fresh corresponding medium) to 
measure the amount dissolved in the aqueous compartment and the amount that partitions into 
the organic phase. Samples were then diluted with the corresponding medium where 
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appropriate, before analysing with the HPLC to determine the amount of TA dissolved and 
permeated. The % dissolved was calculated according to a calibration curve (2-10 µm) in the 
corresponding medium [44]. Results are presented as Mean (% dissolved over time) ± S.D. 
 
4.2.2.4. Biorelevant media (containing HA) sample treatment  
 
Synovial fluid sample preparation took place according to the method described by Sottofattori 
et al. [50]. An amount of hyaluronidase solution prepared based on manufacturer (initial 
concentration of 300-1000 U/mg) was added to the in-vitro BSF samples to reach a final 
concentration of 150 U/mL which degraded HA and decrease the viscosity of the sample 
leading to an easier filtration and analysis. Hyaluronidase was reconstituted at 1 mg/mL in 0.02 
M sodium phosphate buffer, pH 7, containing 77 mM sodium chloride and 0.01 % BSA. For 
the spiked working calibration standards, the diluted TA solution was added afterwards. 
 
4.2.2.5. Triamcinolone Acetonide HPLC Analysis 
 
The solubility samples and standard solutions were analysed using an Agilent 1100 series 
HPLC system (Agilent, UK) consisting of a G1329A autosampler, a G1330A ALS thermostat, 
a G1316A thermostatted column compartment, a G1315A DAD, a G1322A degasser and a 
G1311A quaternary pump. A modification of a published method was used (Chapter 2). 
Reversed phase chromatography was performed using an Agilent Eclipse XDB-C18 column 
(2.6 x 250 mm, 5µm pore size) (Agilent, UK). The flow rate was set at 1 mL/min, temperature 
at 25 oC, the UV detection signal was set at 240 nm and injection volume 20 µL. The HPLC 
method for the analysis of the biorelevant samples had a stop time of 24 min and include a 
gradient with increased water % in the beginning of each run (methanol:water at 10:90 for 8 
min and then at 65:35 for 16 min). For biorelevant samples, the HPLC method included the 
gradient with increased water % in the beginning of each run, in order to wash the column 
before each sample analysis. This reduced the build-up of impurities in the column which could 
lead to increased pressure. The HPLC method for the analysis of non-biorelevant samples had 
a stop time of 12 min and include the mobile phase running at an isocratic mode with 65:35 
methanol:water. For non-biorelevant samples, calibration curves were prepared with the use of 
a stock solution of TA (100 µg/mL) in methanol. Working calibration standards from a range 
of concentrations (2-10 µg/mL) were composed after diluting the stock solution accordingly 
with the selected medium. For biorelevant samples, the samples were diluted with the 
corresponding medium where appropriate, before analysing with the HPLC to determine the 
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amount of TA dissolved. Working calibration standards from a range of concentrations (2-10 
µg/mL) were composed with a solution of hyaluronidase being added to the sample. The 
hyaluronidase solution was added to the sample and then the 20 µg/mL aqueous intermediate 
(PBS) of the stock solution of TA in methanol (5 mg/mL) was added to the synovial fluid-
enzyme solution to prepare the spiked standard following the sample preparation technique. 
Adding the stock solution directly into the blank BSF causes protein precipitation due to the 
strong effect of the organic solvent. The drug amount was chosen to be included before the 
addition of the hyaluronidase, to follow the same process observed in the solubility studies; the 
sample including the drug and the addition of the degrading enzyme following afterwards. The 
% dissolved was calculated according to a calibration curve (2-10 µm) in the corresponding 
medium. 
 
4.2.2.6. Dissolution profile comparisons 
 
The use of f2 similarity factor was chosen for comparing dissolution profiles. The percentages 
of dissolution for all time points were considered until the drug reached 85% dissolution of the 
plateau value; in this occasion one time point after the 85% dissolution was taken into account. 
The similarity factor f2 from 50-100 showed similarity of the compared dissolution profiles. 
The equation used was: !" = 50	× log 1 + 1 - ./ −	1/"/234 56.8×	100 		    (Eq. 1)  
where: 
n is the number of time points 
Rt is the dissolution value of the reference at time t  
Tt is the dissolution value of the test at time t. 
 
The calculations were done with the DDsolver Add-In (DDsolver, Add-In, Microsoft Excel) 









4.3. Results and discussion 
 
4.3.1. Solubility studies 
 
Solubility studies performed in BSF without HA in three state (Healthy state, OA and RA, Fig. 
4.2) showed similar results to the developed BSFs in Chapter 3, with RA BSF having the 
highest solubility followed by OA BSF and Healthy state BSF. 
 
 
Fig. 4.2. Solubility of TA samples in BSF media without HA in three states (Healthy state, 
OA and RA) (n=3) 
 
4.3.2. In-vitro dissolution and diffusion studies with Side-bi-Side setups 
 
4.3.2.1. In-vitro dissolution and diffusion studies with Static Flow setup (I) 
 
4.3.2.1.1. Effect of membrane 
 
Three membranes were tested, GF, PTFE and CA. The TA dissolved in the donor phase reaches 
a plateau of ~ 2% and with the donor phase containing 3.5 mL, this demonstrates that 200 µg 
were dissolved from the 10 mg (1 mL Adcortyl®) injected. This plateau can be partially 
justified from the measured solubility of TA in PBS with Tween (1% v/v) (92 µg/mL) (Chapter 
2). The percentage of drug dissolved (donor compartment) was higher than the amount of drug 




















Healthy state BSF OA BSF RA BSF
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compartment reached a 2% TA dissolved for all membranes tested, while the % drug diffused 
was less than 0.5% with the use of GF/F filter and CA membrane, whereas a negligible % of 
drug permeation to the receptor phase was observed with the use of the PTFE filter (Fig. 4.3). 
As permeation of the drug was evident with the use of a CA membrane and a GF/F filter, with 
the PTFE membrane there was an absence of permeation, making this type of membrane non-
suitable. This may be explained due to the hydrophobicity (repulsion towards water) of the 
PTFE membrane, according to which the medium containing the drug was not able to permeate 
easily from the donor to the receptor phase. Further studies were conducted with the use of the 
GF filters as the diffusion rate might have been similar with CA, but these type of filters have 
a much higher loading capacity. 
 
 
Fig. 4.3. Mean ± SD % TA dissolved from Adcortyl® in PBS with Tween 80 (1% v/v) in donor 
(solid line) and receptor (dotted line) compartment (dose: 1 mL of TA suspension 10 mg/mL) 
 
4.3.2.1.2. Effect of organic medium 
 
The % of drug dissolved (up to 2.6 %) and diffused (up to 0.3 %) in the system with the use of 
1-octanol and with the bi-phasic system in the receptor compartment was similar with the 
results of PBS with Tween 80 (1% v/v) as the medium. The dissolution rate in the donor phase 




















phase. The use of a bi-phasic system in the setup was assessed in order to increase the release 
of the drug in the aqueous phase as the organic phase would act as a “reservoir” due to the 
higher solubility of the drug in 1-octanol [36, 40] exploiting the lipophilicity (logP) of the drug. 
Also with the organic solvents used as media instead of PBS with Tween 80 (1% v/v) which 
was used in the first set of experiments, there is a higher drug solubility and so a higher 
dissolution in the donor phase should take place. With a higher amount of drug dissolved, there 
was a higher amount of drug available to diffuse through the membrane. Due to the limited 
sink conditions and the slow diffusion, this was not witnessed with 1-octanol being used as the 
medium, or as part of the bi-phasic system in the donor phase. With the use of methanol in the 
receptor compartment, a higher drug dissolution (up to 11 %) and drug diffusion (up to 13 %) 
was observed (Fig. 4.4). With methanol, as the organic solvent could be miscible with the 
medium in the donor phase, there was a higher diffusion of drug into the receptor phase. This 




Fig. 4.4. Mean ± SD % TA dissolved from Adcortyl® in donor (solid line) and receptor (dotted 
line) compartment (membrane: GF/F, dose: 1 mL of TA suspension 10 mg/mL) 
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4.3.2.2.1. Effect of applied flow in receptor phase compared to Setup I and Setup III 
 
When a constant flow of medium was applied in the receptor phase (0.2 mL/min), comparing 
setup I to setup II, the % of drug diffused was 0.34 % after 8-h, compared to 0.17 % in setup I. 
 
 
Fig. 4.5. Mean ± SD % TA dissolved though the membrane from Adcortyl® in PBS with Tween 
80 (1% v/v) in Setup I and in Setup II (flow 0.2 mL/min) (Membrane: GF/F, dose: 1 mL of TA 
suspension 10 mg/mL) 
 
With an open flow system having a flow rate of 0.2 mL/min in the receptor phase, the % of TA 
diffused through the membrane was twice the % compared to the static flow setup (!"9:99 =99.76) (Fig. 4.5). The continuous flow present in the receptor, provides sink condition in the 
receptor compartment and therefore a higher drug amount can diffuse through the membrane.  
Comparing flows applied in Setup II and III, led to a significant difference noted (!"99:999 = 
19.24). Comparing diffusion rate from 0.1 mL of Adcortyl, placed in the donor phase, at 8-h, 
in setup II there is a release of 6.4% compared to 71.4% in setup III (Fig. 4.6). With a flow set 
from the donor phase to the receptor phase and samples collected at the receptor phase means 
that the flow proceeds through the membrane aiding drug dissolution. Applying this flow, 
affects the hydration of the material in test. With a high volume of medium flown through the 






















Fig. 4.6. Mean ± SD % TA dissolved though the membrane from Adcortyl® in PBS in Setup 
II and in Setup III (flow 0.1 mL/min) (Membrane: GF/F, dose: 0.1 mL of TA suspension 10 
mg/mL) 
 
4.3.2.3. Transynovial flow Setup (III) 
 
4.3.2.3.1. Effect of drug amount 
 
A suspension volume of 0.3 mL of Adcortyl® (3 mg of TA) led to complete drug dissolution 
(100%) after 10-h when PBS with Tween 80 (1% v/v) was used as the dissolution medium with 
a constant flow rate of 0.2 mL/min. A higher amount of drug present in the donor compartment 
(1 mL of Adcortyl®, 10 mg of TA) led to a 65% of the drug dissolved after 12-h (!">:?.@ =23.25) (Fig. 4.7). Results can be justified according to the Noyes-Whitney equation (Eq. 1), as 
a higher amount of drug in the donor phase will take a longer time to dissolve in the open 





















Fig. 4.7. Mean ± SD % TA dissolved though the membrane from different volumes of 
Adcortyl® (10 mg/mL)  in PBS with Tween 80 (1% v/v) (flow: 0.2 mL/min, membrane: GF/F) 
 
4.3.2.3.2. Effect of flow rate 
 
Placing a dose of 1 mL of Adcortyl in the donor compartment and applying two constant flow 
rates, 0.1 and 0.2 mL/min, resulted in a 24% and 61% TA dissolved respectively after 12-h 
(Fig. 4.8). As the flow rate in the system increased, so did the percentage (%) of TA dissolved 
from the system (!">:?.@ = 35). As the flow rate is increased and more medium is flown from 
the donor to the receptor, the hydration of the material in test is affected, increasing the 
dissolution. As more medium is flown through, more drug is dissolved in the same amount of 






















Fig. 4.8. Mean ± SD % TA dissolved through the membrane from Adcortyl® in PBS with 
Tween 80 (1% v/v) [membrane: GF/F, dose: 1 mL of TA suspension 10 mg/mL] 
 
4.3.2.3.3. Effect of membrane and medium 
 
The glass microfiber filters with binders providing extra mechanical strength [GF-6 (inorganic 
binder), GF-10 (organic binder) and GF-6 + GF-10 combined] have similar dissolution profiles 
up to ~45-50 % of drug dissolved in 12-h (!"DEF:DE>?	 = 93.61, !"DEF:DEFGDE>?	 = 73.67 and !"DE>?:DEFGDE>?	 = 73.76). The glass microfiber filter without binder tested (GF/F) and the CA 
membrane gave similar dissolution profiles but lower drug dissolution in 12-h, ~ 30-35% (!"IJ:DEE	 = 87.41) (Fig. 4.9). The membranes were tested in order to evaluate their effect in 
drug dissolution at a flow of 0.1 mL/min. As the pore size of GF/F and GF-6 are similar (~ 0.7 
µm), the difference in drug dissolved will be relevant to the inorganic binder present in the GF-
6 filter increasing its mechanical and wet strength (!"DEE:DEF	 = 52.17). There are no 
significant differences between the GF filters with binders and their combination although 
particle retention between GF-6 and GF-10 is different, ~0.7 and ~2 µm respectively. CA (pore 
size: 0.45 µm) was not chosen for the subsequent studies with biorelevant media as it had a 
low retention capacity and the viscous biorelevant medium did not flow through it, even at a 






















Fig. 4.9. Mean ± SD % TA dissolved through different membranes  [GF/F (solid line), GF-6 
(dotted line), GF-10 (dashed line), GF-6 + GF-10 (dashed and one dotted line) and CA (dashed 
and two dotted line)] from Adcortyl® in different media [PBS with Tween 80 (1% v/v), Healthy 
state BSF (with HA) and PBS with HA (3 mg/mL)] [flow 0.1 mL/min, dose 1 mL of TA 
suspension 10 mg/mL] 
 
The widely-used PBS with HA (3 mg/mL) was compared with a healthy state BSF developed 
with a similar amount of HA and additional phospholipid PC and proteins (BSA and γ-
globulin). The addition of phospholipids would theoretically increase the dissolution rate of 
TA as they act as natural surfactants [20] and consequently the permeation through the GF 
filters. Interestingly, the use of phospholipids in the HS BSF did not have any significant effect 
on the permeability of TA through the GF membranes compared to PBS containing HA with 
the use of GF/F (!"MN	ONE:PON	MJ	 = 97.27) or GF-6 + GF-10 (!"MN	ONE:PON	MJ	 = 92.6). 
Comparing dissolution with HS BSF and different types of GF filters showed that there is a 
slight increase with the GF/F compared to the GF filters with binders and finally with the 
combination of GF-6 and GF-10. This was also apparent with the use of PBS with HA. With 
the use of HA in the medium, the viscosity is increased leading to a more difficult permeation 
through the GF filter. As GF-6 and GF-10 have a higher mechanical and wet strength due to 





















Fig. 4.10. Mean ± SD % TA diffused through the membrane from Adcortyl® with different 
biorelevant low viscosity media (no HA present) [flow 0.1 mL/min, dose: 0.1 mL of Ta 
suspension 10 mg/mL, membrane: GF-6 + GF-10] 
 
In order to test a less viscous medium, with a value according to high shear rates (1000 1/s) 
assessed, BSF media without the addition of HA were developed. With the use of the GF-6 + 
GF-10 filter combination as the membrane in the setup, HS BSF and two disease state BSFs 
(OA and RA) were evaluated. Noticebly, the RA BSF, although contained a higher amount of 
phospholipids which would increase the solubility of the medium and lead to a higher 
dissolution of TA, had the lowest dissolution compared to HS (!"MN:QJ	 = 61.85 and OA (!"RJ:QJ	 = 63.66). This could be due to the significantly high amount of proteins present in 
the RA BSF, as due to their size, they could accumulate and create a resistance to the diffusion 
of dissolved drug through the membrane [47]. The HS and OA BSF containt the same 
components in similar amounts except the phospholipid PC as OA contains an additional 0.1 
mg/mL compared to the HS. Recording similar results with before, the increased amount of 
phospholipids does not lead to a significant difference between the TA dissolution in the two 
media (!"MN:RJ	 = 88.08) (Fig. 4.10). 
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Dissolution testing in a monophasic setup was performed in PBS and BSF without HA in 
different states (HS and OA). The dissolution profiles reached different plateau values at 4-h 
and onwards, according to the solubility of TA determined experimentally in each one (Fig. 
4.2) due to non-sink conditions. With a dose of 0.1 mL of Adcortyl (TA suspension, 10 mg/mL) 
in 50 mL of medium, the % of TA dissolved reached approximately 70% in 8-h; in the HS BSF 
the % of drug dissolved reached a plateau at an approximate dissolution of 53% due to TA 
solubility of 9.1 µg/mL and in the OA BSF the plateau reached was an approximate 47% due 
to TA solubility of 11.1 µg/mL (Fig. 4.2). Although the drug dissolution in HS BSF kept 
increasing until 4-h reaching a plateau, the TA dissolution in OA BSF seems to reach plateau 
from the first sampling point at 0.5-h. The dissolution rate of TA at 0.5-h seems to be faster in 
OA BSF than PBS and HS BSF with a difference of 10% TA release between them respectively 
(Fig. 4.11). 
 
Fig. 4.11. Mean ± SD of TA dissolved from Adcortyl® in different BSF media without HA 
different in a monophasic setup with glass bottles (dose: 0.1 mL of TA suspension, 10 mg/mL)  
 
4.3.4. In-vitro dissolution/permeation with a bi-phasic set up with glass bottles 
 
Results showed that with the biphasic system, the drug reached complete dissolution in a 2-h 
time period, allowing more drug dissolution in the aqueous phase compared to the monophasic 
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place in a faster rate than the dissolution in the aqueous layer leading to low drug amounts left 
in the aqueous phase as the experiment would progress [40]. When testing a low solubility 
drug, a high volume of medium would be needed to offer these conditions. Using an organic 
immiscible layer would act as a reservoir for the drug which would dissolve in the aqueous 
layer and then partition through and so with this setup, more drug would then be able to dissolve 
in the aqueous layer and partition to the organic solvent. 
It is important for the aqueous layer not to saturate and also for the total dose of drug studied 
to be less than 20% of its solubility in the volume of organic phase in the bi-phasic system [36, 
40] for sink conditions to be maintained (10 mL of 1-Octanol in the organic phase and the 
solubility of TA in 1-octanol: 5.2 mg/mL [57]). The drug dissolved in a faster rate in the RA 
BSF compared to the OA and the HS BSF (Fig. 4.12). This is mainly due to the presence of 
phospholipids as they would increase drug dissolution over time, acting as the body’s natural 
surfactants [20]. There is no significant difference in the dissolution between HS and OA which 
show that the small difference in phospholipids between them is not of primary importance. 
 
  
Fig. 4.12. Mean ± SD of TA dissolved from Adcortyl® in different BSF media without HA 
(dashed line) and partitioned in 1-octanol (solid line) in in a bi-phasic setup with glass bottles 























The biorelevant dissolution methods developed, take into consideration the in-vivo conditions 
of the synovial joint cavity. With the side-Bi-side cell, the setups mimic the volume of the 
synovial fluid and the flows applied, while the dissolution/permeation system would simulate 
the activities taking place in the joint after IA administration allowing the measurement of drug 
dissolution from the formulation in test. In the static flow, permeation through the membrane 
would not be significant, apart from the use of methanol in the donor and receptor phase. With 
Setup I, testing different membranes showed that there was no significant difference apart from 
the use of PTFE that seemed to not allow permeation. A higher permeation was apparent when 
flow was applied in the system (Setup II), while the highest permeation was evident with a 
flow applied from the donor phase through to the receptor phase (Setup III). Using a 
combination of glass microfiber membranes (GF-6 + GF-10), developed BSF tested in three 
states without HA (healthy, OA, RA), with low viscosity associated with high shear rates, 
showed significant differences between RA and the HS and OA BSF. With the bi-phasic 
dissolution in glass bottles, the organic solvent was used as a reservoir for the drug that would 
dissolve in the aqueous phase, providing sink conditions. There was no evident difference 
between the dissolution profiles in BSFs. These approaches provide a valuable tool to compare 
in-vitro drug release in a biorelevant environment and further studies (such as IVIVR or 
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Chapter 5: Dissolution characterisation of intra-articular drugs with 




Purpose: To investigate the real-time dissolution behaviour of IA drugs under UV imaging 
with the use of non-biorelevant and artificial synovial fluid (ASF) media. 
Methods: The optimization of the dissolution process was done by testing drug amount (2 and 
4 mg), flow rate (0.2 and 0.7 mL/min) and compression force (40 and 80 cN.m) with a two-
level factorial design. To test the effect of surfactants, in static flow (0 mL/min), the media 
tested included PBS, PBS with Tween 80 (1% v/v), PBS with SLS (1% w/v) and PBS with 
CTAB (1% w/v). For evaluating the effect of viscosity on the dissolution of TA, three ASFs 
were tested, containing HA, simulating the viscosity of synovial fluid in HS, OA and RA state. 
The effect of surfactants was also tested with a continuous laminar channel flow of 0.2 mL/min 
with PBS, PBS with Tween 80 (1% v/v), PBS with SLS (1% w/v) and PBS with CTAB (1% 
w/v). TA was utilized as a model IA drug, with measurements involving surface concentration, 
Intrinsic Dissolution Rate (IDR) and TA mass dissolved. 
Results: Optimizing the dissolution process, showed that the appropriate compression force to 
use for the analysis is 40 cN.m, the drug amount placed initially in the steel cup 6 mg (to have 
4 mg left in the cup as the sample) and a flow rate of 0.2 mL/min. In static flow, surface 
dissolution was in accordance with visual representations of the dissolution of TA in the media. 
CTAB provided the highest drug dissolution followed by SLS, then Tween 80 and PBS without 
surfactant. With the use of the ASFs, increasing the viscosity led to lower dissolution rates with 
the surface concentration being higher in accordance with RA>OA>HS. With a flow applied 
in media with surfactants the IDR and TA mass dissolved was in accordance to visual 
representations.  
Conclusions: The UV imaging system shows potential for in-vitro drug dissolution testing 











Corticosteroid drugs administered through the IA route provide symptomatic treatment while 
minimising overall systematic exposure, for chronic conditions such as OA and RA [1]. In the 
pharmaceutical industry, in-vitro dissolution testing has an important part in drug/formulation 
development and quality control with certain dissolution methods approved and in use. At the 
moment, there is no standard official dissolution method in the Pharmacopoieia for IA drugs 
[2]. This causes drawbacks to the establishment of the effect of variables in drug dissolution, 
which is of vital importance. Traditional dissolution testing methods such as sample and 
separate, dialysis membranes and continuous flow through apparatus (USP apparatus IV) [3, 
4] have been used for measuring dissolution from parenteral formulations. With these 
methodologies, measuring dissolution of poorly water-soluble drugs might still present 
significant challenges and further difficulties related to dissolution [5]. 
	
An approach involving the use of UV imaging and visualisation of the dissolution procedure 
may help overcome these obstacles. The use of real-time information regarding solution 
concentration is provided [6], as the process is monitored exactly next to the surface of the 
drug. This way, dissolution is not focused on bulk solution concentration measurements over 
time. Being able to visualize the dissolution process is a promising and innovative tool offering 
a more detailed analysis of the drug particles dissolving in solution adjacent to the solid 
powder. UV imaging offers the potential to gain a great deal of information spectrally, spatially 
and temporally [7] by generating recordings of the continuous dissolution near the surface of 
the powder in test, with the chosen medium flowing through. For example, the surface 
concentration measured with the SDI provides real-time results of the dissolution process by 
monitoring the events taking place next to the surface of the tested drug powder [8]. Being able 
to understand in depth how different parameters of the system affect the surface concentration 
of the powder provides essential information about how drug would dissolve when in contact 
with the dissolution medium. The use of UV imaging provides the appropriate visualisation of 
the solute concentrations close to the surface of the powder. During the IA administration of a 
suspension, the drug particulates are injected into the synovial fluid with the possibility to 
follow different pathways. The major determinant according to which a specific pathway will 
be followed, is the size of the particulates. The drug particles may i) be phagocytosed by 
synovial fluid macrophages into the synovial membrane, ii) transfer in the articular cartilage 
of the bone, through convective transport due to change in pressure inside the synovial cavity 
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or iii) remain in the synovial fluid and attach to the articular cartilage or the synovial membrane 
[9]. In all occasions the transfer to the targeted location inside the synovial cavity involves the 
suspension being dispersed in the synovial fluid. With the use of simple buffer solutions in-
vitro, the understanding of the dispersion, solubilisation and dissolution behaviour of the tested 
drug may provide essential information with the application of UV imaging. New insights of 
the dissolution process with images providing its initial stages, may contribute to understanding 
what kind of phenomena are taking place on the surface of the powder that may affect 
dissolution rate, which would be missed in the dissolution of bulk material with traditional 
apparatus [8]. 
	
Considering a more biorelevant dissolution approach, the viscosity of the synovial fluid in the 
healthy state and in disease states may have a significant effect on the solubilisation effect of 
the drugs given through the IA route. The HA is the main component responsible for the 
viscosity found in synovial fluid. The addition of this in buffer, with appropriate amounts 
according to the synovial fluid state, will provide a better prediction of the performance of the 
IA drug in-vivo [10, 11]. When the suspension of TA is injected in the synovial cavity, the 
suspended particles of the drug, according to the particle size, may dissolve in the synovial 
fluid [9]. The lubrication and viscoelastic ability of HA has been determined from a variety of 
studies [4, 11-15] and so its presence in the synovial fluid is vital as a primary determinant for 
viscosity. Being able to understand how the dissolution of TA will take place on the surface of 
the powder in real-time provides the opportunity to capture the initial stages of the dissolution 
process in real-time [16]. Although simulating the viscosity of the synovial fluid in test may 
create conditions physiologically relevant, the type of flow present in the synovial cavity 
should also be taken into account. The transynovial flow is present in the joint as the blood is 
filtrated inside the synovial cavity (with the addition of HA and lubricin forming the synovial 
fluid) and as synovial fluid drains out of the cavity through the terminal lymphatics. In normal 
conditions the transynovial flow is 0.005-0.01 mL/min in a flexed knee joint and up to 0.02-
0.04 mL/min in chronic joint effusion conditions which would lead to approximately 1 mL of 
synovial fluid turn-over in 1- to 2-h [17]; and so an appropriate flow would provide additional 
biorelevance to the conditions tested. 
	
The objective of this study was to investigate the real-time dissolution behaviour of IA drugs 
under UV imaging and evaluate the effect of surfactant in the medium (in static and continuous 
flow) and viscosity of ASFs (in static flow) while also optimising the method with the SDI 
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instrument. In the experiments conducted, we considered the surface concentration, IDR and 
TA mass dissolution from the surface of the sample cup containing the powder. TA, a poorly 
soluble model IA drug with a pKa of 11.75, was used for all experiments in PBS with 
surfactants and in artificial synovial fluid (simulating synovial fluid viscosity in Healthy state, 




































TA (98+%, fine chemical) was purchased from Alfa Aesar (UK). For all experiments ultra-
pure water was used obtained from a Milli-Q purification device. The phosphate buffer saline 
(PBS) was made with sodium chloride (≥99.9%), potassium dihydrogen orthophosphate 
(≥99.5%), di-sodium hydrogen orthophosphate, anhydrous dried (≥99.5%) and potassium 
chloride (≥99.5%) which were purchased from Sigma-Aldrich (UK). HBSS, 1X, without 
calcium, magnesium, phenol red Thermo Scientific HyClone was purchased from Fisher 
Scientific (UK), while the 0.1 M phosphate buffer contained 0.1 M Na2HPO4 (14.2 g/L) and 
0.1 M HCl, also purchased from Fisher Scientific. sodium hyaluronate 95% [hyaluronic acid, 
(HA)] was purchased from Fisher Scientific (UK). Tween 80 (polysorbate) was bought from 
VWR (UK) sodium dodecyl sulphate (≥99.0%) and CTAB (≥99.0%) were purchased from 




5.2.2.1. Media used in the dissolution studies 
	
5.2.2.1.1. Media with surfactants 
	
The media used are PBS, PBS with Tween 80 (1% v/v), PBS with SLS (1% w/v) and PBS with 
CTAB (1% v/v). The media containing surfactants were tested in the static (0 mL/min) and the 
continuous (0.2 mL/min) flow. 
	
5.2.2.1.2. Artificial synovial fluid (ASF) in different states 
	
In order to evaluate the effect of the viscosity of the synovial fluid in HS and in disease state 
(OA and RA), the dissolution of TA was studied in media consisting of the buffers used for the 
development of the BSFs with the addition of the physiologically relevant amounts of HA for 
appropriate viscosity values (Table 5.1, in accordance with Chapter 3). The biorelevant media 
were prepared according to the method proposed by Jantratid et al. [18]. The HBSS buffer was 
adjusted to a pH of 6.8 by adding 0.1 M of HCl before the addition of further components while 
the phosphate buffers for the OA and RA biorelevant synovial fluids were made by adding 0.1 
M Na2HPO4 (955.1 mL/L) and 0.1 M HCl (44.9 mL/L) in 1 L of 0.1 M buffer. The phosphate 
buffer was then adjusted to pH 8.1 and 8 respectively with addition of 0.1 M HCl. The amount 
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of HA added was 8.1 mg/mL for the healthy state, 4.8 mg/mL for the OA and 3.5 mg/mL for 
the RA. The media were tested under static flow (0 mL/min). 
	
Table 5.1. Composition of Biorelevant media simulating synovial fluid viscosity in HS, OA 
and RA 
Components (mg/mL) HS ASF OA ASF RA ASF 
Buffer HBSS 0.1 M NaHPO4 + HCl 0.1 M NaHPO4 + HCl 
HA 8.1 4.8 3.5 
	
5.2.2.2. Surface Dissolution of TA with UV imaging  
 
5.2.2.2.1. UV imaging setup 
	
The UV imaging was performed with the use of an Actipix SDI 300 UV imaging system 
(Paraytec Ltd., York, UK) and with an Actipix flow through dissolution cartilage. The light 
source was a pulsed Xe lamp and the UV filter used had a detection wavelength of 254 nm. 
The UV imaging setup of the SDI system can be equipped with filters of different wavelengths 
but the detection in the analysis takes place with one single suitable filter. In order to decide 
which appropriate wavelength to use, a vital step was to determine the UV absorbance maxima 
of the drug in the medium tested (lambda max for TA= ~240 nm) [8]. The quartz cell (7.5 mm 
height, 3 mm width and 63 mm length) in which the dissolution cartridge is placed, contains a 
volume of approximately 0.56 mL media that may flow through [7]. The detection area 
available is 9 mm x 7 mm (1280 x 1024 pixels) with images recorded at a rate of 2.59 images 
per second and analysed with the Actipix D100 software, version 1.4 (Paraytex Ltd.) with a 10 
x 1 horizontal pixel binning by converting pixel intensities into absorbance. The infusion of 
the dissolution media and standard solutions took place with a syringe pump (Fusion 200, 
Chemyx Ltd.) at specific flow rates at a temperature of 37o C. The extinction coefficients were 
obtained by absorbance values from imaging of TA standard solutions in the media tested. 
Standard TA solutions (2-10 µg/mL) were infused for 5 min each at a flow of 1 mL/min with 
a blank buffer in the beginning of the run as a background reference and for detecting baseline 
drifts. The dissolution experiments were performed with the use of compacted TA samples in 
triplicates. The extinction coefficient used in all the analysis was of the PBS. 
	
5.2.2.2.2. Preparation of compacts 
 
For the dissolution studies in static and continuous flow, compacts were prepared by placing 6 
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mg of TA into stainless-steel cylinder sample cups (inner diameter 2 mm) which were then 
pressed in the manual press (316 SS compression rod and base insert, Paraytec, UK) for 1 min 
with a Quickset MINOR torque screwdriver (Torqueleader, M.H.H. Engineering Co., UK) by 
applying a pressure of 40 c.Nm, leaving approximately 4 mg of TA in the sample cup. 
5.2.2.2.3. Dissolution studies 
	
In all experimental runs, dark images were taken initially (with the lamp turned off, for 10 s) 
and reference images (with the lamp turned on, for 10 s) were recorded with the plastic cartilage 
placed in the flow cell, filled with blank buffer. After 10 s the data recording was paused and 
a compact containing TA was placed into the plastic cartilage, which was then placed again 
into the flow cell. The collection of data was then resumed after flushing the cell with medium 
2 times in a rate of 2 mL/min for a total of 20 s, to ensure that the cell is filled and no bubbles 
are present in the imaging area.  
The flow program then started with the experiments were performed in triplicates, at a 
temperature of 37o C. The data collected in pixel intensities from the automatically adjusted 
measurement zones was converted into absorbance values by the software [Actipix D100 
software version 1.5 (Paraytec, UK)], which were used for the calculation of surface 
concentration, IDR, and sample mass dissolved (SMD) over time. For the static flow, IDR and 
SMD were not considered, as the absorbance contour lines did not reach the measurement IDR 
zone of the UV image and the mass flux is also calculated by the system based on flow rate. 
For all the results given by the software, the pixel intensities are converted into absorbance 
values with the following equation: 
A = log (Sref	–	SoSsig - So )          (Eq. 1) 
where Iref, Io and Isig are the pixel intensity which is measured when the buffer is flowing in the 
cell (reference signal), the pixel intensity because of the dark current (electronic noise which 
is measured with the Xe lamp turned off) and the pixel intensity which is measured as the 
experiment is running respectively.  
	
5.2.2.2.3.1. Process optimisation with Design of Experiments (DoE) 
	
A two-level factorial design was used in order to optimise the conditions used in the analysis 
of TA and the compact preparation in the experiments. Three factors were tested [drug amount 
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(2 and 4 mg in sample cup), flow rate (0.2 and 0.7 mL/min) and compression force (40 and 80 
c.nm)] with PBS as the medium, developing a 23 factorial design, in order to evaluate their 
effect on surface concentration, IDR and TA mass dissolved. This process included eight runs 
in random order with 3 replications each, constituting 3 blocks of testing. Surface 
concentration, IDR and TA mass dissolved over time, showing the effect of each factor are 
presented in thermal analysis surface plots according to flow rate. The results (surface 
concentration, IDR and TA mass dissolved) were calculated by the SDI software, taking into 
account the extinction coefficient and according to the following equations [19]: 
U = VWXYWZ[\M/^W_? ` 	         (Eq. 2) a\ = bc"dZ 1 − "\5d ^d^         (Eq. 3) 
where: 
j = IDR 
 vz = velocity at z 
M = molecular weight  
cz  = concentration at z 
W = width of the flow cell 
Δz =effective pixel height 
S = surface area of the sample 
H =height of the flow cell in the observation region 
Q = volume flow rate 
	
Calculations of TA dissolution rates were done according to different absorbance values 
detected from specific detection areas in the UV image attained [7], located on the right end 
side of the image towards which the buffer would flow. 
The ANOVA analysis in the optimisation of the SDI variables, was conducted using 
Statgraphics Centurion (Statgraphics, USA). The same program was also used to present results 
in 3D thermal analysis graphs showing the effect of variables on surface concentration, IDR 
and TA amount dissolved and Pareto charts showing the effect of each variable tested and also 
the effect of combined factors. In the Pareto charts, in which the ANOVA data is summarized, 
the x-axis presents the t-ratio of the variables tested, while the vertical line indicates statistical 
significance for the variable effect that has passed (P-value = 0.05) [20]. 
	




With a static flow (0 mL/min), the media used were PBS with surfactants and ASFs in three 
states (HS, OA and RA). The drug amount used was 4 mg and the compression force was 40 
cN.m. The results measured were the surface concentration of TA as Mean (µg/mL) ± S.D. 
	
5.2.2.2.3.3. Studies in continuous flow 
	
With a continuous laminar channel flow of 0.2 µL/min the media used were non-biorelevant 
(PBS with surfactants). The drug amount used was 4 mg and the compression force was 40 
cN.m. The results measured were the surface concentration of TA as Mean (µg/mL) ± S.D., 



























5.3. Results and Discussion 
	
5.3.1. Dissolution studies 
	
5.3.1.1. Process optimisation with the use of DoE 
 
Table 5.2. Results from DoE 
block Drug amount Flow rate Compression force Surface conc IDR SMD 
  (mg) (mL/min) (cN.m) (µg/mL) (µg/min/cm2) (mg) 
1 4.0 0.2 40.0 135 3.5 0.004 
1 2.0 0.2 80.0 310 10 0.007 
1 2.0 0.2 40.0 225 10 0.007 
1 4.0 0.2 80.0 42.5 17.5 0.008 
1 4.0 0.7 40.0 85 80 0.04 
1 2.0 0.7 40.0 85 175 0.08 
1 4.0 0.7 80.0 115 0 0 
1 2.0 0.7 80.0 85 2.5 0.003 
2 4.0 0.2 40.0 105 10 0.006 
2 2.0 0.2 80.0 150 35 0.02 
2 2.0 0.2 40.0 275 190 0.09 
2 4.0 0.2 80.0 32 1 0.001 
2 4.0 0.7 40.0 30 1 0.001 
2 2.0 0.7 40.0 255 7 0.003 
2 4.0 0.7 80.0 115 7.5 0.006 
2 2.0 0.7 80.0 240 3 0.002 
3 4.0 0.2 40.0 215 5 0.003 
3 2.0 0.2 80.0 50 0 0.001 
3 2.0 0.2 40.0 235 4 0.002 
3 4.0 0.2 80.0 215 3 0.002 
3 4.0 0.7 40.0 60 25 0.012 
3 2.0 0.7 40.0 65 22.5 0.01 
3 4.0 0.7 80.0 105 8.5 0.004 
3 2.0 0.7 80.0 74 2.5 0.001 
	
5.3.1.1.1. Surface Concentration 
	
The effect of the variables tested on the dissolution of TA and the surface concentration results 
are shown in Fig. 5.2 and in Table 5.2. Increasing the drug amount (2 and 4 mg) in the stainless-
steel compact reduced the average surface concentration, with a higher compression force 
making this effect less significant. According to the Pareto Chart, the highest significant effect 
is when the compression force is considered in combination with the drug amount (P-value = 
0.0112) while the effect of the drug amount on its own is not of high significance (P-value = 
0.1841). Comparing different flows (0.2 and 0.7 mL/min), it was observed that a lower flow 
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rate led to a higher total surface concentration when considered in combination with the 
compression force tested (Fig. 5.1). The flow rate alone had the less significant effect on 
surface concentration (P-value = 0.9295) while a higher effect was noted when combined with 
the drug amount, but again of low significance (P-value = 0.5229) (Fig. 5.1). To understand 
better how the factors tested (drug amount, flow rate and compression force) can affect surface 
dissolution we can consider the solvation of drug particles from the compact due to the presence 
of the medium and the dissolved molecules flown away from the surface of the compact due 
to the flow rate present in the system [21]. A higher flow led to a smaller amount of solvated 
drug particles accumulating in the powder surface and in combination with a high compression 
force of 80 cN.m, the powder is pressed with a higher packing force in the sample cup. 
Increasing the compression leads to increased surface energy, and so the drug dissolution rate 
will be decreased. A larger volume of medium would be required to come into contact with the 
powder surface to cause the dissolution of the drug and so with a higher compression force the 
differences noted in surface concentration are in a lesser effect. Considering the drug amount 
added in the sample cup, a higher drug amount increases the powder density and in both 
compression forces, leads to a smaller surface concentration (Fig. 5.1). As less drug is 
presented in the sample cup, surface concentration seems to be less significantly affected in 
both flows tested, showing that the density of the powder in the compact may not affect the 






Fig. 5.1. Response surface showing the effect of the variables tested in the surface 













































































Fig. 5.2. Standardised Pareto Chart showing the standardized effect of the tested variables and 
their combinations on the surface concentration of the TA dissolved with UV imaging 
	
5.3.1.1.2. Intrinsic Dissolution Rate (IDR) 
	
Results regarding the IDR (Table 5.2), show that each factor tested provides a significant effect 
according to the Pareto Chart (Fig. 5.4). The highest effect was with different compression 
forces (P-value = 0.0008) with the effect of the flow rate and drug amount combination being 
of high significance as well (P-value = 0.001). With a lower compression force, the powder is 
more loosely packed with the compression rod in the stainless steel press and so dissociation 
from the surface and solvation into dissolved molecules can take place faster, leading to higher 
IDR (Fig. 5.3). In both flow rates and compression forces, a higher drug amount led to a higher 
dissolution rate with a more significant effect in the lower compression force (P-value = 
0.0024). The IDR is affected mostly in combination of a variable with the flow rate which 
could be explained by the increased hydration of the material in test [8, 22]. With a higher 
volume flown through the cell, a higher amount of powder particles was dissolved, leading to 
the confirmation of the convective-diffusion theory (P-value = 0.0018); during which mass 
transport of a dissolved component will be a result of concentration gradients causing diffusion 
and convection due to bulk fluid motion [6, 23]. Significant effect is also shown with the 
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compression force in combination with the drug amount (P-value = 0.0055) and flow rate (P-




Fig. 5.3. Response surface showing the effect of the variables tested in the IDR in drug amounts 































































Fig. 5.4. Standardised Pareto Chart showing the standardized effect of the tested variables and 
their combinations on the IDR of the TA dissolved with UV imaging 
	
5.3.1.1.3. Sample mass dissolved (SMD) 
	
The difference noted in results for the TA mass dissolved (Table 5.2) might not be considered 
of high significance due to the low results measured from the dissolution of TA and the non-
significant effect of the variables tested, as shown in the Pareto charts (Fig. 5.6). This is also 
justified due to TA being poorly soluble in PBS with SMD being low (Fig. 5.5) (Chapter 2). In 
a similar way to the results in surface concentration, the high compression force results in less 
drug being solvated from the powder surface (P-value = 0.1197). A more compact sample led 
to reduced amounts of TA dissolved (Fig. 5.5). In the higher flow rate, less compression force 
led to higher results (P-value = 0.1514) with a higher amount of drug in the sample cup, 
increasing the density of the compact powder (P-value = 0.097). The combination of drug 
amount leading to a different powder density in combination with the flow rate seems to affect 
the measurements of SMD conducted with the SDI having a stronger effect than powder 
density on its own (P-value = 0.0672). As a smaller amount of drug is packed with a similar 
compression force, there will be a difference in the porosity affecting the compaction of the 
powder in the sample cup. As the medium will enter the drug sample faster (increased 
hydration), this will increase the drug dissolution rate. Similar significance was depicted with 
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a combination of the compression force with the drug amount (P-value = 0.2324) and the flow 




Fig. 5.5. Response surface showing the effect of the variables tested in the SMD in drug 







































































Fig. 5.6. Standardised Pareto Chart showing the standardized effect of the tested variables and 
their combinations on the SMD of the TA dissolved with UV imaging 
	
5.3.1.2. Dissolution imaging in static flow conditions 
	
5.3.1.2.1. Effect of type of surfactant in PBS on surface concentration  
	
From the absorbance maps of the surface concentration of TA in media containing different 
types of surfactant (Fig. 5.13), it can be observed that dissolved TA shows an equivalent 
intensity with the solubility of the drug in each media and the dissolution rates of TA in the 
studies containing similar media (Chapter 2) [solubility of TA in: PBS, 28.52 µg/mL; PBS with 
Tween 80 (1% v/v), 91.6 µg/mL; PBS with SLS (1% w/v), 478.01 µg/mL; PBS with CTAB 
(1% w/v), 1041.226 µg/mL]. The intensity of the solvated molecules was obvious from the 
expansion of the absorbance area, contour lines and the absorbance value measured through 
the analysis over time (Fig. 5.13) [6]. Results of TA surface concentration show that the 
surfactants added, provide a different solubilisation capacity to the medium leading to the 
solubility of TA in ascending order: PBS (27.6 µg/mL) < PBS with Tween 80 (1% v/v) (58.3 
µg/mL) < PBS with SLS (1% w/v) (86.5 µg/mL) < PBS with CTAB (1% w/v) (171.1 µg/mL) 
(Fig. 5.7). The differences in the surface concentrations of TA in the different media are also 
equivalent with the visual results recorded from the downstream absorbance tails (Fig. 5.13). 
As there is no flow in the system, the amount of drug dissolved from the surface of the powder 
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due to the presence of the medium, expanded above the surface, slowly diffusing. With static 
flow conditions, the dissolved drug particles stayed close to the surface of the dissolving 
powder which affects the local solution distribution within the cell, also obvious from the 
concentrated density gradients (Fig. 5.13) [6]. During dissolution, local supersaturated 
solutions may occur near the sample surface, which leads to the plateau of the surface 
concentration observed in Fig. 5.7. This may also limit the possibility of higher drug dissolution 
rates to be measured [16]. Swelling of the sample was also examined visually after each run, 
confirming that this was not the reason of the increased absorbance above the surface of the 
sample (Fig. 5.13).  
 
 
Fig. 5.7. Mean ± SD of TA surface concentration in different media over time in static flow 
	
5.3.1.2.2. Effect of viscosity of ASFs on surface concentration  
	
Results with ASFs showed that increasing the amount of HA in the medium leads to a lower 
dissolution with the surface concentration of TA in HS being 31.99 µg/mL, in OA 70.3 µg/mL 
and in RA being 78.7 µg/mL at 30 min (Fig. 5.8 and 5.14). Following the Noyes–Whitney 
equation expressing the dissolution rate, the diffusion coefficient D, is partly related to the 
solvent viscosity; and the dissolution rate will decrease with increasing medium viscosity as D 



























PBS PBS + Tween 80 (1% v/v) PBS + SLS (1% w/v) PBS + CTAB (1% w/v)
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as the viscosity of the medium, among other parameters affects the diffusion coefficient and so 
the dissolution rate (Chapter 3, 4). In addition, more viscous fluid will slow down the 
diffusional mass transport of the drug. 
Results confirm that with no flow present in the system (Fig. 5.8), the media with increasing 
viscosity have the least amount of drug dissolved. Visually, from the absorbance maps depicted 
in Fig. 5.9, it was noticed that drug powder aggregates that were dissolving on the surface of 
the powder, detached and separated from the surface. This could be noticed for the ASFs tested 
and while it took place, the surface concentration would slightly reduce and then would start 
to increase again, which can also be noticed in Fig. 5.8 when values drop slightly [e.g. OA ASF 
at 1260 sec (Fig. 5.8) depicted in Fig. 5.9]. 
 
 
Fig. 5.8. Mean ± SD of TA surface concentration in different BSF containing only HA, over 
time in static flow 
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5.3.1.3. Dissolution imaging in continuous flow conditions 
	
5.3.1.3.1. Effect of type of surfactant in PBS 
	
5.3.1.3.1.1. Surface Concentration 
	
Although visual representations of the experiments with a flow present (Fig. 5.15), show a 
higher absorbance and wider quantification region downstream in the analysis of TA in PBS 
with CTAB (1% w/v) and in PBS with SLS (1% w/v) [8], the results of the TA surface 
concertation show a higher value for TA in PBS with SLS (1% w/v) at 66.85 µg/mL followed 
by TA in PBS with CTAB (1% w/v) at 60.05 µg/mL and TA in PBS with Tween 80 (1% v/v) 
at 57.8 µg/mL (Fig. 5.10). Comparing these results shows small difference, although being of 
higher values than the TA surface concentration in PBS without a surfactant (25.5 µg/mL) (Fig. 
5.10). Results according to visual representations in Fig. 5.15, can be explained as the dissolved 
drug will be transferred from the area above the surface of the powder and towards the direction 
of the flow [6], away from the surface of the sample.  
	
 
Fig. 5.10. Mean ± SD of TA surface concentration in different media over time with a flow of 
0.2 mL/min. 
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The rate of intrinsic dissolution of TA seems to be lower in PBS with an average of 0.47 
µg/min/cm2 while with a surfactant in the medium, in PBS with Tween 80 (1% v/v) and PBS 
with SLS (1% w/v) it seems to be higher than in PBS with an average rate of 1.39 and 2.91 
µg/min/cm2 respectively (Fig. 5.11). The rate of TA in PBS with CTAB (1% w/v) is even 
higher with an average of 3.7 µg/min/cm2. As TA in PBS with CTAB (1% w/v) has the highest 
dissolution rate compared to other media (Chapter 2), similar results are noted in this 
experiment with the visualisation of the dissolution showing a thicker downstream “tail” in the 
flow rate used [8] (Fig. 5.15). With surfactant added to the medium, there is reduced surface 
tension with the creation of micelles, while improving wetting properties and increasing the 
dissolution rate of the drug [25]. The molecular weight of Tween 80 is larger compared to the 
molecular weight of the anionic surfactants used [26] and so with similar surfactant molar 
concentrations, more drug molecules will be encapsulated in the SLS micelles, leading to lower 
diffusivity of the drug-micelle complex and so less drug was dissolved from the formulation. 
Furthermore, ionic surfactants such as SLS and CTAB have higher surface activities with a 
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5.3.1.3.1.3.  Sample mass dissolved (SMD) 
	
More drug seems to be dissolved with PBS with CTAB (1% w/v) running through the system 
(0.0036 mg in 30 min) rather than with PBS with SLS (1% w/v) (0.0027 mg in 30 min) and 
PBS with Tween 80 (1% v/v) (0.0012 mg in 30 min) but with no significant difference noted 
between them (Fig. 5.12). The results can be justified from the visual representation of the 
analysis, with the downstream tail showing higher absorbance in accordance with the TA 
dissolved (Fig. 5.15). TA in PBS had the least amount of TA dissolved (0.0004 mg in 30 min) 
which can be also be justified from the dissolution experiments of TA in buffers with 
surfactants (Chapter 2) showing similar results.  
	
 































Fig. 5.13. Absorbance maps of TA in PBS with surfactants (static flow) 
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In this study, the use of UV surface dissolution imaging is studied as a promising tool for 
predictive in-vitro dissolution testing of IA drugs. The process optimization was of significant 
importance to understand which are the optimal conditions of drug amount, flow rate and 
compression force for further experiments. In static flow, testing TA in PBS containing 
different surfactants with increasing solubility showed that results were in accordance with 
what visual representations of the analysis and the dissolution of TA in the media (Chapter 3). 
When flow was applied, visually it was apparent that the highest drug mass dissolved and IDR 
was in the buffer with the highest solubility and the quantified results led to similar conclusions. 
The use of ASFs was also proven successful and the media were compatible with the utilized 
UV surface dissolution imaging setup and showed that increased viscosity of the medium leads 
to a slower dissolution rate. Using the UV imaging detector assists in monitoring drug 
dissolution adjacent to the surface of the drug powder in spatially and temporally conditions 
and results have shown that the media have a significant effect on the dissolution behaviour of 
TA. The UV imaging seems to have vast potential as a future tool for drug dissolution testing, 
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Chapter 6: Conclusions and Perspectives 
 
In this thesis, various dissolution testing methods were used to assess drug dissolution from a 
model IA drug. The objectives were to study and define the effect of various factors of 
dissolution methods affecting drug dissolution from the formulation and use this information 
i) to design appropriate in-vitro compendial tests for IA formulations; ii) to design appropriate 
in-vitro biorelevant tests for IA formulations by using developed BSF media and iii) to use UV 
imaging for characterizing the dissolution process for IA drugs in buffer with surfactants and 
ASFs. The ultimate goal was the development of appropriate and validated in-vitro predictive 
models of the absorption of a drug after IA administration by taking into account the 
physiological factors that affect the absorption process. The methods developed will be used 
for defining critical variables and setting specifications and may also be applied to other 
injectable formulations. 
In this work, the continuous flow through cell, the dialysis membrane and the bi-phasic setup 
were evaluated according to their potential as compendial dissolution tests, while side-Bi-side 
diffusion cells and the bi-phasic setup were evaluated for their potential as biorelevant 
dissolution tests for IA formulations. BSFs of different physiological states (healthy, OA and 
RA) were developed according to the physicochemical characterisation of in-vivo disease state 
synovial fluid, and were also used in the biorelevant dissolution tests. The SDI was also 
evaluated for its potential to provide deeper insights into the early events of the dissolution 
process of IA drugs. In the following parts we summarize the conclusions and perspectives of 
the various aspects of this research.  
	
6.1. Compendial Tests for IA formulations 
 
Evaluating the effect of various parameters of the tested dissolution methods on the drug 
dissolution of IA formulations, provided important information related to the potential of each 
method to be used as a compendial dissolution test. With the USP apparatus I and III, there 
was no dissolution measured, due to the non-permeation of the drug through the dialysis 
membrane of the Float-A-lyzers used within the apparatus. With the the USP apparatus II, the 
suspension dissolved immediately reaching a plateau in the % of drug dissolved before 
complete dissolution, due to the absence of sink conditions. Using the USP apparatus IV in 
open system, to examine the continuous flow through cell method, showed that the system is 
sensitive to the different parameters, with high significance established between the variables. 
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The promising results were confirmed by establishing the discriminating ability of the setup 
with drug microparticles of different size. With the use of the bi-phasic method with the USP 
apparatus IV in closed system, the parameters tested affected the rate of drug permeation to the 
organic phase, with the drug dissolving in the aqueous phase almost immediately, up to the 
amount allowed due to the solubility limit, presenting a plateau of % drug dissolved in results. 
Changing the oil-water interface area led to a faster partitioning rather than dissolution of the 
drug, showing the potential of the method to be used as a compendial dissolution test. The 
dialysis membrane method presented many difficulties with the dissolution and permeation of 
the drug through the membrane. In most setups evaluating various parameters there was no 
drug dissolution measured, similarly to the use of dialysis membranes with the Float-A-lyzers, 
probably due to an evident particle agglomeration of the flocculated suspension. The evaluation 
of various parameters including the length of the dialysis sac, increased temperature and the 
presence of an organic solvent in the receptor phase, enhanced drug permeation through the 
membrane showing that the dialysis membrane method has potential in drug dissolution of IA 
formulations. As these findings form a useful basis for further fundamental research, an 
important future step is to validate the optimal conditions of the tested dissolution methods. 
Testing a higher number of IA drugs and showing the discrimination power of these methods 
will further prove the potential they have, to be established as compendial methods. 
 
6.2. In-vivo synovial fluid measurements and development of Biorelevant 
Synovial Fluid (healthy state, OA and RA) 
 
The BSFs were developed by taking into consideration the in-vivo measurements of the disease 
state synovial fluids and the average amount of key components affecting dissolution, found in 
literature. The buffers chosen, maintained the desired pH, while Molarity was chosen for 
appropriate osmolality values of the developed media. For having appropriate viscosity of the 
developed BSFs, HA was used in higher amounts than the average values found in literature, 
as the three states, in-vivo contain, HA in different molecular weights (which plays an 
important role in enhancing viscosity). To choose the appropriate amount with the HA used, a 
calibration curve was done with the HA in use, at different concentrations vs. viscosity at a low 
shear rate (0.07 s-1). CMC was also tested as a viscosity enhancer to reach the targeted values. 
Regarding the solubility studies performed, Also the addition of the hyaluronidase solution in 
the sample was chosen to be added after the addition of the drug solution in the calibration 
standards. This was decided, to follow the same order of hyaluronidase solution addition as in 
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the experimental samples in which the drug is already dissolved in the synovial fluid (in-vivo 
or in-vitro biorelevant). Comparing the solubility of TA in the developed BSFs and in the in-
vivo disease state, results show that there are still biorelevant aspects of the synovial fluid 
affecting dissolution, to be understood. The potential exists, however, for the developed media 
to be useful for predicting in-vivo behaviour. This is based on their biorelevance compared to 
other existing media simulating synovial fluid and the differences in TA solubility noticed 
between the healthy state and the disease states developed and also in comparison to the widely 
used PBS with HA (3 mg/mL). 
	
6.3. Biorelevant Tests for intra-articular formulations 
 
Both in-vitro biorelevant systems involving the side-Bi-side cells and the bi-phasic setup 
studied have shown great potential in discrimination between dissolution rates of the setup 
parameters tested. The dissolution/permeation methods tested simulated successfully the 
permeation of the synovial fluid through the synovial membrane, the transfer of the dissolved 
drug to the flowing blood circulation and the transynovial flow mimicking the pathway that 
the synovial fluid follows. The transynovial flow setup with the side-Bi-side cells specifically 
has shown great biorelevance by mimicking the condition in the joint (hydrodynamics of setup 
and BSF) and the dissolution of the drug in different states of BSF media. Using TA as the 
model drug, discrimination between the biorelevant media could only be evident between the 
RA BSF and the healthy state and OA BSF. As the BSF tested did not contain HA which affects 
dissolution rate, the difference in composition between the healthy state BSF and the OA BSF 
was 0.15 and 0.25 mg/mL of PC respectively and the different buffers used. Using the BSFs in 
the bi-phasic model tested, did not show any significant differences in the TA dissolution rate. 
Although the systems showed significant promise, testing more drugs and also proving the 
discrimination power of the systems with the use of different drug particle sizes may also 
provide extra insights in the full potential of the systems. Furthermore, more in-vivo work can 
be performed in order to establish pharmacokinetic parameters and then related them with the 
in-vitro data from these biorelevant dissolution methods. This may lead to the development of 
in-vitro-in-vivo relationships (IVIVR) which can be used for the mechanistic understanding 





6.4. Dissolution testing with UV imaging  
 
Optimising the UV imaging process for testing IA drugs, showed that the compression force is 
significantly important for the results obtained, as a more compacted powder will not allow 
drug particles to solvate and dissolve easily. The TA mass released did not seem to be affected 
by any of the variables in test as results were very low and possibly of non-significance due to 
the low solubility of the drug in the medium tested. This study also contains an attempt to 
evaluate the effect of viscosity of ASFs simulating different states of the synovial fluid. In 
static flow, with less viscosity, dissolution rate of TA was higher, as viscosity is part of the 
diffusion coefficient according to the Noyes – Whitney dissolution rate equation affecting the 
process. Using PBS with surfactants, drug dissolution took place in accordance to the visual 
representations of the dissolution process. With the applied flow of 0.2 mL/min, visually, the 
surface concentration, IDR and TA mass released in PBS with CTAB (1% w/v) seemed to be 
higher than the other media, in accordance with quantified results. UV imaging has proved to 
be a promising technique for analysing the dissolution properties of drugs given through the 
IA route and as a future tool for biorelevant dissolution testing, studies may provide further 
significance to these applications. Understanding the effect of flow in the ASFs tested will also 
help to study the dissolution properties of the drug in more detail. Additionally, testing the 
developed BSF in different states, containing all chosen components (HA, proteins and 
phospholipids) could provide a better insight in how the drug dissolves in synovial fluid. Also, 
applying a flow in the cell with the use of BSFs, would show the full potential of this new 
perspective for in-vitro testing of drug dissolution for IA drugs. 
 
